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A B S T R A C T
Background
Anti-tumour necrosis factor (TNF) agents are effective in treating people with rheumatoid arthritis (RA), but are associated with (dose-
dependent) adverse effects and high costs. To prevent overtreatment, several trials have assessed the effectiveness of down-titration
compared with continuation of the standard dose. This is an update of a Cochrane Review published in 2014.
Objectives
To evaluate the benefits and harms of down-titration (dose reduction, discontinuation, or disease activity-guided dose tapering) of anti-
TNF agents on disease activity, functioning, costs, safety, and radiographic damage compared with usual care in people with RA and
low disease activity.
Search methods
We searched MEDLINE, Embase, Web of Science and CENTRAL (29 March 2018) and four trial registries (11 April 2018) together
with reference checking, citation searching, and contact with study authors to identify additional studies. We screened conference
proceedings (American College of Rheumatology and European League Against Rheumatism 2005-2017).
Selection criteria
Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing down-titration (dose reduction, discontinuation,
disease activity-guided dose tapering) of anti-TNF agents (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) to
usual care/no down-titration in people with RA and low disease activity.
Data collection and analysis
We used standard Cochrane methodology.
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Main results
One previously included trial was excluded retrospectively in this update because it was not an RCT/CCT. We included eight additional
trials, for a total of 14 studies (13 RCTs and one CCT, 3315 participants in total) reporting anti-TNF down-titration. Six studies (1148
participants) reported anti-TNF dose reduction compared with anti-TNF continuation. Eight studies (2111 participants) reported
anti-TNF discontinuation compared with anti-TNF continuation (three studies assessed both anti-TNF discontinuation and dose
reduction), and three studies assessed disease activity-guided anti-TNF dose tapering (365 participants). These studies included data
on all anti-TNF agents, but primarily adalimumab and etanercept. Thirteen studies were available in full text, one was available as
abstract. We assessed the included studies generally at low to moderate risk of bias; our main concerns were bias due to open-label
treatment and unblinded outcome assessment. Clinical heterogeneity between the trials was high. The included studies were performed
at clinical centres around the world and included people with early as well as established RA, the majority of whom were female with
mean ages between 47 and 60. Study durations ranged from 6 months to 3.5 years.
We found that anti-TNF dose reduction leads to little or no difference in mean disease activity score (DAS28) after 26 to 52 weeks
(high-certainty evidence, mean difference (MD) 0.06, 95% confidence interval (CI) −0.11 to 0.24, absolute risk difference (ARD)
1%) compared with continuation. Also, anti-TNF dose reduction does not result in an important deterioration in function after 26 to
52 weeks (Health Assessment Questionnaire Disability Index (HAQ-DI)) (high-certainty evidence, MD 0.09, 95% CI 0.00 to 0.19,
ARD 3%). Next to this, anti-TNF dose reduction may slightly reduce the proportion of participants switched to another biologic (low-
certainty evidence), but probably slightly increases the proportion of participants with minimal radiographic progression after 52 weeks
(moderate-certainty evidence, risk ratio (RR) 1.22, 95% CI 0.76 to 1.95, ARD 2% higher). Anti-TNF dose reduction may cause little
or no difference in serious adverse events, withdrawals due to adverse events and proportion of participants with persistent remission
(low-certainty evidence).
Results show that anti-TNF discontinuation probably slightly increases the mean disease activity score (DAS28) after 28 to 52 weeks
(moderate-certainty evidence, MD 0.96, 95% CI 0.67 to 1.25, ARD 14%), and that the RR of persistent remission lies between
0.16 and 0.77 (low-certainty evidence). Anti-TNF discontinuation increases the proportion participants with minimal radiographic
progression after 52 weeks (high-certainty evidence, RR 1.69, 95% CI 1.10 to 2.59, ARD 7%) and may lead to a slight deterioration
in function (HAQ-DI) (low-certainty evidence). It is uncertain whether anti-TNF discontinuation influences the number of serious
adverse events (due to very low-certainty evidence) and the number of withdrawals due to adverse events after 28 to 52 weeks probably
increases slightly (moderate-certainty evidence, RR 1.46, 95% CI 0.75 to 2.84, ARD 1% higher).
Anti-TNF disease activity-guided dose tapering may result in little or no difference in mean disease activity score (DAS28) after 72 to
78 weeks (low-certainty evidence). Furthermore, anti-TNF disease activity-guided dose tapering results in little or no difference in the
proportion of participants with persistent remission after 18 months (high-certainty evidence, RR 0.89, 95% CI 0.75 to 1.06, ARD
−9%) and may result in little or no difference in switching to another biologic (low-certainty evidence). Anti-TNF disease activity-
guided dose tapering may slightly increase proportion of participants with minimal radiographic progression (low-certainty evidence)
and probably leads to a slight deterioration of function after 18 months (moderate-certainty evidence, MD 0.2 higher, 0.02 lower to
0.42 higher, ARD 7% higher), It is uncertain whether anti-TNF disease activity-guided dose tapering influences the number of serious
adverse events due to very low-certainty evidence.
Authors’ conclusions
We found that fixed-dose reduction of anti-TNF, after at least three to 12 months of low disease activity, is comparable to continuation
of the standard dose regarding disease activity and function, and may be comparable with regards to the proportion of participants with
persistent remission. Discontinuation (also without disease activity-guided adaptation) of anti-TNF is probably inferior to continuation
of treatment with respect to disease activity, the proportion of participants with persistent remission, function, andminimal radiographic
damage. Disease activity-guided dose tapering of anti-TNF is comparable to continuation of treatment with respect to the proportion
of participants with persistent remission and may be comparable regarding disease activity.
Caveats of this review are that available data are mainly limited to etanercept and adalimumab, the heterogeneity between studies, and
the use of superiority instead of non-inferiority designs.
Future research should focus on the anti-TNF agents infliximab and golimumab; assessment of disease activity, function, and radio-
graphic outcomes after longer follow-up; and assessment of long-term safety, cost-effectiveness, and predictors for successful down-
titration. Also, use of a validated flare criterion, non-inferiority designs, and disease activity-guided tapering instead of fixed-dose
reduction or discontinuation would allow researchers to better interpret study findings and generalise to clinical practice.
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P L A I N L A N G U A G E S U M M A R Y
Lowering the dose of or stopping anti-tumour necrosis factor drugs in people with rheumatoid arthritis who are doing well
(low disease activity)
We conducted an updated review of studies in which treatment with anti-tumour necrosis factor (anti-TNF) drugs (adalimumab,
certolizumab pegol, etanercept, golimumab, and infliximab) was lowered or stopped in people with rheumatoid arthritis (RA) who
use anti-TNF drugs and are doing well (low disease activity). Our systematic search up to March 2018 identified 14 studies (3315
participants). The included studies were performed at clinical centres around the world and included people with early as well as
established RA, the majority of whom were female with mean ages varying between 47 and 60. Study durations ranged from 6 months
to 3.5 years.
What is rheumatoid arthritis? What is stopping or lowering the dose of anti-TNF drugs?
When you have RA, your immune system, which normally fights infection, attacks the lining of your joints. This makes your joints
swollen, stiff, and painful. There is no cure for RA, so treatments aim to relieve pain and stiffness, improve ability to move, and prevent
damage to the joints.
Anti-TNF agents are biological drugs for RA. They lessen complaints by reducing inflammation in the joints, and they reduce
radiographic joint damage. Reducing or stopping anti-TNF treatment when disease activity is low might reduce dose-dependent side
effects (mainly infections) and costs.
Key results
Data were available for all anti-TNF agents, but mostly for adalimumab and etanercept.
Disease activity
- People who lowered the dose of anti-TNF showed little or no increase in disease activity compared with people who continued anti-
TNF (high-certainty evidence).
- People who stopped anti-TNF had a 0.96 unit increase in disease activity on a scale from 0.9 to 8 compared with people who continued
anti-TNF (absolute difference 14%, moderate-certainty evidence).
- People who gradually lowered the dose of anti-TNF showed little or no increase in disease activity compared with people who
continued anti-TNF (low-certainty evidence).
Persistent remission
- There was little or no difference in the number of people who had persistent remission between those who lowered the dose of anti-
TNF compared with continuation of anti-TNF (low-certainty evidence).
- Data on how stopping anti-TNF affects persistent remission were not pooled because results were not similar across studies (low-
certainty evidence). The absolute difference varied between 15% and 68% fewer people that remained in remission when stopping
anti-TNF compared to continuation of anti-TNF.
- There was little or no difference in the number of people who had persistent remission between those who gradually lowered the dose
of anti-TNF compared with continuation of anti-TNF (high-certainty evidence).
X-ray progression
- 24 more people per 1000 had a greater than 0.5 point progression of joint damage after a year when lowering the dose of anti-TNF
(scale 0 to 448) (absolute difference 2%, moderate-certainty evidence).
- 73 more people per 1000 who stopped anti-TNF had a greater than 0.5 point progression of joint damage after a year than people
who continued anti-TNF (absolute difference 7%, high-certainty evidence).
- 110 more people per 1000 had greater than 0.5 or greater than 1.0 point progression of joint damage after 1.5 years when gradually
lowering the dose of anti-TNF (low-certainty evidence).
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Function
- People who lowered the dose of anti-TNF had a 0.09 unit worsening of function (scale 0 to 3) compared with people who continued
anti-TNF (absolute difference 3%, high-certainty evidence).
- People stopping anti-TNF had a 0.18 unit worsening of function compared with people who continued anti-TNF (absolute difference
6%, low-certainty evidence).
- People gradually lowering the dose of anti-TNF had a 0.2 unit worsening in function compared with people who continued anti-
TNF (absolute difference 7%, moderate-certainty evidence).
Side effects
- There was little or no difference in number of serious adverse events in people lowering the dose of anti-TNF compared to continuation
anti-TNF (low-certainty evidence).
- It is uncertain whether gradually lowering the dose of or stopping anti-TNF influences the number of serious adverse events (very
low-certainty evidence).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Anti-TNF dose reduction compared to anti-TNF continuation for rheumatoid arthritis in patients with low disease activity
Patient or population: people with rheumatoid arthrit is with low disease act ivity using a standard dose of ant i-TNF agents
Setting: clinical research centres
Intervention: ant i-TNF dose reduct ion
Comparison: ant i-TNF cont inuat ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments What happens
Risk with anti-TNF
continuation
Risk with anti-TNF
dose reduction
Disease activity
score
Assessed with:
DAS28
Scale f rom 0.9 to 8;
higher scores indi-
cate worse disease
act ivity
Follow-up: range 26
weeks to 52 weeks
The mean disease
act ivity score was 2.
34
MD 0.06 higher
(0.11 lower to 0.24
higher)
- 501
(2 RCTs)
⊕⊕⊕⊕
HIGH
Absolute risk dif -
ference: 1% higher
(95% CI 2% lower to
3% higher)
Relat ive percentage
change: 2% higher
(95% CI 5% lower to
10% higher)
Ant i-TNF dose re-
duct ion results in lit -
t le or no dif ference
in disease act ivity
score (DAS28)
Proportion of par-
ticipants with per-
sistent remission
As-
sessed with: DAS28
< 2.6 (remission)
Follow-up: 52 weeks
653 per 1000 659 per 1000
(522 to 835)
RR 1.01
(0.80 to 1.28)
612
(2 RCTs)
⊕⊕©©
LOW 1
Absolute risk dif -
ference: 1% higher
(95%CI 13%lower to
18% higher)
Relat ive percentage
change: 1% higher
(95%CI 20%lower to
28% higher)
NNTB: not applica-
ble (not stat ist ically
signif icant)
Ant i-TNF dose re-
duct ion may result
in lit t le or no dif fer-
ence in the propor-
t ion of part icipants
with persistent re-
m ission (DAS28 < 2.
6)
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Proportion of par-
ticipants switched
to another biologic
Mean follow-up of 3.
5 ± 1.5 years
110 per 1000 44 per 1000
(19 to 102)
RR 0.40
(0.17 to 0.93)
323
(1 RCT)
⊕⊕©©
LOW 2
Absolute risk dif f er-
ence: 7% lower (95%
CI 9% lower to 1%
lower)
Relat ive percentage
change: 60% (95%
CI 83% lower to 7%
lower)
NNTB: 15 (95%CI 12
to 100)
Ant i-TNF dose re-
duct ion may slight ly
reduce the propor-
t ion of part icipants
switched to another
biologic
Proportion of par-
ticipants with min-
imal radiographic
progression
Assessed with:
mSvdH score > 0.5
Follow-up: 52 weeks
105 per 1000 129 per 1000
(80 to 206)
RR 1.22
(0.76 to 1.95)
553
(2 RCTs)
⊕⊕⊕©
MODERATE 3
Absolute risk dif -
ference: 2% higher
(95% CI 3% lower to
10% higher)
Relat ive percentage
change: 22% higher
(95%CI 34%lower to
95% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
Ant i-
TNF dose reduct ion
probably slight ly in-
creases the propor-
t ion of part icipants
with minimal radio-
graphic progression
(mSvdH > 0.5)
Function
Assessed
with: Health Assess-
ment Quest ionnaire
Scale f rom 0 to 3;
higher scores indi-
cate worse funct ion
Follow-up: range 26
weeks to 52 weeks
The mean funct ion
was 0.52
MD 0.09 higher
(0 to 0.19 higher)
- 501
(2 RCTs)
⊕⊕⊕⊕
HIGH
Absolute risk dif -
ference: 3% higher
(95%CI 0%higher to
6% higher)
Relat ive percentage
change: 15% higher
(95%CI 0%higher to
31% higher)
Ant i-TNF dose re-
duct ion does not re-
sult in an impor-
tant deteriorat ion in
funct ion
Number of serious
adverse events
Follow-up: range 26
weeks to 52 weeks
52 per 1000 56 per 1000
(34 to 94)
RR 1.09
(0.65 to 1.82)
1084
(5 RCTs)
⊕⊕©©
LOW 34
Absolute risk dif f er-
ence: 0% (95%CI 2%
lower to 4% higher)
Relat ive percentage
Anti-TNF dose re-
duct ion may cause
lit t le or no dif fer-
ence in the number
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(mean follow-up for
Raf feiner 2015 3.5 ±
1.5 years)
change: 9% higher
(95%CI 35%lower to
82% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
of serious adverse
events.
Withdrawals due to
adverse events
Follow-up: 52 weeks
(mean follow-up for
Raf feiner 2015 3.5 ±
1.5 years)
31 per 1000 33 per 1000
(16 to 70)
RR 1.07
(0.51 to 2.24)
937
(3 RCTs)
⊕⊕©©
LOW 34
Absolute risk dif f er-
ence: 0% (95%CI 2%
lower to 4% higher)
Relat ive percentage
change: 7% higher
(95%CI 49%lower to
124% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
Ant i-TNF dose re-
duct ion may cause
lit t le or no dif fer-
ence in the number
of withdrawals due
to adverse events
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval;DAS28: disease act ivity score in 28 joints;MD: mean dif ference;mSvdH: modif ied Sharp van der Heijde;NNTB: number needed to treat for an addit ional
benef icial outcome; NNTH: number needed to treat for an addit ional harmful outcome; RCT: randomised controlled trial: RR: risk rat io; TNF: tumour necrosis factor
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded two levels due to heterogeneity (I2=73%)
2Downgraded two levels due to concerns about study risk of bias (high risk of select ion bias, performance bias, detect ion
bias and other bias).
3Downgraded one level due to imprecision (insuf f icient sample size/ low number of events).
4Downgraded one level due to concerns about study risk of bias (mainly due to high risk of attrit ion bias in Smolen 2013
(PRESERVE) and high risk of bias on several domains in Raf feiner 2015).
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B A C K G R O U N D
Description of the condition
Rheumatoid arthritis (RA) is a chronic systemic autoimmune
disease characterised by symmetrical joint inflammation that
often leads to joint damage. Tumour necrosis factor-blocking
(anti-TNF) agents have proved effective as therapies for RA
(Blumenauer 2002; Blumenauer 2003; Navarro-Sarabia 2005;
Ruiz Garcia 2014; Singh 2009; Singh 2010). They improve clin-
ical symptoms and functioning and inhibit joint destruction, and
have become an important part of treatment prescribed for RA.
Description of the intervention
Treatment of individuals with RA has been evolving from tradi-
tional step-up regimens to more aggressive step-down strategies.
Pivotal to these changes are the early start of treatment (hit early),
the use of combination therapy including steroids with rapid es-
calation to biologics (hit-hard), and, most important, frequent as-
sessment of disease activity and treatment modification based on
assessment (tight control). Strategies incorporating these concepts
lead to the swift achievement of low disease activity or remission
in most patients, which prevents joint damage and improves func-
tion and quality of life (Schipper 2010). An important disadvan-
tage of the hit-hard approach compared with the traditional step-
up approach, however, is that the former method does not allow
for individual titration of the minimal effective treatment. Indeed,
the traditional step-up approach largely prevents overtreatment,
but high(er) disease activity at the beginning of the disease has to
be accepted. To prevent overtreatment when high-dose or mul-
tidrug strategies are used, treatment must be tapered down when
low disease activity is reached up to the point that disease activ-
ity increases again or medication can be stopped. In this way, the
minimal effective dose is found and overtreatment is prevented.
Optimal dosing of biologics is especially important because of the
risk of dose-dependent adverse effects and the risk of low cost-
effectiveness due to high cost (den Broeder 2010; Ramiro 2017;
Singh 2011). The concept of dose reduction has been incorpo-
rated into current guidelines for the treatment of RA (Singh 2016;
Smolen 2017).
The intervention that is the subject of this review is therefore dose
reduction of anti-TNF agents (by adaptation of dose or dosing
interval) or discontinuation or both in people with RA and low
disease activity status.
How the intervention might work
Successful dose reduction or discontinuation of anti-TNF agents
can be expected for several reasons. First, amongst patients who
seem to respond to treatment with anti-TNF agents are those who
show spontaneous improvement (regression to the mean) (den
Broeder 2010; van Vollenhoven 2004); this phenomenon applies
to 10% to 30% of all patients, as was shown by proportions of
placebo group response (Doherty 2009; St Clair 2004). Second,
often concomitant medication is given that might induce a re-
sponse. Both mechanisms are supported by the fact that a propor-
tion of patients who seem to do well while taking the drug have
(neutralising) antibodies (less than 5% to 43%) (Bartelds 2007;
Klareskog 2011; Wolbink 2006). Finally, a substantial proportion
of patients might need a lower than standard dose for a clinical re-
sponse (Fautrel 2015; Verhoef 2017). Anti-TNF agents are regis-
tered at the dose that shows the best response for the most patients
(top of group level dose-response curve). However, individual pa-
tients might respond to a lower dose as well, which is reflected in
response percentages of lower doses in these initial trials (Genovese
2002; Maini 1998; Weinblatt 2003).
Uncontrolled research has shown that down-titration of anti-TNF
agents can be successful in a relevant proportion of patients. Most
data are available for infliximab, adalimumab, and etanercept, and
most are derived from discontinuation studies (Brocq 2009; den
Broeder 2002; Kavanaugh 2012; Nawata 2008; Saleem 2010;
Tanaka 2010; Tanaka 2012; van den Bemt 2008; van der Bijl
2007; van der Maas 2012).
Why it is important to do this review
Although the adverse effects of anti-TNF agents reported in clin-
ical trials were generally mild in severity, these drugs are associ-
ated with unintended effects including increased risk of infection
and perhaps a dose-dependent increased risk of malignancy and
rare severe adverse events (Bongartz 2006). The introduction of
anti-TNF agents - and other biological drugs - has also led to an
increase in cost because they are much more expensive than tra-
ditional disease-modifying antirheumatic drugs (DMARDs) (van
Vollenhoven 2009).
It was appropriate at this time to conduct an update of this
Cochrane Review of randomised controlled trials (RCTs) of anti-
TNF down-titration as well as discontinuation studies, because
several new RCTs on this topic are emerging, and additional in-
formation on the already included studies has been published.
O B J E C T I V E S
To evaluate the benefits and harms of down-titration (dose reduc-
tion, discontinuation, or disease activity-guided dose tapering) of
anti-TNF agents (adalimumab, certolizumab pegol, etanercept,
golimumab, infliximab) on disease activity, functioning, costs, sa-
fety, and radiographic damage compared with usual care in people
with RA and low disease activity.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials (RCTs) and con-
trolled clinical trials (CCTs) (including cluster randomised and
cross-over trials) according to the Cochrane definition compar-
ing down-titration of tumour necrosis factor-blocking (anti-TNF)
agents versus usual care/no down-titration for inclusion. Themin-
imal required follow-upwas sixmonths. Both superiority and non-
inferiority trials were included.
Types of participants
People with RA (1987, Arnett 1988, or 2010, Aletaha 2010 RA
criteria, or both) American College of Rheumatology (ACR) cri-
teria) using anti-TNF agents in a standard (or lower) dosing reg-
imen (adalimumab 40 mg every other week, etanercept 50 mg
every week or 25 mg twice a week, infliximab 3 mg/kg every eight
weeks, golimumab 50 mg every month, certolizumab pegol 200
mg every other week) for longer than six months and with a low
disease activity state (clinical judgement of rheumatologist or dis-
ease activity score in 28 joints (DAS28) < 3.2; DAS < 2.4; Clinical
Disease Activity Index (CDAI) < 10; Simplified Disease Activity
Index (SDAI) < 11 or DAS28 < 2.6; DAS < 1.6; CDAI < 2.8;
SDAI < 3.3, Aletaha 2005; Fransen 2005, or 2011 ACR/European
League Against Rheumatism (EULAR) remission (Felson 2011)).
Types of interventions
Protocolised down-titration or discontinuation of the anti-TNF
agent for optimal dose finding (not for other reasons, includ-
ing reduction of side effects, availability, planned surgery, preg-
nancy). Non-protocolised change inmedication (DMARDs, non-
steroidal anti-inflammatory drugs (NSAIDs), corticosteroids) was
allowed. Comparison was usual care/no down-titration/continu-
ation of anti-TNF.
Types of outcome measures
Major outcomes
• Mean disease activity score; DAS28/DAS/CDAI/SDAI at
six, 12, 18, and 24 months (Aletaha 2005; Prevoo 1995; Smolen
2003; van der Heijde 1990).
• Proportion of participants with persistent remission (as
specified above) after six, 12, 18, and 24 months.
• Proportion of participants that switched to another biologic
due to persistent loss of response, refractory to re-instalment of
the tapered anti-TNF in the intervention group.
• Proportion of participants with minimal radiographic
progression, as measured by Larsen (Larsen 1973), Sharp (Sharp
1971), or modified Sharp-van der Heijde score (mSvdH score)
(van der Heijde 2000).
• Function (as measured by Health Assessment Questionnaire
(HAQ)/Arthritis Impact Measurement Scale (AIMS)).
• Number of serious adverse events.
• Withdrawals due to adverse events.
Minor outcomes
• Proportion of participants with a flare (or loss of response)
(defined as any composite disease activity index-based flare
criteria) during follow-up time.
• Quality of life as measured by Short Form (SF) Health
Survey-12/36, Health Utilities Index (HUI), or EuroQoL
Quality of Life Scale (EQ-5D).
• Costs (direct (e.g. medication, consultations, travel costs)
and indirect (e.g. health-related absenteeism)).
• Decremental cost-effectiveness ratio (difference in costs
divided by difference in quality of life expressed as utility, thus
the potential savings when accepting the loss of one quality-
adjusted life year (QALY)).
• Time to flare.
• Change in other medication (including DMARDs,
NSAIDs, corticosteroids).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases: MEDLINE (1946
to 29 March 2018), Embase (1974 to 29 March 2018), Web of
Science (1945 to 2018) and the Cochrane Central Register of
Controlled Trials (CENTRAL) 2018 issue 3. The specific search
strategy for each of the databases is shown in the appendices (
Appendix 1; Appendix 2; Appendix 3; Appendix 4). Our search
was not limited by language, year of publication, or publication
type. The search period for all databases extended from inception
to September 2013 for the original review, and from 2013 to 29
March 2018 for the update.
Searching other resources
We searched proceedings of conferences from 2005 to 2017 of
the ACR and from 2005 to 2017 of the European League Against
Rheumatism (EULAR) for abstracts of RCTs and CCTs. We
searched reference lists of identified clinical trials and performed
citation tracking of the included trials in the ISI Web of Knowl-
edge citation index. We searched trial registries for completed and
ongoing trials (Appendix 5). We contacted experts (first authors
of included studies) to ask about additional trials.
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Data collection and analysis
Selection of studies
We selected studies based on the inclusion criteria outlined in the
Criteria for considering studies for this review section. Two re-
view authors (NvH and BJFvdB for the original review; LMV and
BJFvdB for the update) independently screened titles and abstracts
for inclusion, obtaining full articles if necessary. Any differences
were resolved by discussion and consensus or by consultation with
a third review author (AAdB) if needed. In case the same study
population was described in more than one publication, all publi-
cations were used, but for the analysis, all were grouped, with the
most informative publication as the primary reference and with
other publications as secondary references. We recorded reasons
for exclusion of studies.
Data extraction and management
Two review authors (NvH and BJFvdB for the original review;
LMV and BJFvdB for the update) independently abstracted data
from each study using a data extraction form. Any differences were
resolved by discussion and consensus or by consultation with a
third review author (AAdB) if needed. We pilot-tested the data
extraction form on a selection of trials. If necessary, we contacted
the authors of a given study to ask for missing data.
We extracted the following data.
• General study information: first author, author affiliation,
publication source, publication year, and source of funding.
• Study characteristics: design, setting, participant selection,
method of randomisation, allocation procedure, blinding,
inclusion/exclusion criteria, and study duration.
• Population characteristics: age, sex, diagnostic criteria,
disease duration, DMARD comedication, previous DMARD
use, previous anti-TNF use, rheumatoid factor status, anti-cyclic
citrullinated peptide (CCP) status, disease activity state, total
number of participants screened, total number of participants
recruited, total number of participants randomly assigned, total
number of participants followed, and numbers in each group.
• Intervention characteristics: anti-TNF agent, type of
intervention (dose reduction/interval widening/discontinuation),
treatment comparators.
• Outcome measures as noted above.
• Analysis: statistical technique used, intention-to-treat
analyses and/or per-protocol analyses used.
• Results with number, mean and standard deviation.
Assessment of risk of bias in included studies
Two review authors (NvH and BJFvdB for the original review;
LMV and BJFvdB for the update) assessed risk of bias in the
included studies in accordance with the recommendations in
the Cochrane Handbook for Systematic Reviews of Interventions
(Appendix 6) (Higgins 2011).
We assessed the following ’Risk of bias’ domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective reporting.
• Other sources of bias (baseline imbalance in possible
prognostic variables: DMARD comedication, duration of anti-
TNF use, and disease duration).
We judged each of these domains as having low, high, or unclear
risk of bias.
Measures of treatment effect
We analysed the results of the included studies using Review
Manager 2014. Continuous data were expressed as mean differ-
ences (MDs) or standardised mean differences (SMDs). Dichoto-
mous data were expressed as risk ratios (RRs). Rates were expressed
as rate ratios (RaRs). We summarised data in meta-analyses if the
studies were sufficiently homogeneous, both clinically and statis-
tically.
Unit of analysis issues
The participant was the unit of analysis. Post-hoc, it was chosen
to pool the data from the two dose reduction arms in the study by
Ibrahim 2017 (OPTTIRA) for outcomes in which data frommul-
tiple studies could be pooled because this facilitated comparison
with the 50% dose reduction applied in all other included dose
reduction studies (mean dose reduction of 33% and 66% being
50%).
Dealing with missing data
We accepted missing clinical data in trials when they represented
less than 20% of findings. We planned to perform a sensitivity
analysis if more than 20% of the data from a given study were
missing in order to explore the impact of including or excluding
such studies. We attempted to obtain missing information on pa-
rameter variability by contacting the authors of the trial. In the
event that study authors were not able or were unwilling to provide
this information, it was estimated from ranges if provided or from
comparable trials.
Assessment of heterogeneity
We evaluated heterogeneity first clinically by considering compa-
rability across trials on the following variables: type of intervention
(dose reduction/discontinuation/disease activity-guided dose ta-
pering), type of anti-TNF agent, duration of anti-TNF use, base-
line disease activity (low disease activity versus remission), disease
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duration, DMARD comedication, and presence of anti-TNF res-
cue strategy. We examined forest plots and tested for heterogene-
ity using the Chi2 test with a P < 0.10 indicating significant het-
erogeneity. We used the I2 statistic to describe the percentage of
variability in effect estimates that is due to heterogeneity rather
than to chance (Higgins 2003). A value greater than 50% may
indicate substantial heterogeneity (Higgins 2011). If we detected
significant heterogeneity (I2 > 80%), we did not pool data but
performed subgroup analyses in an attempt to explain the hetero-
geneity.
Assessment of reporting biases
Publication bias implies that studies that report favourable results
are more likely to be published than those describing negative
or inconclusive (non-significant) results, leading to a bias in the
overall published literature. To minimise the effect of selective
reporting of results, we searched trial registries for completed but
unpublished studies. We planned to use a funnel plot to assess
potential publication bias. However, due to the small number of
studies, the funnel plot was not informative. We also searched the
trial registries for ongoing studies that are potentially interesting
for a future update of this review (see Characteristics of ongoing
studies for details), and for additional data on included studies.
We assessed reporting bias at the outcome level by using published
protocols of the studies along with published results of the study
to compare outcomes intended to be analysed with those actually
analysed.
Data synthesis
Whenpossible, we analysed data using an intention-to-treatmodel
and, for non-inferiority studies, by also using a per-protocolmodel.
Our reason for this was that intention-to-treat analyses can lead
to false conclusions of non-inferiority in non-inferiority trials.
We analysed outcomes of included studies using a random-effects
model.
Subgroup analysis and investigation of heterogeneity
Weplanned that if sufficient data were available we would perform
subgroup analyses for the following candidate effect modifiers:
type of intervention (dose reduction/discontinuation/disease ac-
tivity-guided dose tapering), type of anti-TNF agent, duration of
anti-TNF use, baseline disease activity (low disease activity versus
remission), disease duration, DMARD comedication, and pres-
ence of anti-TNF rescue strategy.
Sensitivity analysis
We planned to perform the following sensitivity analyses when
possible.
• Effect of risk of bias of included studies.
• Effect of imputation of missing data or statistical
transformations.
’Summary of findings’ tables
We completed three separate ’Summary of findings’ tables in-
cluded in Review Manager 2014 to improve the readability of the
review. We examined seven outcomes in a table for each of the
three subgroups of down-titration: (1) dose reduction, (2) discon-
tinuation, and (3) disease activity-guided dose tapering. The study
population consisted of people with RA with low disease activity
using a standard dose of anti-TNF. The intervention provided was
down-titration (dose reduction, discontinuation, or disease activ-
ity-guided dose tapering). The intervention was compared with
usual care (continuation or no formalised dose reduction of anti-
TNF). In addition to the absolute and relative magnitude of effect,
the number needed to treat for an additional beneficial outcome
(NNTB) and number needed to treat for an additional harmful
outcome (NNTH) were calculated by comparing the intervention
group with the control group. We used GRADEpro 2015 to con-
duct an overall grading of the quality of evidence.
The GRADE approach specifies four levels of certainty (high,
moderate, low, and very low). The highest certainty rating is given
for randomised trial evidence. Randomised trial evidence can be
downgraded to moderate, low, or very low depending on the pres-
ence of five factors.
• Limitations in the design and implementation of available
studies suggesting high likelihood of bias.
• Indirectness of evidence.
• Unexplained heterogeneity or inconsistency of results.
• Imprecision of results.
• High probability of publication bias.
R E S U L T S
Description of studies
The results of the search are presented in Figure 1 and are described
in detail in the following sections of the review.
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Figure 1. Flow chart of study selection.
Results of the search
The previous version of this review included seven studies.
Database searches for this update (2013 to March 2018) resulted
in 2352 records, and after de-duplication 1565 search results. Ref-
erence checking, contact with experts, and performing additional
searches in congress abstract databases and trial registers resulted
in 42 additional records. After title and abstract screening of these
1607 records, 21 studies remained. After assessing these 21 stud-
ies for eligibility, we identified eight new studies for inclusion in
the review. One of the previously included studies, Harigai 2012
(BRIGHT), was retrospectively excluded for this updated version
of the review because we considered their method of allocation (at
the discretion of the physician) as not random or quasi-random,
which is a prerequisite for the classification as RCTor CCT.Newly
found studies that used allocation based on physician or patient
preference were also not included in this updated version (Tanaka
2013 (HONOR); Tanaka 2014 (HOPEFUL-2)). Finally, a total
of 14 studies were included in this update of the systematic review,
consisting of six old studies and eight new studies. All of the old
studies were now available as full text. Of the eight new studies,
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one was published as abstract and seven as full text.
We contacted the authors of 11 studies to obtain missing data or
to clarify methods/results. We received a response from authors of
10 studies.
The total number of participants in the studies included in this
review was 3315. Most participants (2111) were included in the
eight studies comparing anti-TNF discontinuation versus anti-
TNF continuation. Six studies (1148 participants) compared anti-
TNF dose reduction versus continuation. Three studies (365 par-
ticipants) compared disease activity-guided anti-TNF dose taper-
ing versus continuation. Eleven studies used a superiority design;
two studies used a non-inferiority design; and one study reported
an equivalence design.
Included studies
Anti-TNF dose reduction versus anti-TNF continuation
studies
Design
Six studies compared anti-TNF fixed-dose reduction versus
anti-TNF continuation (El Miedany 2016; Ibrahim 2017
(OPTTIRA); Raffeiner 2015; Smolen 2013 (PRESERVE); van
Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY)).
Weinblatt 2017 (C-EARLY), Smolen 2013 (PRESERVE), and
van Vollenhoven 2016 (DOSERA) were randomised, blinded,
placebo-controlled, superiority studies that reported three arms
(discontinuation, dose reduction, and continuation). The ran-
domisation ratiowas 1:1:1 for Smolen 2013 (PRESERVE) and van
Vollenhoven 2016 (DOSERA); for Weinblatt 2017 (C-EARLY)
this was 2:3:2 (stop; dose reduction; continuation). El Miedany
2016, Raffeiner 2015, and Ibrahim 2017 (OPTTIRA) were open-
label superiority studies. The study byRaffeiner 2015 was reported
as a prospective long-term follow-up study; randomisation was
done in a consecutive manner (alternation) in a ratio 1:1, which
we defined as quasi-random, making the study a CCT. The ran-
domisation ratio for Ibrahim 2017 (OPTTIRA) was 1:1:2, and
for El Miedany 2016 it was 1:1:1:1:1 (only group 1 and group 5
were relevant for this review).
The duration of the included studies was 6 months in
Ibrahim 2017 (OPTTIRA); 40 weeks in van Vollenhoven 2016
(DOSERA); 52 weeks in Smolen 2013 (PRESERVE), ElMiedany
2016, and Weinblatt 2017 (C-EARLY); and a mean follow-up of
3.5 ± 1.5 years in Raffeiner 2015. The study by Smolen 2013
(PRESERVE) had a total follow-up of 88 weeks, however 52
weeks of follow-up were provided after randomisation for dose
reduction or continuation of etanercept. The total follow-up for
van Vollenhoven 2016 (DOSERA) was 48 weeks, and 40 weeks
of follow-up were provided after randomisation for dose reduc-
tion or continuation of etanercept. The study by Weinblatt 2017
(C-EARLY) describes period 2 of the C-EARLY study with a du-
ration of 52 weeks, which was a re-randomisation of participants
from the first period, which also lasted 52 weeks.
Sample size
The sample size for this comparison varied from 50 participants in
the study by vanVollenhoven2016 (DOSERA) (73 participants in
total study due to multiple intervention arms) to 404 participants
in Smolen 2013 (PRESERVE) (604 participants in total study due
to multiple intervention arms).
Setting
Ibrahim 2017 (OPTTIRA) reported that participants were
screened at 20 centres in the United Kingdom. The study by
Raffeiner 2015 was reported as a single-centre study in Italy.
Smolen 2013 (PRESERVE) was reported to have been conducted
in 80 centres in Europe, Latin America, Asia, and Australia. The
study by van Vollenhoven 2016 (DOSERA) was performed in
16 rheumatology units in Sweden (5), Denmark (2), Finland
(2), Norway (3), Hungary (3), and Iceland (1). Weinblatt 2017
(C-EARLY) reported that it recruited participants at 103 centres
in in Europe, Australia, North America, and Latin America. El
Miedany 2016 did not report a specific setting.
Participants
El Miedany 2016 did not provide information on participant
characteristics. Most participants were female in the studies by
van Vollenhoven 2016 (DOSERA), Smolen 2013 (PRESERVE),
Weinblatt 2017 (C-EARLY), and Raffeiner 2015. Mean age was
approximately 47 years in Smolen 2013 (PRESERVE); 49 years
in Weinblatt 2017 (C-EARLY); 56 years in Raffeiner 2015; and
57 years in van Vollenhoven 2016 (DOSERA) and Ibrahim 2017
(OPTTIRA). Disease duration ranged from around 2.6 months
in Weinblatt 2017 (C-EARLY) (median disease duration at base-
line of C-EARLY period 1) to 14 years in Raffeiner 2015 and van
Vollenhoven 2016 (DOSERA). Duration of anti-TNF agents had
to be > 3 months in Ibrahim 2017 (OPTTIRA); ≥ 6 months
in El Miedany 2016; ≥ 12 months in Raffeiner 2015; and ≥
14 months in van Vollenhoven 2016 (DOSERA). Smolen 2013
(PRESERVE) started the anti-TNF agent at study start 36 weeks
before randomisation for dose reduction or discontinuation. In
the study by Weinblatt 2017 (C-EARLY), all participants had
started certolizumab pegol treatment one year earlier (period 1 of
C-EARLY). ElMiedany 2016 and Ibrahim 2017 (OPTTIRA) did
not report previous use of DMARDs. Participants in Raffeiner
2015 and Smolen 2013 (PRESERVE) were biologic disease-mod-
ifying antirheumatic drug (bDMARD) naive before the study.
Raffeiner 2015 reported a mean (standard deviation (SD)) of 2.4
(1.1) previously used DMARDs in the dose reduction group and
2.4 (1.3) in the continuation group. Participants in Weinblatt
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2017 (C-EARLY) were bDMARD and conventional synthetic
disease-modifying antirheumatic drug (csDMARD) naive. van
Vollenhoven 2016 (DOSERA) described that 66% of the partici-
pants had used aDMARD other thanmethotrexate (MTX) before
the study.
In all included studies, participants had to have low disease ac-
tivity, Ibrahim 2017 (OPTTIRA); Smolen 2013 (PRESERVE);
van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY),
or remission, El Miedany 2016; Raffeiner 2015. Duration of
low disease activity/remission had to be > 3 months in Ibrahim
2017 (OPTTIRA); ≥ 6 months in El Miedany 2016; ≥ 12
months in Raffeiner 2015; or ≥ 11 months in van Vollenhoven
2016 (DOSERA). Participants in the study by Smolen 2013
(PRESERVE) had to have a mean DAS28 ≤ 3.2 in the 24-week
period before randomisation and a DAS28 ≤ 3.2 at the moment
of randomisation. In the study by Weinblatt 2017 (C-EARLY),
participants needed to have a DAS28 ≤ 3.2 12 weeks before ran-
domisation and at the moment of randomisation. All included
studies used a DAS28-based criterion to define low disease activity
or remission.
Intervention and comedication
Raffeiner 2015 reported etanercept dose reduction by compar-
ing etanercept 25 mg twice a week versus etanercept 25 mg once
a week. Smolen 2013 (PRESERVE) and van Vollenhoven 2016
(DOSERA) reported etanercept dose reduction (25 mg/week)
compared with etanercept continuation (50 mg/week). Ibrahim
2017 (OPTTIRA) reported 33% and 66% dose reduction of adal-
imumab and etanercept versus 100%. El Miedany 2016 reported
50%dose reductionof bDMARDs versus continuation.Weinblatt
2017 (C-EARLY) reported 50% dose reduction of certrolizumab
pegol (200 mg/4 weeks) versus continuation (200 mg/2 weeks).
Participants were required to useMTX comedication (dose ranged
from 7.5 to 25 mg/week) in Smolen 2013 (PRESERVE) and
van Vollenhoven 2016 (DOSERA). In Raffeiner 2015, steroids,
NSAIDs, and DMARDs were continued at the same dosages.
No intra-articular steroids were permitted during the study pe-
riod. Smolen 2013 (PRESERVE) allowed up to three intra-artic-
ular corticosteroid injections during the study. In the study by
van Vollenhoven 2016 (DOSERA), participants continued MTX
and other medications at the same dose. Participants in Weinblatt
2017 (C-EARLY) used MTX in the maximum tolerated (“opti-
mised”) dose throughout the study. Use of intra-articular, intra-
muscular, or intravenous corticosteroids at any dose was prohib-
ited. The maximum allowed dose of oral corticosteroids during
the study was ≥ 10 mg/day prednisone or equivalent, and no
changes in dose were allowed during the study period. In the study
of El Miedany 2016, participants in the relevant study arms used
a stable dose of a csDMARD during the trial. No intramuscu-
lar or local steroid joint injections were allowed. In five studies
(El Miedany 2016; Ibrahim 2017 (OPTTIRA); Raffeiner 2015;
van Vollenhoven 2016 (DOSERA);Weinblatt 2017 (C-EARLY)),
participants could return to their initial dose of anti-TNF after dis-
ease flare. In Smolen 2013 (PRESERVE), no attempt was made to
recapture low disease activity by reintroducing etanercept in par-
ticipants whose condition had deteriorated after etanercept with-
drawal.
Outcomes
All studies reported a primary outcome measure. Three studies
reported proportion of participants with low disease activity or re-
mission as the primary outcome. Raffeiner 2015 and El Miedany
2016 used DAS28 ≤ 2.6, and Smolen 2013 (PRESERVE) used
DAS28 ≤ 3.2. The primary outcome in the study by van
Vollenhoven 2016 (DOSERA) was proportion of non-failures for
etanercept 50 mg/week versus placebo. The primary outcome
for Ibrahim 2017 (OPTTIRA) was reported to be time to flare.
Weinblatt 2017 (C-EARLY) reported maintenance of low disease
activity (disease activity score in 28 joints using erythrocyte sedi-
mentation rate (DAS28-ESR) of≤ 3.2) for all 5 consecutive study
visits to week 52 without flares as the primary outcome measure.
Secondary outcomes reported in the included studies were very
different. None of the included studies provided data on costs or
change in comedication. All studies were analysed with a (modi-
fied) intention-to-treat approach.
Anti-TNF discontinuation versus anti-TNF continuation
studies
Design
Eight of the included studies reported anti-TNF discontinua-
tion compared with anti-TNF continuation (Chatzidionysiou
2016 (ADMIRE); Ghiti Moghadam 2016 (POEET); Pavelka
2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA);
van Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-
EARLY); Yamanaka 2016 (ENCOURAGE)). All included stud-
ies were randomised controlled superiority studies comparing
anti-TNF discontinuation versus continuation. Smolen 2014
(OPTIMA), Smolen 2013 (PRESERVE), van Vollenhoven 2016
(DOSERA), Pavelka 2017, and Weinblatt 2017 (C-EARLY)
were blinded placebo-controlled studies. The other studies were
open-label studies (Chatzidionysiou 2016 (ADMIRE); Ghiti
Moghadam 2016 (POEET); Yamanaka 2016 (ENCOURAGE)).
Chatzidionysiou 2016 (ADMIRE)was reported to be a pilot study.
Smolen 2013 (PRESERVE), van Vollenhoven 2016 (DOSERA),
and Weinblatt 2017 (C-EARLY) reported three arms (both dis-
continuation and dose reduction compared with continuation).
Smolen 2013 (PRESERVE) and van Vollenhoven 2016
(DOSERA) reported a 1:1:1 randomisation ratio, and Weinblatt
2017 (C-EARLY) a randomisation ratio of 2:3:2. Chatzidionysiou
2016 (ADMIRE), Pavelka 2017, Smolen 2014 (OPTIMA), and
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Yamanaka 2016 (ENCOURAGE) reported a 1:1 randomisation
ratio. Ghiti Moghadam 2016 (POEET) randomised in a ra-
tio of 2:1 (discontinuation versus continuation). Smolen 2013
(PRESERVE), Smolen 2014 (OPTIMA), Pavelka 2017, and van
Vollenhoven2016 (DOSERA) reported a “run-in” period inwhich
anti-TNF treatment was given open-label, before randomisation
was provided for anti-TNF continuation, discontinuation, or dose
reduction in a double-blind phase.
The duration of the included studies was 48 weeks for van
Vollenhoven 2016 (DOSERA) (40 weeks double-blind period);
52weeks forChatzidionysiou 2016 (ADMIRE),GhitiMoghadam
2016 (POEET), and Pavelka 2017 (28 weeks double-blind pe-
riod). Weinblatt 2017 (C-EARLY) reported a total follow-up of
104 weeks, in which the second 52-week double blind period was
of interest for this review. Smolen 2014 (OPTIMA) and Smolen
2013 (PRESERVE) reported a total follow-up of 78 weeks and
88 weeks, respectively; however, both described 52-week follow-
up after randomisation for discontinuation or continuation of the
anti-TNF agent. Yamanaka 2016 (ENCOURAGE) described a
period of one year in which participants were treated with open-
label etanercept and MTX before they were randomised to open-
label continuation or discontinuation.
Sample size
The sample size varied from 31 participants in Chatzidionysiou
2016 (ADMIRE) to 817 in Ghiti Moghadam 2016 (POEET).
Setting
All eight studies were reported as multicentre studies.
Chatzidionysiou 2016 (ADMIRE) was performed in several hos-
pitals in Sweden, and Ghiti Moghadam 2016 (POEET) in 47
rheumatology centres throughout the Netherlands. Smolen 2013
(PRESERVE) reported that the study was conducted in 80 centres
in Europe, Latin America, Asia, and Australia. van Vollenhoven
2016 (DOSERA) recruited participants at 16 rheumatology units
in Sweden (5), Denmark (2), Finland (2), Norway (3), Hungary
(3), and Iceland (1). Pavelka 2017 was conducted at 61 centres in
19 countries in Africa, Asia, Central and Eastern Europe, Latin
America, and theMiddle East. Smolen 2014 (OPTIMA) reported
161 sites around the world. Weinblatt 2017 (C-EARLY) was con-
ducted at 103participating sites inEurope, Australia,NorthAmer-
ica, and Latin America. Yamanaka 2016 (ENCOURAGE) was
a co-operation of rheumatology institutes/departments in Japan
and Korea.
Participants
Six studies reported a minimum age of 18 years for inclusion
(Chatzidionysiou 2016 (ADMIRE); Pavelka 2017; Smolen 2013
(PRESERVE); Smolen 2014 (OPTIMA); van Vollenhoven 2016
(DOSERA); Weinblatt 2017 (C-EARLY)). Ghiti Moghadam
2016 (POEET) was reported to include people 18 years of age
or older. Smolen 2013 (PRESERVE) reported an upper age
limit (70 years) for inclusion. Yamanaka 2016 (ENCOURAGE)
did not report any age criteria. The mean age of participants
varied from around 47 in Pavelka 2017 and Smolen 2013
(PRESERVE) to early 60s in Chatzidionysiou 2016 (ADMIRE)
and Ghiti Moghadam 2016 (POEET). Most participants in
the included studies were female. Mean disease duration ranged
from seven to 14 years, except in Smolen 2014 (OPTIMA),
in which the mean disease duration was only 3.9 months;
Weinblatt 2017 (C-EARLY), in which median disease duration
was around 2.7 months (measured one year before randomisa-
tion); and Yamanaka 2016 (ENCOURAGE), in which mean dis-
ease duration was two years. Duration of the anti-TNF agent had
to be ≥ 6 months in Chatzidionysiou 2016 (ADMIRE); ≥ 1
year in Ghiti Moghadam 2016 (POEET); and ≥ 14 months in
van Vollenhoven 2016 (DOSERA). Pavelka 2017, Smolen 2014
(OPTIMA), Smolen 2013 (PRESERVE), and Yamanaka 2016
(ENCOURAGE) started the anti-TNF agent at study start, 24
weeks, 26 weeks, 36 weeks, and 1 year, respectively before ran-
domisation for dose reduction or discontinuation. In the study
by Weinblatt 2017 (C-EARLY), participants were treated with
certolizumab pegol (blinded) one year before randomisation for
dose reduction or discontinuation. Participants in Smolen 2013
(PRESERVE), Smolen 2014 (OPTIMA), and Weinblatt 2017
(C-EARLY) were bDMARD naive before study start. Smolen
2014 (OPTIMA) reported that 8.8% of participants in the dis-
continuation group and 9.5% in the continuation group had used
≥ 1 DMARD. Chatzidionysiou 2016 (ADMIRE) reported a me-
dian of 1 (interquartile range (IQR) 0 to 1) number of previous
bDMARDs and 2 (IQR 1 to 3) previous csDMARDs. In the study
by Ghiti Moghadam 2016 (POEET), 13.4% of participants in
the discontinuation group and 15% in the continuation group
had previously used a bDMARD. In Pavelka 2017, 34% of par-
ticipants in the discontinuation group had previously used a csD-
MARD versus 38% in the continuation group. van Vollenhoven
2016 (DOSERA) reported that 66% of all participants had used
a DMARD other than MTX before study start. Yamanaka 2016
(ENCOURAGE) did not report on prior DMARD use.
Participants in all included studies had to have low disease
activity, Ghiti Moghadam 2016 (POEET); Pavelka 2017;
Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); van
Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY), or
remission, Chatzidionysiou 2016 (ADMIRE); Yamanaka 2016
(ENCOURAGE). The duration of low disease activity had
to be 4 weeks in Smolen 2014 (OPTIMA); ≥ 3 months
in Chatzidionysiou 2016 (ADMIRE); ≥ 6 months in Ghiti
Moghadam 2016 (POEET); or ≥ 11 months in van Vollenhoven
2016 (DOSERA). Participants in the study by Smolen 2013
(PRESERVE) had to have a mean DAS28 ≤ 3.2 in the 24-week
period before randomisation and a DAS28 ≤ 3.2 at the moment
of randomisation. In the study by Weinblatt 2017 (C-EARLY),
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participants needed to have a DAS28 ≤ 3.2 12 weeks before ran-
domisation and at the moment of randomisation. In Yamanaka
2016 (ENCOURAGE), participants had to have a DAS < 2.6 at
6 and 12 months after study start. Pavelka 2017 reported that
participants had to have low disease activity after period 1 (24
weeks after study start). All included studies used a DAS28-based
criterion to define low disease activity or remission.
Intervention and comedication
Smolen 2013 (PRESERVE), van Vollenhoven 2016 (DOSERA),
Yamanaka 2016 (ENCOURAGE), and Pavelka 2017 reported
etanercept discontinuation compared with etanercept continu-
ation. The studies by Chatzidionysiou 2016 (ADMIRE) and
Smolen 2014 (OPTIMA) reported adalimumab discontinuation
comparedwith adalimumab continuation.Ghiti Moghadam 2016
(POEET) reported discontinuation of all anti-TNF agents ver-
sus anti-TNF continuation. Weinblatt 2017 (C-EARLY) reported
discontinuation of certolizumab pegol compared to continuation
of the standard dose.
Participants in most included studies were required to use
MTX comedication (dose ranged from 6 to 25 mg/week). Ghiti
Moghadam 2016 (POEET) included participants using any cs-
DMARD comedication. Participants included in Smolen 2014
(OPTIMA) were MTX naive at the start of the study (26 weeks
before randomisation for discontinuation or continuation of adal-
imumab). Seven studies stated that participants could restart the
anti-TNF after disease flare (Chatzidionysiou 2016 (ADMIRE);
Ghiti Moghadam 2016 (POEET); Pavelka 2017; Smolen 2014
(OPTIMA); van Vollenhoven 2016 (DOSERA); Weinblatt 2017
(C-EARLY); Yamanaka 2016 (ENCOURAGE)). The study by
Smolen2013 (PRESERVE) allowedup to three intra-articular cor-
ticosteroid injections during the study; however, no attempt was
made to recapture low disease activity by reintroducing etanercept
in participants whose condition had deteriorated after etanercept
withdrawal.
Outcomes
All studies reported a primary outcome measure; for most studies
this was proportion of participants with low disease activity or re-
mission. All studies used DAS28-based criteria, but different def-
initions were employed. Chatzidionysiou 2016 (ADMIRE) and
Yamanaka 2016 (ENCOURAGE) usedDAS28 remission (< 2.6).
Smolen 2013 (PRESERVE) and Pavelka 2017 used DAS28 low
disease activity (≤ 3.2 for Smolen 2013 (PRESERVE) and<3.2 for
Pavelka 2017).Weinblatt 2017 (C-EARLY) reportedmaintenance
of low disease activity (DAS28-ESR of ≤ 3.2) for all 5 consecu-
tive study visits to week 52 without flares as the primary outcome
measure. Ghiti Moghadam 2016 (POEET) reported proportion
of participants with a flare (DAS28 ≥ 3.2 plus an increase > 0.6)
as the primary outcome. The primary outcome in the study by
van Vollenhoven 2016 (DOSERA) was proportion of non-failure.
The primary outcome in Smolen 2014 (OPTIMA) was the pro-
portion of participants with both low disease activity and radio-
graphic non-progression; however, this concerned a comparison of
study groups that was not of interest for this review (adalimumab
continuation versus methotrexate monotherapy). Secondary out-
comes reported in the included studies concerned many differ-
ent domains, including participant-reported outcomes (function,
quality of life), radiographic outcomes, number of flares, relapse-
free survival, and safety outcomes. None of the included studies
provided data on costs or change in comedication. All studies were
analysed with a (modified) intention-to-treat approach.
Disease activity-guided dose tapering until stop versus anti-
TNF continuation studies
Design
Three studies compared disease activity-guided anti-TNF dose
taperingwith anti-TNFcontinuation (Bejerano 2016 (OPTIBIO)
(abstract only); Fautrel 2016 (STRASS); van Herwaarden 2015
(DRESS)). All studies were open-label RCTs. van Herwaarden
2015 (DRESS) and Bejerano 2016 (OPTIBIO) were reported to
be non-inferiority studies. Fautrel 2016 (STRASS) reported an
equivalence design. Randomisation ratio was 2:1 (dose tapering
versus continuation) in van Herwaarden 2015 (DRESS) and 1:1
in Fautrel 2016 (STRASS) and Bejerano 2016 (OPTIBIO). Study
durationwas 1 year for Bejerano 2016 (OPTIBIO) and 18months
for van Herwaarden 2015 (DRESS) and Fautrel 2016 (STRASS).
Sample size
The sample size varied from 48 in Bejerano 2016 (OPTIBIO) (66
in the total study, which also included other biologics besides anti-
TNF) to 180 in van Herwaarden 2015 (DRESS). The projected
sample size for the study by Fautrel 2016 (STRASS) was 250
participants; however, only 137 participants were included. The
abstract on Bejerano 2016 (OPTIBIO) reported preliminary data.
Setting
van Herwaarden 2015 (DRESS) and Fautrel 2016 (STRASS)
were reported to be multicentre studies. van Herwaarden 2015
(DRESS) included patients from twohospitals in theNetherlands,
and Fautrel 2016 (STRASS) recruited participants at 22 rheuma-
tology departments in France and one department in Monaco.
Bejerano 2016 (OPTIBIO) was a monocentre study conducted
in a hospital in Spain.
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Participants
The abstract by Bejerano 2016 (OPTIBIO) provided no infor-
mation on participant characteristics of anti-TNF users only. The
mean age of participants was 56 years in the study by Fautrel
2016 (STRASS) and 59 years in the study by van Herwaarden
2015 (DRESS). Most participants were female in Fautrel 2016
(STRASS) and van Herwaarden 2015 (DRESS). Mean disease
duration at baseline was about 10 years for both Fautrel 2016
(STRASS) and van Herwaarden 2015 (DRESS). Participants in
van Herwaarden 2015 (DRESS) had a median of 2 (IQR 1 to 3)
previous DMARDs and 0 (IQR 0 to 1) previous anti-TNF agents.
Fautrel 2016 (STRASS) reported a mean (SD) of 2.7 (1.7) pre-
vious DMARDs, and 24% of participants had previously used a
bDMARD.
The duration of anti-TNF agents had to be ≥ 6 months in
van Herwaarden 2015 (DRESS) and > 1 year in Fautrel 2016
(STRASS). Bejerano 2016 (OPTIBIO) reported no minimal du-
rationof anti-TNFuse. Participants in Bejerano 2016 (OPTIBIO)
had to have clinical remission (DAS < 2.6, SDAI < 5, or ACR/EU-
LAR 2011 criteria) for ≥ 6 months. Participants in Fautrel 2016
(STRASS) needed to have a DAS28 ≤ 2.6 for ≥ 6 months with
no structural damage progression. Participants in van Herwaarden
2015 (DRESS) had to have stable low disease activity (DAS28 <
3.2) at two subsequent visits.
Intervention and comedication
All three studies reported disease activity-guided dose tapering.
Bejerano 2016 (OPTIBIO) included all anti-TNF agents, while
Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS) in-
cluded adalimumab and etanercept.Dose tapering in Fautrel 2016
(STRASS) was done by increasing the interval between two sub-
cutaneous injections by 50% every three months up to a com-
plete stop in the fourth step; if DAS28 remission (DAS28 ≤ 2.6)
was not maintained, dose tapering was suspended or was reversed
to the previous interval based on DAS28 level. The dose reduc-
tion strategy in van Herwaarden 2015 (DRESS) consisted of step-
wise increases of the time interval between injections every three
months until complete stop in the third step. In the instance of a
flare ( DAS28-CRP score > 1.2, or DAS28-CRP > 0.6, and a
current score of ≥ 3.2), the last effective interval was reinstated.
The dose reduction strategy in Bejerano 2016 (OPTIBIO) con-
sisted of a stepwise increase in interval every year with withdrawal
as the third step. In case of flare (DAS28 > 2.6 or SDAI > 5 or
ACR/EULAR criteria not fulfilled), participants returned to the
standard dose. In all studies, the dose-tapering intervention was
compared with unchanged continuation of the anti-TNF agents.
Outcomes
All studies reported a primary outcome measure that was based
on the DAS28 score. Fautrel 2016 (STRASS) reported standard-
ised difference of DAS28 slopes based on a linear mixed-effects
model as the primary outcome compared to an equivalence mar-
gin of ±30%. For van Herwaarden 2015 (DRESS), this was dif-
ference in proportions of participants with major flare (DAS28-
CRP-based flare longer than three months) compared with a non-
inferiority margin of 20%. The primary outcome measure in
Bejerano 2016 (OPTIBIO) was the proportion of participants
that maintained clinical remission after one year. The abstract for
this study did not report on secondary outcome measures. Sev-
eral secondary measures were reported in Fautrel 2016 (STRASS)
and van Herwaarden 2015 (DRESS), including function, radio-
graphic progression, and adverse events. Fautrel 2016 (STRASS)
and van Herwaarden 2015 (DRESS) primarily performed a per-
protocol analysis and additionally performed an intention-to-treat
analysis. Bejerano 2016 (OPTIBIO) did not specify their analysis
approach, which was therefore labelled as intention-to-treat.
Excluded studies
We excluded 29 articles from this review (15 for the original pub-
lication and 14 from the updated version). Fourteen articles (con-
cerning 13 studies) reported anti-TNF down-titration without an
anti-TNF continuation control arm (Awan 2011; Bejarano 2010;
Detert 2013 (HIT-HARD); Emery 2013 (PRIZE); Heimans
2016 (IMPROVED);Klarenbeek2011;Oba2017 (RRRR study);
Quinn 2005; Seddighzadeh 2014 (NORD-STAR); Smolen 2012
(CERTAIN); van den Broek 2011; van der Kooij 2009; Villeneuve
2012; Wiland 2016 (PRIZE)). In four studies, allocation to anti-
TNF continuation or discontinuation was based on patient or
physician preference (Harigai 2012 (BRIGHT); Rakieh 2013;
Tanaka 2013 (HONOR); Tanaka 2014 (HOPEFUL-2)), there-
fore these study were not classified as RCT or CCT. Tada 2012
(PRECEPT) reported low-dose versus standard-dose etanercept
from study start. In the study by Haschka 2016 (RETRO), par-
ticipants were randomised to dose reduction or discontinuation
of all DMARDs, therefore the intervention was too broad for this
review. The studies by Kobelt 2011 and Kobelt 2014 provided
data from a Markov model. Aletaha 2010, Ichikawa 2007, and
Keystone 2003 were overview articles. Ramírez-Herráiz 2013 was
a retrospective study; CADTH Report 2014 described a literature
study; and Greenberg 2014 was a cohort study. In the study by
Haraoui 2014, no doses below standard dose were investigated.
See Characteristics of excluded studies for more information.
Risk of bias in included studies
See Characteristics of included studies for ’Risk of bias’ tables with
information on all aspects of risk of bias. Graphic summaries of the
risk of bias in included studies are shown in Figure 2 and Figure
3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Seven included studies described an adequate random sequence
generation and allocation concealment procedure, resulting in
an assessment of low risk of selection bias (Fautrel 2016
(STRASS); Ibrahim 2017 (OPTTIRA); Pavelka 2017; Smolen
2013 (PRESERVE); van Herwaarden 2015 (DRESS); van
Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY)).
The precise method of random sequence generation was not
described in three studies (Chatzidionysiou 2016 (ADMIRE);
Smolen 2014 (OPTIMA); Yamanaka 2016 (ENCOURAGE)).
Ghiti Moghadam 2016 (POEET) did not describe allocation con-
cealment. The methods of randomisation and allocation con-
cealment were not described in the abstract by Bejerano 2016
(OPTIBIO) and the study by El Miedany 2016. The study by
Raffeiner 2015 described alternation as the method of randomisa-
tion, which resulted in a judgement of high risk of selection bias.
Blinding
Five studies were reported to be placebo controlled (Pavelka
2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA);
van Vollenhoven 2016 (DOSERA);Weinblatt 2017 (C-EARLY)).
The remaining nine studies were open-label (Bejerano 2016
(OPTIBIO); Chatzidionysiou 2016 (ADMIRE); El Miedany
2016; Fautrel 2016 (STRASS); GhitiMoghadam 2016 (POEET);
Ibrahim 2017 (OPTTIRA); Raffeiner 2015; van Herwaarden
2015 (DRESS); Yamanaka 2016 (ENCOURAGE)); five of these
described blinding of X-ray reading (Fautrel 2016 (STRASS);
Ibrahim 2017 (OPTTIRA); Raffeiner 2015; van Herwaarden
2015 (DRESS); Yamanaka 2016 (ENCOURAGE), and the study
by Fautrel 2016 (STRASS) also reported blindedDAS28measure-
ments, which resulted in an assessment of low risk of detection
bias.
Incomplete outcome data
We used three criteria for judging this item: intention-to-treat
analyses, imputation of missing data, and attrition rate.
Most studies performed an intention-to-treat analysis (
Chatzidionysiou 2016 (ADMIRE); Fautrel 2016 (STRASS);Ghiti
Moghadam 2016 (POEET); Ibrahim 2017 (OPTTIRA); Pavelka
2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA); van
Herwaarden 2015 (DRESS); van Vollenhoven 2016 (DOSERA);
Weinblatt 2017 (C-EARLY); Yamanaka 2016 (ENCOURAGE)).
The abstract by Bejerano 2016 (OPTIBIO) and the studies by
Raffeiner 2015 and El Miedany 2016 did not report on the type
of analysis. Five studies did not report any imputation of missing
data (El Miedany 2016; Fautrel 2016 (STRASS); Ibrahim 2017
(OPTTIRA); Raffeiner 2015; van Herwaarden 2015 (DRESS)).
Smolen 2013 (PRESERVE) reported a modified non-respon-
der imputation analysis in which participants who discontinued
early due to poor efficacy were imputed as non-responders for all
time points; all other participants were analysed by the last ob-
servation carried forward (LOCF) method. All other postbase-
line analyses were based on the LOCF method (except radio-
graphic endpoints). Chatzidionysiou 2016 (ADMIRE) used non-
responder imputation for participants with no available DAS28
at the time of the primary outcome (this included most par-
ticipants who had a flare in the adalimumab discontinuation
group). Ghiti Moghadam 2016 (POEET) reported imputation of
DAS28 components based on the expectation-maximisation al-
gorithm using the participant’s values of the remaining compo-
nents of the DAS28. Pavelka 2017 reported that efficacy anal-
yses were conducted in the full analysis set population in each
period using the last observation before rescue carried forward
approach. The study by Smolen 2014 (OPTIMA) used non-re-
sponder imputation for the primary endpoint, and non-respon-
der imputation and LOCF, or both, for additional clinical out-
comes; LOCF was used for functional outcomes. Markov chain
Monte Carlo method was used to impute missing radiographic
data 10 times (multiple imputation). Weinblatt 2017 (C-EARLY)
reported that missing data from participants who entered pe-
riod 2 but withdrew before the end of the study were imputed
using non-responder imputation for the primary and key sec-
ondary endpoints. Radiographic analyses used linear extrapola-
tion. In post hoc analyses, LOCF imputation was used for the
proportions of participants achieving low disease activity, remis-
sion, and normative physical function. The study by Yamanaka
2016 (ENCOURAGE) described LOCF to impute missing data.
van Vollenhoven 2016 (DOSERA) reported that a non-respon-
der imputation was applied for dichotomous clinical outcomes.
The abstract by Bejerano 2016 (OPTIBIO) did not describe the
procedure for handling missing data. Most studies reported some
participants that were lost to follow-up (Chatzidionysiou 2016
(ADMIRE); El Miedany 2016; Fautrel 2016 (STRASS); Ghiti
Moghadam 2016 (POEET); Ibrahim 2017 (OPTTIRA); Pavelka
2017; Raffeiner 2015; Smolen 2014 (OPTIMA); vanHerwaarden
2015 (DRESS); van Vollenhoven 2016 (DOSERA); Weinblatt
2017 (C-EARLY)). The study by Smolen 2013 (PRESERVE) re-
ported that fewer participants completed the study in the placebo
group than in the etanercept 50 mg and 25 mg groups (141 versus
181 and 175 participants). Yamanaka 2016 (ENCOURAGE) re-
ported high dropout rates in both groups (16/49 in the continua-
tion group and 16/50 in the discontinuation group). The abstract
by Bejerano 2016 (OPTIBIO) did not describe completion rate.
Selective reporting
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Most studies, with the exceptionofRaffeiner 2015 andElMiedany
2016, had a study protocol that was available. Bejerano 2016
(OPTIBIO) was published as abstract only, and therefore did not
report all prespecified outcomes. All other studies reported the pre-
specified outcomes (Chatzidionysiou 2016 (ADMIRE); Fautrel
2016 (STRASS); Ghiti Moghadam 2016 (POEET); Ibrahim
2017 (OPTTIRA); Pavelka 2017; Smolen 2013 (PRESERVE);
Smolen 2014 (OPTIMA); van Herwaarden 2015 (DRESS); van
Vollenhoven 2016 (DOSERA); Weinblatt 2017 (C-EARLY);
Yamanaka 2016 (ENCOURAGE)).
Other potential sources of bias
Eight studies appeared to be free of other potential sources of bias
(Chatzidionysiou 2016 (ADMIRE); El Miedany 2016; Ibrahim
2017 (OPTTIRA); Pavelka 2017; Smolen 2013 (PRESERVE);
Smolen 2014 (OPTIMA); van Herwaarden 2015 (DRESS); van
Vollenhoven 2016 (DOSERA)). There was insufficient informa-
tion in the abstract by Bejerano 2016 (OPTIBIO) to assess this
domain. The study by Ghiti Moghadam 2016 (POEET) reported
a different flare criterion in their final publication compared to the
information in the trial register. No study protocol was present for
Raffeiner 2015, but information from an earlier abstract indicated
that the inclusion criteria, outcome measures, and duration of fol-
low-up had changed over time. A lower than anticipated number
of participants was included in Yamanaka 2016 (ENCOURAGE),
Weinblatt 2017 (C-EARLY), and Fautrel 2016 (STRASS).
Effects of interventions
See: Summary of findings for the main comparison Anti-
TNF dose reduction versus anti-TNF continuation; Summary
of findings 2 Anti-TNF discontinuation versus anti-TNF
continuation; Summary of findings 3 Anti-TNF disease
activity-guided dose tapering versus anti-TNF continuation
We have presented study results by type of intervention: (1) dose
reduction, (2) discontinuation, and (3) disease activity-guided
dose tapering.
Anti-TNF dose reduction versus anti-TNF
continuation
Major outcomes
See Summary of findings for the main comparison.
• Mean disease activity: Of the six studies included for this
comparison (1148 participants), two studies, Smolen 2013
(PRESERVE) and Ibrahim 2017 (OPTTIRA), with 501
participants provided data on mean disease activity (DAS28).
Anti-TNF dose reduction resulted in little or no difference in
mean disease activity score after 26 to 52 weeks’ follow-up (mean
difference (MD) 0.06, 95% confidence interval (CI) −0.11 to
0.24). We pooled data from the two dose reduction arms in the
study by Ibrahim 2017 (OPTTIRA) for this outcome. Analysis
1.1
• Proportion persistent remission: Of the six studies included
for this comparison (1148 participants), two studies, Smolen
2013 (PRESERVE) and Weinblatt 2017 (C-EARLY), with 612
participants provided data on persistent remission. Anti-TNF
dose reduction may result in little or no difference in the
proportion of participants with persistent remission (DAS28 <
2.6) after 52 weeks (risk ratio (RR) 1.01, 95% CI 0.80 to 1.28).
Analysis 1.2
• Proportion of participants that switched to another
biologic: Of the six studies included for this comparison (1148
participants), only one study with 323 participants provided data
on this outcome (Raffeiner 2015). The data showed that anti-
TNF dose reduction may slightly reduce the proportion of
participants who are switched to another biologic (RR 0.40,
95% CI 0.17 to 0.93; mean follow-up period 3.5 ± 1.5 years).
This result might be explained by a difference in treatment
strategy after flare in the two treatment groups. In the
continuation group, a flare resulted in a switch of biologic
treatment, while in the dose reduction group the standard dose
of etanercept was reinstated first (Raffeiner 2015). Analysis 1.3
• Proportion of participants with minimal radiographic
progression: Of the six studies included for this comparison
(1148 participants), two studies provided data on radiographic
progression, Smolen 2013 (PRESERVE) and Weinblatt 2017
(C-EARLY), with 553 participants. Anti-TNF dose reduction
probably slightly increases the proportion of participants with
minimal radiographic progression (mSvdH > 0.5) after 52 weeks
(RR 1.22, 95% CI 0.76 to 1.95). Analysis 1.4
• Function: Of the six studies included for this comparison
(1148 participants), two studies, Smolen 2013 (PRESERVE)
and Ibrahim 2017 (OPTTIRA), with 501 participants provided
data on this outcome. Anti-TNF dose reduction does not result
in an important deterioration in function (HAQ Disability
Index (HAQ-DI)) after 26 to 52 weeks’ follow-up (MD 0.09,
95% CI 0.00 to 0.19). We pooled data from the two dose
reduction arms in the study by Ibrahim 2017 (OPTTIRA) for
this outcome. Analysis 1.5
• Number of serious adverse events: Of the six studies
included for this comparison (1148 participants), five studies
with 1084 participants provided data on this outcome (Ibrahim
2017 (OPTTIRA); Raffeiner 2015; Smolen 2013 (PRESERVE);
van Vollenhoven 2016 (DOSERA); Weinblatt 2017
(C-EARLY)). Anti-TNF dose reduction may cause little or no
difference inthe number of serious adverse events after 26 to 52
weeks’ follow-up (RR 1.09, 95% CI 0.65 to 1.82). We pooled
data from the two dose reduction arms in the study by Ibrahim
2017 (OPTTIRA) for this outcome. Analysis 1.6
• Withdrawals due to adverse events: Of the six studies
included for this comparison (1148 participants), three studies
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with 937 participants provided data on this outcome (Raffeiner
2015; Smolen 2013 (PRESERVE); Weinblatt 2017
(C-EARLY)). Anti-TNF dose reduction may cause little or no
difference in the number of withdrawals due to adverse events
after 52 weeks (RR 1.07, 95% CI 0.51 to 2.24). Analysis 1.7
Minor outcomes
• Proportion of participants with a flare: Of the six included
studies for this comparison (1148 participants), three studies
with 357 participants provided data on this outcome (Ibrahim
2017 (OPTTIRA); van Vollenhoven 2016 (DOSERA);
Weinblatt 2017 (C-EARLY)). The three studies used different
criteria for flare. Ibrahim 2017 (OPTTIRA) defined a flare as an
increase in DAS28 scores ≥ 0.6 resulting in a DAS28 > 3.2
together with an increase in the swollen joint count; both had to
be present on two occasions at least one week apart. An increase
in DAS28 score ≥ 1.2 resulting in DAS28 > 3.2 was defined as
flare irrespective of changes in swollen joints. van Vollenhoven
2016 (DOSERA) defined a flare as (a) a DAS28-ESR > 5.1; (b) a
DAS28-ESR > 3.2 and an increase ≥ 1.2 from baseline; (c)
DAS28-ESR > 3.2 and an increase in DAS28 ≥ 0.6 from
baseline on two consecutive visits at least one to three weeks
apart; or (d) disease progression as determined by either the
investigator or disease flare as experienced by the participant.
Weinblatt 2017 (C-EARLY) stated that participants reporting a
flare also had to meet the following three criteria at two
consecutive visits two weeks apart: 1) an increase in the DAS28-
ESR of ≥ 0.6 above the DAS28-ESR at week 52; 2) a DAS28-
ESR of > 3.2; and 3) in the investigator’s judgement, an increase
in the participant’s RA activity. Furthermore, Ibrahim 2017
(OPTTIRA) included two intervention groups: 33% and 66%
dose reduction. Due to this heterogeneity data were not pooled.
The studies did not show a difference between the anti-TNF
dose reduction group(s) and the continuation group; risk ratios
were found between 0.29 and 1.79.
• Quality of life: Of the six studies included for this
comparison (1148 participants), two studies, Smolen 2013
(PRESERVE) and Ibrahim 2017 (OPTTIRA), with 501
participants provided data on this outcome. Anti-TNF dose
reduction resulted in little or no difference in mean EQ-5D after
26 to 52 weeks’ follow-up (MD 0.00, 95% CI −0.04 to 0.03).
We pooled data from the two dose reduction arms in the study
by Ibrahim 2017 (OPTTIRA) for this outcome.
• Costs: None of the six included studies provided data on
this outcome.
• Decremental cost-effectiveness ratio: None of the six
included studies provided data on this outcome.
• Time to flare: Of the six studies included for this
comparison (1148 participants), one study with 50 participants
provided data on this outcome (van Vollenhoven 2016
(DOSERA)). Median time to failure was 48 weeks in the
etanercept 50 mg/week continuation group and 36 weeks in the
etanercept 25 mg/week dose reduction group, but no SDs were
available.
• Change in other medication: None of the six included
studies reported data on this outcome.
Anti-TNF discontinuation versus anti-TNF
continuation
See Summary of findings 2.
Major outcomes
• Mean disease activity: Of the eight studies (2111
participants) included for this comparison, three studies, Smolen
2013 (PRESERVE), Ghiti Moghadam 2016 (POEET), and
Pavelka 2017, with 402, 692, and 331 participants, respectively,
provided data on mean disease activity. We pooled data from
Pavelka 2017 and Smolen 2013 (PRESERVE). Anti-TNF
discontinuation probably increases the mean disease activity
score (DAS28) slightly after 28 to 52 weeks’ follow-up (MD
0.96, 95% CI 0.67 to 1.25). We considered the study by Ghiti
Moghadam 2016 (POEET) to be different since participants
could return to standard dose in case of flare, and no LOCF was
described, therefore the results will reflect the effect of a
discontinuation and restarting strategy. This strategy resulted in
a small, possibly unimportant increase in mean disease activity
score after 52 weeks (MD 0.29, 95% CI 0.14 to 0.44). Analysis
2.1
• Proportion persistent remission: Of the eight studies
reporting on this comparison (2111 participants), six studies
with 1188 participants provided data on the proportion of
participants with persistent remission (Chatzidionysiou 2016
(ADMIRE); Pavelka 2017; Smolen 2013 (PRESERVE); Smolen
2014 (OPTIMA); Weinblatt 2017 (C-EARLY); Yamanaka 2016
(ENCOURAGE)). We were unable to pool data due to
heterogeneity. The RR after 28 to 52 weeks varied between 0.16
in Chatzidionysiou 2016 (ADMIRE) and 0.77 in Smolen 2014
(OPTIMA) and Weinblatt 2017 (C-EARLY). The absolute risk
difference varied between 15% fewer in Weinblatt 2017
(C-EARLY) and 68% fewer in Chatzidionysiou 2016
(ADMIRE). Analysis 2.2
• Proportion of participants that switched to another biologic
due to persistent loss of response (refractory to re-instalment of
the tapered anti-TNF in the intervention group): None of the
eight included studies provided data on this outcome. Smolen
2013 (PRESERVE) reported that no attempt was made to
recapture low disease activity by reintroducing etanercept in
participants whose condition had deteriorated after etanercept
withdrawal, raising some ethical issues in our view.
• Proportion of participants with minimal radiographic
progression: Of the eight studies (2111 participants) included for
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this comparison, three studies, Smolen 2013 (PRESERVE),
Weinblatt 2017 (C-EARLY), and Yamanaka 2016
(ENCOURAGE)), with 549 participants provided data on this
outcome. The meta-analysis showed that anti-TNF
discontinuation increases the proportion of participants with
minimal radiographic progression > 0.5 mSvdH point after 52
weeks (RR 1.69, 95% 1.10 to 2.59). Analysis 2.3
• Function: Of the eight studies (2111 participants) included
for this comparison, four studies with 1498 participants provided
data on this outcome (Ghiti Moghadam 2016 (POEET);
Pavelka 2017; Smolen 2013 (PRESERVE); Smolen 2014
(OPTIMA)). The results showed that anti-TNF discontinuation
may lead to a slight deterioration in function after 28 to 52
weeks’ follow-up (MD 0.18, 95% CI 0.05 to 0.31). Analysis 2.4
• Number of serious adverse events: All eight studies included
for this comparison provided data on this outcome, with 2095
participants. Due to the very low certainty of the evidence and
imprecision of the results, it is uncertain whether anti-TNF
discontinuation influences the number of serious adverse events
after 28 to 52 weeks (RR 1.29, 95% CI 0.82 to 2.03). Analysis
2.5
• Withdrawals due to adverse events: Of the eight studies
(2111 participants) included for this comparison, four studies
with 1116 participants provided data on this outcome (Pavelka
2017; Smolen 2013 (PRESERVE); Smolen 2014 (OPTIMA);
Weinblatt 2017 (C-EARLY)). Anti-TNF discontinuation
probably slightly increases the number of withdrawals due to
adverse events after 28 to 52 weeks (RR 1.46, 95% CI 0.75 to
2.84). Analysis 2.6
Minor outcomes
• Proportion of participants with a flare: Of the eight studies
(2111 participants) included for this comparison, five studies
provided data on this outcome (Chatzidionysiou 2016
(ADMIRE); Ghiti Moghadam 2016 (POEET); Pavelka 2017;
van Vollenhoven 2016 (DOSERA); Weinblatt 2017
(C-EARLY)), with 31, 46, 331, 817, and 163 participants,
respectively. We did not pool data because of clinical and
statistical heterogeneity. The study by Chatzidionysiou 2016
(ADMIRE) defined flare as DAS28 ≥ 2.6 or an increase of more
than 1.2 from baseline. After 28 weeks, proportion of flare in the
adalimumab discontinuation group was not statistically
significantly different from that in the adalimumab continuation
group (RR 1.6, 95% CI 0.92 to 2.78). van Vollenhoven 2016
(DOSERA) defined flare as (a) a DAS28-ESR > 5.1; (b) a
DAS28-ESR > 3.2 and an increase ≥ 1.2 from baseline; (c)
DAS28-ESR > 3.2 and an increase in DAS28 ≥ 0.6 from
baseline on two consecutive visits at least one to three weeks
apart; or (d) disease progression as determined by either the
investigator or disease flare as experienced by the participant.
After 48 weeks’ follow-up, the proportion of participants with
flare was higher in the discontinuation group compared to the
continuation group (RR 1.82, 95% CI 1.15 to 2.87). Ghiti
Moghadam 2016 (POEET), Pavelka 2017, and Weinblatt 2017
(C-EARLY) used the same criterion for flare: DAS28 ≥ 3.2 and
an increase of 0.6 or more. Ghiti Moghadam 2016 (POEET)
found that the proportion of participants with flare was higher in
the anti-TNF discontinuation group than in the continuation
group (after 24 weeks RR 3.37, 95% CI 2.42 to 4.70; after 52
weeks RR 2.82, 95% CI 2.17 to 3.65). Pavelka 2017 found a
higher proportion of flare in the participants that stopped anti-
TNF after 28 weeks (RR 1.53, 95% CI 1.30 to 1.81). Weinblatt
2017 (C-EARLY) found no difference in the proportion of
participants with flare between the anti-TNF discontinuation
group and the continuation group (RR 1.52, 95% CI 0.61 to
3.80).
• Quality of life: Of the eight studies (2111 participants)
included for this comparison, two studies, Smolen 2013
(PRESERVE) and Pavelka 2017, with 733 participants provided
data on this outcome. Anti-TNF discontinuation led to a
deterioration in quality of life after 28 to 52 weeks (MD −0.10,
95% CI −0.13 to −0.07).
• Costs: None of the eight included studies provided data on
direct or indirect costs.
• Decremental cost-effectiveness ratio: None of the eight
included studies provided data on this outcome.
• Time to flare: Of the eight studies included for this
comparison (2111 participants), two studies, Chatzidionysiou
2016 (ADMIRE) and van Vollenhoven 2016 (DOSERA),
provided data on this outcome, with 31 and 46 participants,
respectively. These two studies used different flare/failure criteria.
Chatzidionysiou 2016 (ADMIRE) reported that survival curves
suggested higher flare-free survival over time in participants
randomised to continue treatment with adalimumab, but that
the difference did not reach statistical significance (P = 0.07).
The study by van Vollenhoven 2016 (DOSERA) reported a
median time to failure of 48 weeks in the etanercept 50 mg/week
continuation group and six weeks in the etanercept
discontinuation (placebo) group, but no SDs were available.
• Change in other medication: None of the eight included
studies provided data on change in other medication.
Anti-TNF disease activity-guided dose tapering
versus anti-TNF continuation
See Summary of findings 3.
Primary outcomes
• Mean disease activity: All three studies included in this
comparison reported on this outcome, with 357 participants
(Bejerano 2016 (OPTIBIO) (abstract only); Fautrel 2016
(STRASS); van Herwaarden 2015 (DRESS)). Anti-TNF disease
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activity-guided dose tapering may result in little or no difference
in mean disease activity score (MD 0.25, 95% CI −0.17 to
0.67). Analysis 3.1
• Proportion persistent remission: Of the three studies
included in this comparison (365 participants), one study with
180 participants reported on this outcome (van Herwaarden
2015 (DRESS)). Anti-TNF disease activity-guided dose tapering
resulted in little or no difference in the proportion of
participants with persistent remission (DAS28 < 2.6) after 18
months (RR 0.89, 95% CI 0.75 to 1.06). Analysis 3.2
• Proportion of participants that switched to another biologic
due to persistent loss of response (refractory to re-instalment of
the tapered anti-TNF in the intervention group): Of the three
studies included in this comparison (365 participants), two
studies, Fautrel 2016 (STRASS) and van Herwaarden 2015
(DRESS), with 317 participants reported on this outcome. Anti-
TNF disease activity-guided dose tapering may result in little or
no difference in the proportion of participants that switch to
another biologic after 18 months (RR 0.62, 95% CI 0.25 to
1.54). Analysis 3.3
• Proportion of participants with minimal radiographic
progression: Of the three studies included in this comparison
(365 participants), two studies, Fautrel 2016 (STRASS) and van
Herwaarden 2015 (DRESS), with 312 participants reported on
this outcome. Although Fautrel 2016 (STRASS) used a cut-off
value of 1 point and van Herwaarden 2015 (DRESS) a cut-off
value of 0.5 point mSvdH score, data could be pooled. Anti-
TNF disease activity-guided dose tapering may slightly increase
the proportion of participants with minimal radiographic
progression (mSvdH > 0.5 or > 1.0) after 18 months (RR 1.45,
95% CI 0.77 to 2.73). Analysis 3.4
• Function: Of the three studies included in this comparison
(365 participants), one study with 123 participants reported on
this outcome (Fautrel 2016 (STRASS)). IAnti-TNF disease
activity-guided dose tapering probably leads to a slight
deterioration in function after 18 months (MD 0.20, 95% CI
−0.02 to 0.42). Analysis 3.5
• Number of serious adverse events: Of the three studies
included in this comparison (365 participants), two studies,
Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS),
reported on this outcome, with 137 and 180 participants,
respectively. Due to the very low certainty of the evidence and
imprecision, it is uncertain whether anti-TNF disease activity-
guided dose tapering influences the number of serious adverse
events after 18 months. Analysis 3.6
• Withdrawals due to adverse events: None of the three
included studies provided data on this outcome.
Minor outcomes
• Proportion of participants with a flare: All three studies
(365 participants) included in this comparison reported on this
outcome. The studies used different criteria for flare. In Bejerano
2016 (OPTIBIO) (abstract only), participants had a flare if
DAS28 > 2.6; SDAI > 5; or when ACR/EULAR criteria were
not fulfilled. Bejerano 2016 (OPTIBIO) (abstract only) found
no difference in the proportion of participants with a flare
between the anti-TNF disease activity-guided dose tapering
group and the anti-TNF continuation group after 24, 48, 72,
and 96 weeks’ follow-up (24 weeks: RR 3.25, 95% CI 0.14 to
76.01; 48 weeks: RR 1.09, 95% CI 0.24 to 4.86; 72 weeks: RR
1.09, 95% CI 0.36 to 3.27; 96 weeks: RR 1.27, 95% CI 0.50 to
3.22). Fautrel 2016 (STRASS) defined flare as DAS28 > 2.6 with
an increase in DAS28 of > 0.6. They reported a higher
proportion of participants with flare in the anti-TNF disease
activity-guided dose tapering group compared to the anti-TNF
continuation group after 18 months’ follow-up (RR 1.64, 95%
CI 1.24 to 2.18). In van Herwaarden 2015 (DRESS),
participants had a flare if DAS28 increased > 1.2, or if DAS28
increased > 0.6 and current DAS28 was ≥ 3.2. The authors
reported a higher proportion of participants with flare in the
anti-TNF disease activity-guided dose tapering group compared
to the anti-TNF continuation group after 9 and 18 months (9
months: RR 2.68, 95% CI 1.58 to 4.56; 18 months: RR 2.68,
95% CI 1.74 to 4.13). van Herwaarden 2015 (DRESS) found
no difference in major flares (duration > 3 months) after 9 and
18 months (9 months: RR 1.71, 95% CI 0.37 to 7.96; 18
months: RR 1.22, 95% CI 0.50 to 2.98).
• Quality of life: Of the three studies included in this
comparison (365 participants), two studies, Fautrel 2016
(STRASS) and van Herwaarden 2015 (DRESS), reported on this
outcome, with 98 and 180 participants, respectively. Both
studies reported mean quality-adjusted life years (QALYs) of the
18-month study period. Fautrel 2016 (STRASS) found that the
anti-TNF disease activity-guided dose tapering group gained
fewer QALYs during the 18-month study period than the anti-
TNF continuation group (MD −0.158). No confidence
intervals were available. van Herwaarden 2015 (DRESS)
reported no difference between the anti-TNF disease activity-
guided dose tapering group versus the anti-TNF continuation
group (MD −0.02, 95% percentiles −0.06 to 0.02).
• Costs: Of the three studies included in this comparison
(365 participants), two studies, Fautrel 2016 (STRASS) and van
Herwaarden 2015 (DRESS), reported on this outcome, with 98
and 180 participants, respectively. Both studies reported lower
costs in the anti-TNF disease activity-guided dose tapering
group compared to the anti-TNF continuation group after 18
months’ follow-up (Fautrel 2016 (STRASS): MD EUR −8440.
No confidence intervals were available. van Herwaarden 2015
(DRESS): MD EUR −9051, 95% percentiles −10,278 to
−7731 (rectification submitted)).
• Decremental cost-effectiveness ratio: Of the three studies
included in this comparison (365 participants), two studies,
Fautrel 2016 (STRASS) and van Herwaarden 2015 (DRESS),
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reported on this outcome, with 98 and 180 participants,
respectively. Fautrel 2016 (STRASS) reported a decremental
cost-effectiveness ratio (DCER) of EUR 53,417 per QALY loss.
van Herwaarden 2015 (DRESS) reported a DCER of EUR
379,433 per QALY loss (rectification submitted).
• Time to flare: None of the three included studies reported
data on this outcome.
• Change in other medication: Of the three studies included
in this comparison (365 participants), one study with 180
participants reported on this outcome (van Herwaarden 2015
(DRESS)). No difference was found between the anti-TNF
disease activity-guided dose tapering group and the anti-TNF
continuation group after 18 months concerning use of
intramuscular or intra-articular glucocorticosteroids (RR 1.50,
95% CI 0.89 to 2.51); use of oral glucocorticosteroids (RR 0.65,
95% CI 0.24 to 1.79); DMARD initiation or dose escalation
(RR 3.90, 95% CI 0.93 to 16.41); and use of a DMARD (RR
0.88, 95% CI 0.71 to 1.10). The proportion of participants that
reduced the dose of their DMARD or discontinued the
DMARD after 18 months’ follow-up was lower in the anti-TNF
disease activity-guided dose tapering group compared to the
anti-TNF continuation group (RR 0.37, 95% CI 0.19 to 0.72).
Subgroup and sensitivity analyses
We planned to perform a subgroup analysis as described in the
Subgroup analysis and investigation of heterogeneity section.
However, because of the small number of included studies, anal-
yses were not informative.
We also planned to perform sensitivity analyses as described in the
Sensitivity analysis section. However, because of the small number
of included studies, analyses were not informative.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Anti-TNF discontinuation compared to anti-TNF continuation for rheumatoid arthritis in patients with low disease activity
Patient or population: people with rheumatoid arthrit is with low disease act ivity using a standard dose of ant i-TNF agents
Setting: clinical research centres
Intervention: ant i-TNF discont inuat ion
Comparison: ant i-TNF cont inuat ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments What happens
Risk with anti-TNF
continuation
Risk with anti-TNF
discontinuation
Disease activity
score -
assessed with:
DAS28
Scale f rom: 0.9 to
8; higher scores indi-
cate worse disease
act ivity
follow up: range 28
weeks to 52 weeks
Discontinua-
tion without restart-
ing, or with restart-
ing and LOCF analy-
sis
Mean disease act iv-
ity score was 2.82
MD 0.96 higher
(0.67 higher to 1.25
higher)
- 733
(2 RCTs)
⊕⊕⊕©
MODERATE 1
Absolute risk dif -
ference: 14% higher
(95%CI 9%higher to
18% higher)
Relat ive percentage
change: 25%(95%CI
18% higher to 33%
higher)
Ant i-TNF discont in-
uat ion probably in-
creases the dis-
ease act ivity score
slight ly
Proportion of par-
ticipants with per-
sistent remission
As-
sessed with: DAS28
< 2.6 (remission)
Follow-up: range 28
weeks to 52 weeks
RR values range f rom 0.16 to 0.77. Absolute risk dif f erences
range f rom 15% lower to 68% lower
1188
(6 RCTs)
⊕⊕©©
LOW 2
Data not pooled due
to heterogeneity.
Ant i-TNF discont in-
uat ion may re-
duce the propor-
t ion of part icipants
with persistent re-
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Proportion partici-
pants that switched
to another biologic
due to loss of re-
sponse - not mea-
sured
- - - - - No studies were
found that evalu-
ated the proport ion
of part icipants that
switched to another
biologic due to per-
sistent loss of re-
sponse
Proportion partici-
pants with minimal
radiographic pro-
gression
Assessed with:
mSvdH > 0.5
Follow-up: mean 52
weeks
105 per 1000 178 per 1000
(116 to 273)
RR 1.69
(1.10 to 2.59)
549
(3 RCTs)
⊕⊕⊕⊕
HIGH
Absolute risk dif -
ference: 7% higher
(95%CI 1%higher to
17% higher)
Relat ive percentage
change: 69% higher
(95% CI 10% higher
to 159% higher)
NNTH: 15 (95% CI 6
to 100)
Ant i-TNF discont in-
uat ion increases the
proport ion part ici-
pants with min-
imal radiographic
progression > 0.5
mSvdH point
Function
Assessed
with: Health Assess-
ment Quest ionnaire
Scale f rom 0 to 3;
higher scores indi-
cate worse funct ion-
ing
Follow-up: range 28
weeks to 52 weeks
The mean funct ion
was 0.52
MD 0.18 higher
(0.05 higher to 0.31
higher)
- 1498
(4 RCTs)
⊕⊕©©
LOW 2
Absolute risk dif -
ference: 6% higher
(95%CI 2%higher to
17% higher)
Relat ive percentage
change: 26% higher
(95%CI 7%higher to
44% higher)
Ant i-TNF discont in-
uat ion may lead to a
slight deteriorat ion
in funct ion
Number of serious
adverse events
Follow-up: range 28
weeks to 52 weeks
57 per 1000 74 per 1000
(47 to 116)
RR 1.29
(0.82 to 2.03)
2095
(8 RCTs)
⊕©©©
VERY LOW 134
Absolute risk dif -
ference: 2% higher
(95% CI 1% lower to
6% higher)
Relat ive percentage
change: 29% higher
It
is uncertain whether
ant i-TNF discont inu-
at ion inf luences the
number of serious
adverse events be-2
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(95%CI 18%lower to
103% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
cause the certainty
of the evidence is
very low and be-
cause of impreci-
sion
Withdrawals due to
adverse events
Follow-up: range 28
weeks to 52 weeks
27 per 1000 39 per 1000
(20 to 76)
RR 1.46
(0.75 to 2.84)
1116
(4 RCTs)
⊕⊕⊕©
MODERATE 3
Absolute risk dif -
ference: 1% higher
(95% CI 1% lower to
5% higher)
Relat ive percentage
change: 46%(95%CI
25% lower to 184%
higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
Ant i-
TNF discont inuat ion
probably slight ly in-
creases the number
of withdrawals due
to adverse events
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; DAS28: disease act ivity score in 28 joints; LOCF: last observat ion carried forward;MD: mean dif ference;mSvdH: modif ied Sharp van der Heijde; NNTH:
number needed to treat for an addit ional harmful outcome; RCT: randomised controlled trial: RR: risk rat io; TNF: tumour necrosis factor
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level due to heterogeneity (I2=61% for disease act ivity score and I2=31% for number of serious adverse
events).
2Downgraded two levels due to heterogeneity (I2=80% for proport ion of part icipants with remission and I2=79% for funct ion).
3Downgraded one level due to imprecision (low number of events).
4Downgraded one level due to concerns about study risk of bias (high risk of select ion bias, detect ion bias, attrit ion bias and
other bias).
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Anti-TNF disease activity-guided dose tapering compared to anti-TNF continuation for rheumatoid arthritis in patients with low disease activity
Patient or population: people with rheumatoid arthrit is with low disease act ivity using a standard dose of ant i-TNF agents
Setting: clinical research centres
Intervention: ant i-TNF disease act ivity-guided dose tapering
Comparison: ant i-TNF cont inuat ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments What happens
Risk with anti-TNF
continuation
Risk with anti-
TNF disease activ-
ity-guided dose ta-
pering
Disease activity
score
Assessed with:
DAS28
Scale f rom 0.9 to 8;
higher scores indi-
cate worse disease
act ivity
Follow-up: range 72
weeks to 78 weeks
The mean disease
act ivity score was 2.
34
MD 0.25 higher
(0.17 lower to 0.67
higher)
- 357
(3 RCTs)
⊕⊕©©
LOW 1
Absolute risk dif -
ference: 4% higher
(95% CI 2% lower to
9% higher)
Relat ive percentage
change: 10% higher
(95% CI 7% lower to
26% higher)
Ant i-TNF disease
act ivity-guided dose
tapering may result
in lit t le or no dif fer-
ence in disease ac-
t ivity score
Proportion of par-
ticipants with per-
sistent remission
As-
sessed with: DAS28
< 2.6 (remission)
Follow-up: 18
months
797 per 1000 709 per 1000
(597 to 844)
RR 0.89
(0.75 to 1.06)
180
(1 RCT)
⊕⊕⊕⊕
HIGH
Absolute risk dif f er-
ence: 9% lower (95%
CI 20% lower to 5%
higher)
Relat ive percentage
change: 10% higher
(95% CI 7% lower to
26% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
Ant i-TNF disease
act ivity-guided dose
tapering results in
lit t le or no dif fer-
ence in the propor-
t ion of part icipants
with persistent re-
m ission
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Proportion of par-
ticipants switched
to another biologic
due to loss of re-
sponse
Follow-up: 18
months
76 per 1000 47 per 1000
(19 to 117)
RR 0.62
(0.25 to 1.54)
317
(2 RCTs)
⊕⊕©©
LOW 2
Absolute risk dif f er-
ence: 3% lower (95%
CI 6% lower to 4%
higher)
Relat ive percentage
change: 38% higher
(95%CI 75%lower to
54% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
Ant i-TNF disease
act ivity-guided dose
tapering may result
in lit t le or no dif fer-
ence in the propor-
t ion of part icipants
that switch to an-
other biologic
Proportion of par-
ticipants with min-
imal radiographic
progression
Assessed
with: mSvdH score >
0.5 or > 1.0
Follow-up: mean 18
months
242 per 1000 352 per 1000
(187 to 662)
RR 1.45
(0.77 to 2.73)
312
(2 RCTs)
⊕⊕©©
LOW 34
Absolute risk dif -
ference: 11% higher
(95% CI 6% lower to
42% higher)
Relat ive percentage
change: 45% higher
(95%CI 23%lower to
173% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
Ant i-
TNF disease act iv-
ity-guided dose ta-
pering may slight ly
increase the propor-
t ion of part icipants
with minimal radio-
graphic progression
(mSvdH > 0.5 or > 1.
0)
Function
Assessed
with: Health Assess-
ment Quest ionnaire
Scale f rom 0 to 3;
higher scores indi-
cate worse funct ion
Follow-up: mean 18
months
The mean funct ion
was 0.4
MD 0.2 higher
(0.02 lower to 0.42
higher)
- 123
(1 RCT)
⊕⊕⊕©
MODERATE 4
Absolute risk dif -
ference: 7% higher
(95% CI 1% lower to
14% higher)
Relat ive percentage
change: 33% higher
(95% CI 3% lower to
70% higher)
Ant i-TNF disease
act ivity-guided dose
tapering probably
leads to a slight de-
teriorat ion of func-
t ion
3
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Number of serious
adverse events
Follow-up: 18
months
129 per 1000 160 per 1000
(54 to 477)
RR 1.24
(0.42 to 3.70)
317
(2 RCTs)
⊕©©©
VERY LOW 12
Absolute risk dif -
ference: 3% higher
(95% CI 8% lower to
35% higher)
Relat ive percentage
change: 24% higher
(95%CI 58%lower to
270% higher)
NNTH: not applica-
ble (not stat ist ically
signif icant)
It
is uncertain whether
ant i-TNF disease ac-
t ivity-guided dose
tapering inf luences
the number of seri-
ous adverse events
because the cer-
tainty of the evi-
dence is very low
and because of im-
precision
Withdrawals due to
adverse events - not
measured
- - - - - No studies were
found that evaluated
the number of with-
drawals due to ad-
verse events
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; DAS28: disease act ivity score in 28 joints; MD: mean dif ference; mSvdH: modif ied Sharp van der Heijde; NNTH: number needed to treat for an
addit ional harmful outcome; RCT: randomised controlled trial: RR: risk rat io; TNF: tumour necrosis factor
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded two levels due to heterogeneity (I2=70% for disease act ivity score and I2=69% for number of serious adverse
events).
2Downgraded two levels due to imprecision (insuf f icient sample size/ low number of events).
3Downgraded one level due to heterogeneity (I2=59%).
4Downgraded one level due to imprecision (insuf f icient sample size).
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D I S C U S S I O N
This is the first update of the original Cochrane Review first pub-
lished in 2014. We identified eight new studies for inclusion in
this update and additional data on old studies, which changed
some results. We retrospectively excluded one study that had been
included in the original review. Our main conclusions remained
largely the same.
Summary of main results
This systematic review summarises evidence from 14 studies (13
RCTs and one CCT) of down-titration of anti-TNF agents in peo-
ple with RA with low disease activity. We considered three down-
titration strategies to be sufficiently different to warrant separate
reviewing: (1) anti-TNF dose reduction, (2) anti-TNF discontin-
uation, and (3) anti-TNF disease activity-guided dose tapering.
We presented the available data on these strategies separately.
Anti-TNF dose reduction compared with anti-TNF
continuation
Six studies (three on etanercept, one on etanercept and adali-
mumab, one on certolizumab pegol, and one on all anti-TNF
agents) reported data on fixed anti-TNF dose reduction compared
with anti-TNF continuation. After pooling of data where possi-
ble, we can conclude that anti-TNF dose reduction leads to little
or no difference in mean disease activity, the proportion of partic-
ipants with persistent remission, number of serious adverse events
and withdrawals due to adverse events compared to continuation.
Also, anti-TNF dose reduction does not result in an important de-
terioration in function but probably slightly increases the propor-
tion of participants with minimal radiographic damage. Next to
this, anti-TNF dose reduction may slightly reduce the proportion
of participants switched to another biologic. We found no data on
important outcomes like cost-effectiveness.
Anti-TNF discontinuation compared with anti-TNF
continuation
Eight RCTs reported data on anti-TNF discontinuation com-
pared with anti-TNF continuation for all anti-TNF agents, but
mainly adalimumab and etanercept. Different types of outcome
measures were reported, and marked heterogeneity was present.
The results showed that anti-TNF discontinuation probably in-
creases the mean disease activity score slightly, and that the risk
ratio of persistent remission lies between 0.16 and 0.77 (data not
pooled). Anti-TNF discontinuation increases the proportion par-
ticipants with minimal radiographic progression of > 0.5 mSvdH
point per year and may lead to a slight deterioration in function
and probably slightly increases the number of withdrawals due to
adverse events. It is uncertain whether anti-TNF discontinuation
influences the number of serious adverse events due to very low-
certainty evidence. Again, we found no data on cost-effectiveness.
Anti-TNF disease activity-guided dose tapering compared
with anti-TNF continuation
Three studies (all anti-TNF agents, but again mostly etaner-
cept and adalimumab) compareddisease activity-guided anti-TNF
dose tapering with anti-TNF continuation. Anti-TNF disease ac-
tivity-guided dose tapering may result in little or no difference
in mean disease activity score and the proportion of participants
switched to another biologic. Furthermore, anti-TNF disease ac-
tivity-guided dose tapering results in little or no difference in the
proportion of participants with persistent remission. Next to this,
tapering may result in a slight increase in the proportion of partici-
pants with minimal radiographic progression and probably causes
a slight deterioration in function. It is uncertain whether anti-
TNF disease activity-guided dose tapering influences the number
of serious adverse events due to very low-certainty evidence. No
data were available on withdrawals due to adverse events. In the
two studies that reported on cost-effectiveness, costs were signifi-
cantly lower, and decremental cost-effectiveness ratios were found
to be between EUR 53,000 and EUR 379,000 per QALY lost.
Overall completeness and applicability of
evidence
The number of controlled studies on this matter is increasing, al-
though they are mostly limited to adalimumab and etanercept.
Data were available on all three strategies, although discontinu-
ation was studied most extensively. We considered the included
studies to be quite comparable clinically and decided to accept
some clinical heterogeneity in order to obtain more precision. One
study was reported as abstract only (Bejerano 2016 (OPTIBIO)).
Excluding the results reported in this abstract did not change our
conclusions.
An important issue remains that the superiority design of the fixed-
dose reduction or discontinuation studies hampers interpretability
and generalisability to clinical practice. With regard to the first is-
sue, these studies do provide point estimates about between-group
differences in important outcomes between the strategies, but they
do not compare these point estimates and their confidence in-
tervals with a prespecified relevant non-inferiority margin. Con-
sequently, independent of whether superiority tests demonstrate
a significant difference, the interpretation has to be made post
hoc whether this (non-)significant difference is relevant compared
to a non-inferiority claim, although this issue might become less
important in meta-analyses where sample sizes are large. Next to
this, the preferred method of analysis for non-inferiority trials is
per protocol, while an intention-to-treat analysis is favoured for
superiority trials. This hampers comparison of studies with differ-
ent approaches.With regard to generalisability, it seems important
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to mention that for patients and clinicians alike, the outcome of
fixed-dose reduction or discontinuation is valuable to know. How-
ever, it would be much more valuable to know whether disease
activity-guided dose reduction and discontinuation is non-infe-
rior with regard to important outcomes, as this supports shared
decision making with patients.
The participants included in these studies vary from early RA
with short treatment duration and no prior DMARD treatment
to longstanding, established RA patients who have been treated
for a long time with several other DMARDs, and also include
patients with and without concomitant DMARD. This increases
generalisability, although it also has been shown that no clinical
patient-, disease-, or treatment-related variable is clearly an effect
modifier for the chance of successful dose reduction or discontin-
uation (Tweehuysen 2017).
With regard to outcome measures, we noted that domains are of-
ten missing, such as functioning, radiographic damage progres-
sion, or cost (effectiveness). Also, when a domain is included as an
outcome, there is marked heterogeneity in the way the outcome is
assessed, leaving much room for improvement of outcome stan-
dardisation.
Quality of the evidence
Anti-TNF dose reduction compared with anti-TNF
continuation
Using the GRADE approach, we assessed the overall certainty of
evidence as high for two of the seven ’Summary of findings’ out-
comes in the anti-TNF dose reduction versus continuation com-
parison: mean disease activity and function. We assessed the cer-
tainty of the evidence for the proportion of participants with min-
imal radiographic progression as moderate because of imprecision.
We assessed the certainty of the evidence for the remaining four
main outcomes as low. For the proportion of participants with per-
sistent remission, this was the result of heterogeneity (downgraded
two times). For the proportion of participants that switched to
another biologic, this was due to concern about risk of bias in
the reporting study (downgraded two times). We downgraded the
evidence on the number of serious adverse events and the number
of withdrawals due to adverse events one level for risk of bias and
one level for imprecision.
Anti-TNF discontinuation compared with anti-TNF
continuation
The overall certainty of the evidence was high for one of the seven
’Summary of findings’ outcomes in the anti-TNF discontinuation
versus continuation comparison: proportion of participants with
minimal radiographic progression. We assessed the certainty of the
evidence for the outcomes mean disease activity and withdrawals
due to adverse events as moderate. We performed a subanalysis for
the outcome mean disease activity, since heterogeneity was present
between the studies that could be explained by the study charac-
teristics. We downgraded the evidence on mean disease activity
for discontinuation without restarting or with restarting and with
LOCF analysis one level because of imprecision. We downgraded
the evidence for mean disease activity with restarting and with-
out LOCF analysis one level due to concerns about risk of bias.
We downgraded the evidence on withdrawals one level because
of imprecision. We assessed the certainty of the evidence on the
proportion of participants with persistent remission and function
as low because of substantial heterogeneity (downgraded two lev-
els). Lastly, we assessed the certainty of the evidence on the num-
ber of serious adverse events as very low because of (1) concerns
about risk of bias, (2) moderate heterogeneity between effect es-
timates, and (3) imprecision. The included anti-TNF discontin-
uation studies did not report the proportion of participants that
switched to another biologic.
Anti-TNF disease activity-guided dose tapering compared
with anti-TNF continuation
The certainty of the evidence for the outcome proportion of par-
ticipants with persistent remission was high in the anti-TNF dis-
ease activity-guided dose tapering versus continuation compari-
son. The data came from one study with a low risk of bias, and
there were no other reasons to downgrade the certainty of the ev-
idence. We assessed the certainty of the evidence on function as
moderate because of imprecision. We assessed the certainty of the
evidence on mean disease activity as low because of heterogeneity
(downgraded two levels). We graded the certainty of the evidence
on the proportion of participants that switched to another bio-
logic as low because of imprecision (downgraded two levels). We
graded the certainty of the evidence on the proportion of partic-
ipants with minimal radiographic progression as low due to het-
erogeneity and imprecision. We assessed the certainty of the evi-
dence for serious adverse events as very low because of substantial
heterogeneity (downgraded two levels) and imprecision (down-
graded two levels). The included studies for this comparison did
not report on withdrawals due to adverse events.
Potential biases in the review process
Two review authors independently reviewed all titles and abstracts,
extracted data, and performed bias and quality assessment. Con-
sequently, errors in extraction have been minimised. Risk of bias
could not be completely assessed for some studies due to restricted
information despite efforts to obtain additional information from
study authors. Post-hoc decisions had to be made regarding the
presentation and pooling of outcomes (e.g. time of follow-up,
threshold values) which could have had implications on the re-
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sults. The authors have tried to be as transparent as possible about
choices that have been made, although they remain subjective.
Agreements and disagreements with other
studies or reviews
A few other systematic reviews have examined anti-TNF down-
titration, although the focus differed to some extent (Galvao 2016;
Kuijper 2015; Navarro-Millán 2013; Yoshida 2014). Galvao 2016
focused on discontinuation of biological DMARDs, and Kuijper
2015 on discontinuation of biologic and synthetic DMARDs.
Navarro-Millán 2013 investigated discontinuation of anti-TNF
agents specifically. The results of these reviews are comparable to
the findings in our review. The systematic review by Yoshida 2014
looked into the design and failure definitions in anti-TNF discon-
tinuation studies. The review authors concluded that heterogene-
ity can be seen across studies in both study design and failure defi-
nition. This is consistent with the findings reported in our review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review of the data has several implications for clinical practice
with regard to the three different strategies studied: dose reduc-
tion, discontinuation, and disease activity-guided tapering of anti-
tumour necrosis factor (anti-TNF).
Firstly, fixed-dose reduction of anti-TNF (especially etanercept)
in people with rheumatoid arthritis (RA) with at least three to
12 months of low disease activity is comparable with continuing
the standard dose with regard to mean disease activity, the pro-
portion of participants remaining in remission, and mean func-
tion. Consequently, an attempt to reduce the dose (or increase the
dosage interval) in people with low disease activity with RA on
full-dose anti-TNF seems sensible in clinical practice. It should be
mentioned, however, that all treatment changes in RA should be
done carefully on a background of ’treat to target’, that is guided
by disease activity. Dose reduction probably slightly increases the
proportion of participants withminimal radiographic progression.
Anti-TNFdose reductionmay cause little or no difference in num-
ber of serious adverse events andwithdrawals due to adverse events,
although certainty of evidence was low. This review showed that
slightly fewer participants undergoing anti-TNF dose reduction
may switch to another biologic disease-modifying antirheumatic
drug (bDMARD) compared to continuation. An explanation for
this might be that temporary disease flares (inherent to the disease)
are treated in the dose reduction group by increasing the dose,
while in the continuation group patients are switched to another
biologic.
Secondly, this review shows that anti-TNF discontinuation (with-
out disease activity-guided restarting of treatment) is an inferior
strategy compared with continuation of anti-TNF in terms of
disease control (mean disease activity and the proportion of par-
ticipants remaining in remission), minimal radiographic damage,
function and the number of withdrawals due to adverse events.
Although a sizeable proportion of patients can stop the anti-TNF
without deterioration, the large majority of patients who cannot
discontinue the drug are harmed if the treatment is not reinstated.
The effect of discontinuation on the number of serious adverse
events remains uncertain. However, given the current evidence,
discontinuation should not be attempted without regular assess-
ment of disease activity, setting a treatment goal, and reinstate-
ment of treatment when necessary.
The abovementioned findings converge finally in the evidence
on the disease activity-guided dose tapering strategy. This review
shows that disease activity-guided tapering is comparable to con-
tinuation with regard to mean disease activity, the proportion of
participants remaining in remission and the proportion of partici-
pants switched to another biologic. Tapering may result in a slight
increase in the proportion of participants with radiographic pro-
gression and probably leads to a slight deterioration in function.
The effect of disease activity-guided dose tapering of anti-TNF on
the number of serious adverse events and withdrawals due to ad-
verse events could not be determined with certainty. This evidence
is similar to that for fixed-dose reduction. Because disease activity-
guided dose tapering provides the opportunity to find the lowest
effective dose for each individual patient and to discontinue treat-
ment as the final step of the tapering process, this may be the most
cost-effective and feasible approach in clinical practice. Since un-
certainty remains on several important outcome measures, more
data on, for example, radiographic damage progression, function,
(serious) adverse events, and costs are warranted.
With respect to interpretation, it should be noted that the burden
of proof in this case does not lie solely with dose reduction or
stopping compared with continued use. To our knowledge, no
controlled data are available on anti-TNF continued use after week
52, including all registration studies. Consequently, there remains
equipoise on what is the best strategy after one year of treatment
with anti-TNF.
Implications for research
Our review highlights what is already known about anti-TNF
down-titration in people with low RA disease activity, and on the
other hand identifies gaps in our knowledge. Here we would like
to mention a number of aspects that could be targeted in future
studies.Of note,most of these points are currently being addressed
in several ongoing studies.
• The design selected for studies comparing an anti-TNF
down-titration strategy versus an anti-TNF continuation strategy
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should include a non-inferiority approach instead of the classical
superiority analyses, as the aim is to maintain and not improve
clinical outcomes, while minimising the amount of treatment
that is needed. Superiority analyses can be reserved for domains
were superiority can be expected, such as drug use, infections,
and costs. As guidelines for performing a systematic review on
non-inferiority studies are absent, development of such
guidelines would be helpful.
• The intervention should include disease activity-guided
dose tapering or stopping of the anti-TNF agent using tight
control/treat to target instead of fixed-dose adaptation or
stopping, as the former is more compatible with clinical practice.
• The domain in which an intervention should be non-
inferior is long-term RA disease control. Although temporary
flaring will inevitably be seen more often in the trial-and-error
dose-tapering arm, both the incidence of more severe or
prolonged flaring and mean disease activity at study end should
be comparable.
• Consequently, in addition to mean disease activity at study
end, cumulative incidence of a validated RA flare criterion could
be used. Use of (one of ) validated Outcome Measures in
Rheumatology Clinical Trials (OMERACT) disease activity
score in 28 joints (DAS28)-based flare criteria should be
considered (van der Maas 2013 Flare). Use of a validated flare
criterion also increases standardisation for future meta-analyses.
• Other outcomes besides disease activity that should be
included are cost, quality of life, cost-effectiveness, and (long-
term) safety, because these constitute the reason why down-
titration is contemplated in the first place.
• The drugs that are studied should preferably also include
other anti-TNF agents like certolizumab pegol, golimumab, and
infliximab.
• Prediction of (un)successful dose tapering would perhaps
further improve outcomes of individualised disease activity-
guided dose tapering, and prediction modelling should be
considered, using, for example, genetics, imaging, biomarkers,
and drug levels. Possible gains when using a good prediction rule
include (1) prevention of unnecessary flaring in patients that
cannot be dose reduced; and (2) prevention of months of slow
dose tapering in patients that can be stopped directly.
• Finally, although outside the scope of this review, efforts
should be (and already are) directed toward other non-anti-TNF
biologicals (abatacept, tocilizumab) and toward other
inflammatory diseases in which biologicals are used, both within
rheumatology (ankylosing spondylitis, psoriatic arthritis) and
within other medical specialties (gastroenterology, dermatology).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bejerano 2016 (OPTIBIO)
Methods Open, randomised and controlled study in a hospital in Spain
Participants Inclusion criteria:
• RA
• treated with anti-TNF therapies (etanercept, infliximab, adalimumab,
certolizumab, golimumab), tocilizumab and abatacept
• in clinical remission (DAS28 < 2.6 or SDAI < 5 or ACR/EULAR 2011 criteria) at
least 6 months followed in Third level Hospital Rheumatology Department
Exclusion criteria: none described
Baseline characteristics: not reported
Interventions Participants are assigned to 2 groups randomly:
• Intervention group: according to a standardised protocol of dose reduction of
biological therapies (n = 32, n = 23 for anti-TNF)
• Control group: according to standard dose regimen (n = 34, n = 25 for anti-TNF)
Outcomes Primary endpoint is to evaluate the proportion of patients that after 1 year are maintained
in clinical remission with a dose reduction treatment regimen of biological therapy in
people with RA, and to evaluate if the proportion of participants in remission with new
regimen dose of treatment is not inferior to participants in remission with standard dose
regimen
Analyses: ITT
Notes Acronym: OPTIBIO
At time of review, study presented in abstract form only (preliminary results)
EudraCT: 2012-004482-40
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described in this abstract
Allocation concealment (selection bias) Unclear risk Not described in this abstract
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk “Open-label study”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
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Bejerano 2016 (OPTIBIO) (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Open-label study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement of ‘low risk’ or
‘high risk’
Selective reporting (reporting bias) Unclear risk Study protocol available. Not all outcome
measures described in this abstract
Other bias Unclear risk Insufficient information to assess whether
an important risk of bias exists
Chatzidionysiou 2016 (ADMIRE)
Methods 52-week, multicentre, randomised, controlled, open-label pilot study in Sweden
Participants Inclusion criteria:
• age ≥ 18 years
• diagnosis of RA based on the 1987 revised ACR classification criteria, positive RF
or at least 1 erosion on the radiograph of hands or feet
• treatment with adalimumab in the approved dose of 40 mg every other week for
at least 6 months; concomitant treatment with methotrexate at a dose of at least 10
mg/week for a minimum of 6 months (stable dose for a minimum of 2 months)
• stable remission according to the DAS28 (DAS28 < 2.6) for at least 3 months
based on assessments at study entry = baseline and on at least 1 more occasion 3 to 6
months prior to baseline, documented in patient record or registry
• concomitant corticosteroids were allowed if the dose was 10 mg/day or less
(prednisolone or equivalent) and had been stable for at least 3 months at baseline
Baseline characteristics: median age 61 (IQR53 to 65) years, 65% female,median disease
duration 8 (IQR 5 to 16) years, median DAS28 1.9 (IQR 1.55 to 2.39), median number
of previous DMARDs 2 (IQR 1 to 3), median number of previous bDMARDs 0 (IQR
0 to 1)
Interventions People fulfilling the inclusion criteriawere randomised in a 1:1 ratio to armAM(continue
with adalimumab andmethotrexate) or to armM(discontinue adalimumab and continue
with methotrexate monotherapy) for 52 weeks. Any participant experiencing disease
“flare” at any visit could continue in the rescue arm, where adalimumab would be re-
instituted. Disease flare was defined as DAS28 ≥ 2.6 or a change in DAS28 (1DAS28)
> 1.2 from baseline at any time
• M arm: discontinue adalimumab and continue methotrexate (n = 15)
• AM arm: continue both adalimumab and methotrexate (n = 16)
Outcomes Primary outcome: proportion of participants in remission (DAS28 < 2.6) at week 28 in
both arms
Secondary outcomes:
• Incidence of disease flare (DAS28 ≥ 2.6 or a 1DAS28 > 1.2 from baseline at any
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Chatzidionysiou 2016 (ADMIRE) (Continued)
time)
• Incidence of at least 1 DAS28 ≥ 2.6 from baseline to week 28
• Incidence of at least 1 1DAS28 > 1.2 from baseline to week 28
• Proportion of participants with at least 1 of the following from baseline to week
28: 1DAS28 > 0.6, DAS28 ≥ 2.6 AND 1DAS28 > 1.2, DAS28 ≥ 2.6 AND
1DAS28 > 0.6
• Proportion of participants in DAS28 remission at week 52
• Flare-free survival during the first 28 weeks
• Change in functional status (assessed by HAQ) at week 28
• Change in radiological status (analysis of radiographic data at week 52)
• Frequency of remission according to the EULAR/ACR Boolean remission criteria
• Adverse events
Analyses: ITT; non-responder imputation (i.e. “flare” imputed) was performed for par-
ticipants with no available DAS28 score at week 28 (this included most participants who
had a flare in the M arm and who restarted treatment with adalimumab)
Notes Acronym: ADMIRE
Pilot study
Funding: AbbVie
Disclosures: KC has received consultancy fees and/or speaker honoraria from Pfizer
and Roche. CT has received consultancy fees and/or speaker honoraria from AbbVie,
Bristol-Myers Squibb, Janssen,MSD, Pfizer, Roche,Novartis, andUCB, and has received
unrestricted research grants fromAbbVie, Pfizer, andRoche. KFhas received consultancy
fees and/or speaker honoraria from AbbVie, Bristol-Myers Squibb, MSD, and Pfizer.
RvV has received research support and/or honoraria from AbbVie, Biotest, BMS, GSK,
Lilly, Merck, Pfizer, Roche, UCB, and Vertex. MH is an employee of AbbVie
EudraCT: 2008-004398-16
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described; “The randomization was 4
patients in each block”
Allocation concealment (selection bias) Low risk “Use of an independent person and a
sealed, opaque envelope system”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk “Open-label study”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Open-label study”
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Chatzidionysiou 2016 (ADMIRE) (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias Low risk The study appears to be free of other
sources of bias.
El Miedany 2016
Methods 12-month randomised controlled trial
Participants Inclusion criteria:
• RA for at least 18 months
• sustained clinical remission with a DAS28 based on ESR of < 2.6 for at least 6
months. Remission had to be assessed clinically and documented at least at 3 sequential
visits covering a screening period of 6 months.
• stable treatment with csDMARDs (methotrexate, leflunomide,
hydroxychloroquine, and sulfasalazine) as well as bDMARD therapy (infliximab,
adalimumab, etanercept, golimumab, certolizumab, tocilizumab, or abatacept) without
alteration in dose for at least 6 months
Exclusion criteria:
• patients receiving rituximab or those taking oral steroids within 12 months prior
to screening were excluded from the study
Baseline characteristics: mean (SD) DAS28 group 1: 1.97 (0.4), group 5: 2.2 (0.5); RF+
group 1: 55%, group 5: 56%; ACPA+ group 1: 61%, group 5: 59%
Interventions Participants were randomised 1:1:1:1:1 to 5 groups (group 1 and 5 of interest for this
review):
• Group 1 (n = 32): (tapering) reduced the bDMARDs by 50% whilst continuing
to take the full csDMARD(s) therapy dose
• Group 2 (n = 32): (tapering) reduced the dose of both csDMARD and bDMARD
therapy by 50%
• Group 3 (n = 32): (stop) stop bDMARD therapy whilst reducing csDMARD(s)
dose by 50
• Group 4 (n = 32): stop both csDMARD and bDMARD therapy
• Group 5 (n = 32): (control group continuation) kept existing bDMARD as well
as csDMARD
Outcomes Primary endpoint was the maintenance of remission for 12 months. Secondary end-
point was identifying the potential predictors, whether ultrasonographic, clinical, or lab
measures, for relapses in patients tapering and/or stopping DMARD(s) and/or biologic
therapy
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El Miedany 2016 (Continued)
Analyses: ITT
Notes This study included participants using anti-TNF as well as non-anti-TNF. The authors
provided data for the participants using anti-TNF only for this review
Disclosures: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk Blinding not described, however very unlikely
due to the absence of a description of placebo
treatment
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome measure assessment was unblinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant lost to follow-up, in group
1.
Selective reporting (reporting bias) Unclear risk No study protocol present, therefore insuffi-
cient information to permit judgement of ‘low
risk’ or ‘high risk’
Other bias Low risk The study appears to be free of other sources
of bias.
Fautrel 2016 (STRASS)
Methods 18-month, multicentre randomised controlled equivalence trial in France
Participants Inclusion criteria:
• ≥ 18 years old
• diagnosis of RA according to the 1987 ACR classification criteria
• received subcutaneous injections of etanercept or adalimumab at a standard and
stable dosage (i.e. 50 mg weekly for etanercept or 40 mg every other week for
adalimumab) for at least 1 year as monotherapy or combined with a stable csDMARD
(methotrexate or leflunomide) for at least 6 months
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Fautrel 2016 (STRASS) (Continued)
• prednisone was allowed if daily doses were stable and at ≤ 5 mg for at least 6
months
• patients needed to be in clinical remission according to the DAS28 (i.e. DAS28 ≤
2.6) for at least 6 months with no structural damage progression seen on hand and foot
X-rays in the year before inclusion according to the treating rheumatologist
Exclusion criteria
• contraindications to TNF-blocker therapy maintenance
• prednisone use > 5 mg/day
• planned surgical intervention or pregnancy within the 18-month study period
• women of childbearing age without efficacious contraception
• history of cancer
• diagnosis of an autoimmune disorder other than RA
• non-affiliation with the French social security system
• presence of factors preventing informed consent or protocol adherence (e.g.
inability to communicate in the French language, mental incapacity, guardianship)
Baseline characteristics: age (mean, SD) 55.6 (11.2) years, female 78%, disease duration
9.5 (8.0) years, 69% rheumatoid factor positive, 78% anti-CCP positive, DAS28 1.
8 (0.6), 54% etanercept, 46% adalimumab, number of previous DMARDs 2.7 (1.7),
percentage of participants with previous bDMARD treatment 24%
Interventions Participants were randomised into 1 of 2 arms: maintenance of the subcutaneous injec-
tions at the standard full regimen (M-arm) or injections spacing by 50% every 3 months
up to complete stop (S-arm). Spacing was reversed to the previous interval in case of
relapse, and eventually reattempted after remission was re-achieved
• Spacing arm: n = 64
• Maintenance arm: n = 73
Outcomes Primary outcome: evolution in RA inflammatory activity over 18 months as measured
by the DAS28 every 3 months
Secondary outcomes:
• Evolution of RA inflammatory activity during the 18 months as measured by the
DAS44 every 3 months
• Evolution of functional ability over 18 months as measured by the HAQ score
• Relapse during the 18 months defined as DAS28 > 2.6 with DAS28 increase > 0.
6 since the previous study visit
• X-ray damage progression assessed by mSvdH (progression defined as change in
mSvdH score > 1)
• Safety of the 2 strategies: rate of non-serious and serious adverse events
Analyses: primary analysis PP, supplemented by an ITT analysis
Notes Acronym: STRASS
Funding: the trial was conducted under the auspices of the CRI-IMIDIATE clini-
cal research FCRIN network. Institutional support by a grant from the Ministry of
Health (PHRC national 2007, AOM 07 127/P 070120), France. The sponsor was
the Département à la Recherche Clinique et au Développement, Assistance Publique-
Hôpitaux de Paris
Disclosures: none declared
EudraCT: 2007-004483-41
ClinicalTrials.gov: NCT00780793
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Fautrel 2016 (STRASS) (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation list was generated by
use of a computer-generated sequence with
blocks of variable (2-6) andundisclosed size
stratified by centre and TNF-blocker (ie,
ETA or ADA)”
Allocation concealment (selection bias) Low risk “Treatment allocation was concealed to
patients, research staff and clinical staff
until randomisation by use of an inter-
net-based randomisation module (Clean-
web, Telemedecine technologies S.A.S,
Boulogne-Billancourt, France).”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk Open study
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Most important outcome assessments
(DAS28 and X-ray) blinded. Other out-
comes likely to be influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias High risk Number of included participants was lower
than anticipated in the sample size calcula-
tion
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Ghiti Moghadam 2016 (POEET)
Methods 12-month, open-label randomised controlled study in the Netherlands
Participants Inclusion criteria:
• age > 18 years
• RA diagnosis according to the ACR 1987 criteria, anti-TNF treatment for at least
1 year with stable concomitant csDMARDs use for at least 6 months prior to inclusion
• patients were in remission or had stable low disease activity for at least 6 months,
defined as either DAS28 < 3.2 or the rheumatologist’s clinical impression of remission
or stable low disease activity in combination with a baseline DAS28 < 3.2 and at least 1
CRP level < 10 mg/L in the 6 months prior to inclusion
There were no exclusion criteria.
Participant characteristics: mean (SD): age intervention 60.0 (11.8), control 59.7 (10.
6); female: intervention 68%, control 66%; disease duration: intervention 12.0 (8.8),
control 11.1 (8.4); previous bDMARD: intervention 13.4%, control 15%
Interventions Participants were randomised 2:1 to either stop or continue their anti-TNF. All other
medications, including csDMARDs, glucocorticoids, and NSAIDs, were left at the dis-
cretion of the treating rheumatologist and were continued unchanged as much as possi-
ble. In case of flare, defined as a DAS28 ≥ 3.2 plus an increase ≥ 0.6 compared to the
baseline DAS28, anti-TNF treatment could be restarted in the stop group or switched
in the continuation group
• 531 participants stopped their anti-TNF therapy.
• 286 continued their anti-TNF therapy.
Outcomes Primary outcome: percentage of participants who experienced a flare (DAS28≥ 3.2 and
DAS28 increase ≥ 0.6) of RA during the first year
Secondary outcomes:
• Time to flare
• Change in DAS28 from baseline
• Change in functional status
• Number of participants and time to regain remission (DAS28 < 2.6) or low
disease activity (DAS28 < 3.2) after restarting anti-TNF (only in stop group)
• Proportion of participants with (serious) adverse events
Analyses: ITT with participants that were correctly included
Notes Acronym: POEET
Dutch trial register: NTR3112
Funding: The Netherlands Organization for Health Research and Development
(ZonMw)/Government of the Netherlands, Ministry of Health, Welfare and Sport
(VWS)
Disclosures: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer block randomization was used
to achieve balance in allocation per center.
”
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Ghiti Moghadam 2016 (POEET) (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk “Open-label study”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Open-label study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias High risk The flare criterion differs between the trial
register and the final publication, which
might have introduced risk of bias
Ibrahim 2017 (OPTTIRA)
Methods Open-label, 6-month, multicentre randomised controlled proof-of-principle trial in the
United Kingdom
Participants 103 RA patients receiving etanercept or adalimumab plus a DMARD who achieved
sustained good responses with DAS28 scores of ≤ 3.2 without increases of > 0.6 during
the previous 3 months
Baseline characteristics: mean (SD): age 57 (11), female 74%, median disease duration
11.3 (IQR 7.3 to 16.7)
Interventions Participants were randomised 1:1:2 to:
• dose reduction of 66% (n = 21);
• dose reduction of 33% (n = 26);
• continuation (n = 50).
Note: in months 6 to 12, controls tapered anti-TNF and experimental groups discon-
tinued anti-TNF (data not included in review)
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Ibrahim 2017 (OPTTIRA) (Continued)
Outcomes Primary outcome: time to first flare, defined as an increase in DAS28 scores ≥ 0.6
resulting in a DAS28 > 3.2 together with an increase in the swollen joint count; both
had to be present on 2 occasions at least 1 week apart. An increase in DAS28 score ≥ 1.
2 resulting in DAS28 > 3.2 was defined as flare irrespective of changes in swollen joints
Secondary outcomes:
• Function: HAQ
• Quality of life: EQ-5D, SF-36, FACIT
• Radiographic damage: X-ray, modified Larsen scores
• DAS28-ESR
Analyses: ITT, participants without flares who withdrew or were lost to follow-up were
censored at the time of their last visit
Notes Acronym: OPTTIRA
The trial was funded by Arthritis Research UK (grant reference number 18813)
Disclosures: JBG has received honoraria for speaking from UCB, Pfizer, Celgene, and
Bristol-Myers Squibb. All other authors declared no conflicts of interest
EudraCT: 2010-020738-24
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation by online electronic data
capture system using minimization proto-
col with randomly permuted blocks”
Allocation concealment (selection bias) Low risk “Trial team were blinded to allocation pro-
cess and sequences”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk Open-label study
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study, and most outcomes
likely to be influenced. “X-ray reading was
blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers of participants included in differ-
ent analysis sets clearly described. 100% of
participants included in ITT analyses
Selective reporting (reporting bias) Low risk Study protocol available; similar outcome
measures in the paper compared to the pro-
tocol
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Ibrahim 2017 (OPTTIRA) (Continued)
Other bias Low risk The study appears to be free of other
sources of bias.
Pavelka 2017
Methods 52-week, double-blind, multicentre randomised controlled study in locations around
the world
Period 1: 24 weeks open-label; period 2: 28 weeks double-blind
Participants Inclusion criteria (period 1):
• individual has a minimum 1-year history/diagnosis of rheumatoid arthritis based
on the 1987 ACR Revised criteria for RA
• individual must have active moderate to severe rheumatoid arthritis despite
methotrexate therapy of ≥ 10 mg/week for at least 12 weeks. The methotrexate dose
must be stable for at least 4 weeks immediately prior to screening.
• age 18 to 70 years
Exclusion criteria (period 1):
• individuals who used any of the following systemic treatments during the washout
periods given below:
◦ oral corticosteroid dose of prednisone > 7.5 mg/day (or equivalent) or a
change in dose within 28 days of baseline
◦ treatment with more than 1 NSAID within 14 days of baseline
◦ methotrexate dose greater than 25 mg/week, or change in the dose of
methotrexate within 28 days of baseline
◦ participants will be allowed to continue the following non-biologic
DMARDs: sulfasalazine, hydroxychloroquine, and leflunomide. All other non-biologic
DMARDs (including but not limited to gold, penicillamine, azathioprine,
cyclophosphamide) and biologic DMARDs must have been discontinued at least 2
months prior to week 1.
◦ any biologic B cell depleting agent (e.g. rituximab) within 2 years of week 1
• receipt of any live (attenuated) vaccine within 4 weeks prior to baseline
Inclusion criteria (period 2):
• individuals achieving low disease activity (DAS28 < 3.2) after period 1
Baseline characteristics: mean (SD): age: intervention 47.2 (11.8), control 46.1 (12.9)
; female: intervention 85%, control 83%; symptom duration in years: intervention 8.3
(6.8), control 8.0 (7.4); prior csDMARD (not MTX): intervention 34%, control 38%
Interventions Period 1:
• Etanercept 50 mg once weekly + methotrexate with or without other DMARDs
(n = 489)
Period 2:
• Group A: etanercept 50 mg once weekly + methotrexate with or without other
DMARDs (n = 169)
• Group B: etanercept placebo once weekly + methotrexate with or without other
DMARDs (n = 177)
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Pavelka 2017 (Continued)
Outcomes Primary outcome measure: proportion of participants who remained in LDA (DAS28
< 3.2) at week 52 without rescue medication
Secondary outcome measures:
• Proportion of remission and LDA
• Proportion of flare
• Change in DAS28, CDAI, SDAI
• Adverse events
• HAQ-DI
• EQ-5D
Analyses: ITT with LOCF approach on the full analysis set, which included participants
who had taken at least 1 dose of study medication and had at least 1 DAS28-ESR
evaluation
Notes EudraCT: 2011-005448-87
ClinicalTrials.gov: NCT01578850
Funding: Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Screening, enrollment, and randomiza-
tion were accomplished using an auto-
mated internet/telephone randomization
system (i.e., the Interactive Web Response
System).”
Allocation concealment (selection bias) Low risk “Screening, enrollment, and randomiza-
tion were accomplished using an auto-
mated internet/telephone randomization
system (i.e., the Interactive Web Response
System).”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk The study was participant-, investigator-
, and sponsor-blinded. Prefilled syringes
were labelled in such a way that partici-
pants’ treatment assignment could not be
determined
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk “Double-blind trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind trial”
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Pavelka 2017 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data < 10% and balanced
in numbers across intervention groups,
with similar reasons for missing data across
groups
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias Low risk The study appears to be free of other
sources of bias.
Raffeiner 2015
Methods Open-label quasi-randomised controlled study in a hospital in Italy
Participants Inclusion criteria:
• individuals with RA as defined by 1987 ACR treated with etanercept 25 mg
biweekly after the failure of traditional synthetic DMARDs
• among this cohort, individuals with DAS28-ESR < 2.6 for at least 12 months
Baseline characteristics: mean (SD): age: intervention 55.7 (13.5), control 55.6 (12.8);
female: intervention 85%, control 81%; disease duration: intervention 14.3 (9), control
13.4 (5.9); number of previous DMARDs: intervention 2.4 (1.1), control 2.4 (1.3)
Interventions Participants were randomised to 1 of the following 2 subcutaneous dose regimens: etan-
ercept 25 mg weekly (group A) or etanercept 25 mg biweekly (group B). The randomi-
sation was done in a consecutive manner, 1:1, and treatment was continued until disease
flare-up
• Group A, half dose etanercept: n = 159
• Group B, standard dose etanercept: n = 164
Outcomes Primary outcome: maintained DAS28 remission (DAS28 < 2.6)
Secondary outcomes:
• Clinical and laboratory evidence of adverse events
• Joint damage
Analyses: ITT
Notes Funding: This study was supported in part by AIFA (Agenzia Italiana del Farmaco)
Disclosures: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
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Raffeiner 2015 (Continued)
Random sequence generation (selection
bias)
High risk “The randomisation was done according to
the order of the recruitment. The first pa-
tient recruitedwas allocated to groupA, the
second one to group B, and so on.” Com-
ment: semi-randomisation
Allocation concealment (selection bias) High risk Predictability of allocation due to consecu-
tive randomisation
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk “Patients, physicians and study nurses were
not blinded.”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study, and most outcomes
likely to be influenced; “the radiologist was
blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Unclear risk No study protocol present, therefore insuf-
ficient information to permit judgement of
‘low risk’ or ‘high risk’
Other bias High risk No study protocol present, but information
from earlier abstract indicates that inclu-
sion criteria, outcome measures, and dura-
tion of follow-up have changed over time
Smolen 2013 (PRESERVE)
Methods 88-week, randomised, placebo-controlled trial in 80 centres in Europe, Latin America,
Asia, and Australia
Open-label period: weeks 0 through 36. Randomisation at week 36. Double-blind pe-
riod: weeks 36 through 88
Participants Open-label period:
• Inclusion criteria: rheumatoid arthritis, aged between 18 and 70 years, moderate
disease activity at screening and at baseline (DAS28 > 3.2 and ≤ 5.1), stable
methotrexate (15 to 25 mg/week) for at least 8 weeks before screening
• Exclusion criteria: previous/current biologicals, DMARD other than
methotrexate within 28 days of baseline, more than 1 NSAID at baseline, prednisone >
10 mg/d or a dose that was changed within 14 days of screening, IA or IV or IM or SC
glucocorticoids within 28 days of screening, live vaccine within 28 days of baseline,
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Smolen 2013 (PRESERVE) (Continued)
tuberculosis in the previous 2 years, latent tuberculosis infection and not treated
according to local guidelines or not started before etanercept
Double-blind period:
• Inclusion criteria: completed the open-label stage, sustained low disease activity
(mean DAS28 ≤ 3.2 from weeks 12 to 36 and DAS28 ≤ 3.2 at week 36)
• Exclusion criteria: dose of NSAID or prednisone changed within 14 days of
randomisation, prednisone > 10 mg/d, methotrexate dose changed within 8 weeks of
randomisation (except for reducing dose because of adverse events)
Baseline characteristics:
• Etanercept 50 mg/week (n = 202): age (mean, SD) 48.1 (12.0) years, 164 (81%)
female, disease duration 6.8 (7.2) years, 147 (73%) RF positive, 161 (80%) anti-CCP
positive, DAS28 at week 36: 2.0 (0.6)
• Etanercept 25 mg/week (n = 202): age (mean, SD) 46.4 (12.2) years, 157 (78%)
female, disease duration 6.4 (7.1) years, 142 (71%) RF positive, 156 (78%) anti-CCP
positive, DAS28 at week 36: 2.1 (0.6)
• Placebo (n = 200): age (mean, SD) 48.3 (12.2) years, 167 (84%) female, disease
duration 7.3 (6.7) years, 147 (74%) RF positive, 156 (79%) anti-CCP positive,
DAS28 at week 36: 2.1 (0.6)
Interventions Open-label period:
• Etanercept 50 mg/week + MTX (n = 834)
Double-blind period:
• Etanercept 50 mg/week + MTX (n = 202), etanercept 25 mg/week + MTX (n =
202), placebo + MTX (n = 200)
• Methotrexate dose maximum 25 mg/week
Outcomes Primary outcome (double-blind period): proportion of participants with DAS28 ≤ 3.
2 in the etanercept 50 mg/week versus placebo group at week 88 (52 weeks after ran-
domisation)
In case of significantly more low disease activity in the etanercept 50 mg/week group
compared with the placebo group, the conditional primary endpoint was proportion of
participants receiving etanercept 25 mg/week who achieved DAS28 ≤ 3.2
Secondary outcomes:
• Remission (DAS28 < 2.6, SDAI ≤ 3.3, ACR/EULAR Boolean-based definition)
• LDA (SDAI ≤ 11)
• ACR20, ACR50, or ACR70 response
• EULAR good or moderate response
• Physical function HAQ-DI
• Change from baseline in DAS28, CDAI, SDAI
• Change from baseline in TJ counts, SJ counts, CRP, ESR
• Change from baseline in morning stiffness
• Change from baseline in participant global, GH and pain
• Change from baseline in physician global
• Time to loss of efficacy (loss of DAS28 LDA and change in DAS28 ≥ 0.6;
discontinuation due to poor efficacy, protocol violation, or other reason)
• Participant-reported outcomes: HAQ-DI, EQ-5D total, medical outcomes, study
sleep scale, functional assessment of chronic illness, therapy measurement, brief pain
inventory, work productivity and activity impairment scale for RA
• Radiographic outcome (proportion of participants - non-progressors - achieving
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Smolen 2013 (PRESERVE) (Continued)
an mSvdH score progression rate of up to 0.5 units per year or up to 2.0 units per year
(smallest detectable difference))
• Adverse events
Analyses: modified ITT population made up of participants who had received at least 1
dose of study drug and had 1 or more DAS28 evaluations. A modified non-responder
analysis was done in which participants who discontinued early because of poor efficacy
were imputed as non-responders for all time points; all other participants were analysed
with the LOCF method
Notes Acronym: PRESERVE
Funding: “PRESERVE was sponsored by Wyeth, which was acquired by Pfizer in Oc-
tober 2009. Pfizer was responsible for data collection and analyses. The academic au-
thors and sponsors representatives were involved in the study design, data analyses, data
interpretation, writing of the report, and the final decision to submit for publication.
Biostatisticians at Pfizer did and verified all data analyses. The corresponding author had
full access to all data in the study and had final responsibility for the decision to submit
for publication.”
Disclosures: JSS has received honoraria for consultations or speaking engagements, or
grant support, or both, from Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, Cel-
gene, GlaxoSmithKline, MSD, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, and UCB.
PN has received grant support and honoraria for consultations from Pfizer. FI-P has
received grant support and honoraria for consultations or speaking engagements from
Bristol-Myers Squibb, Janssen, Pfizer, and Roche. PM has received grant support from
Abbott, Bristol-Myers Squibb, Celltrion, Centocor, GlaxoSmithKline, Human Genome
Sciences,Merck,Neovacs, and Pfizer. KP has received honoraria for lectures fromAbbott,
Fidia, MSD, Pfizer, Roche, and UCB. RP, CH, ASK, and BV are employees of Pfizer
and own Pfizer stock. AS is an employee of Inventive Health, who are paid contractors
for Pfizer, providing statistical support for the PRESERVE study and the development
of this report. The other authors declare that they have no conflicts of interest
EudraCT: 2007-000896-41
ClinicalTrials.gov: NCT00565409
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly assigned by a centralised sys-
tem”
Allocation concealment (selection bias) Low risk “allocation of patients to treatment groups
was done with the ICOPhone interactive
voice response system on the basis of infor-
mation supplied by the investigator or the
study staff ”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk “patients, investigators, data-analysts and
study staff were all masked to treatment al-
location”
“etanercept packages for each patient were
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Smolen 2013 (PRESERVE) (Continued)
identical”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk “Double-blind trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “patients, investigators, data-analysts and
study staff were all masked to treatment al-
location”
Incomplete outcome data (attrition bias)
All outcomes
High risk “Patients who discontinued early because
of poor efficacy were imputed as non-re-
sponders for all time points”
“Significantly more patients discontinued
in group given placebo than in 50 mg and
25 mg groups”
Selective reporting (reporting bias) Low risk Study protocol available; similar outcome
measures in the paper compared to the pro-
tocol
Other bias Low risk The study appears to be free of other
sources of bias.
Smolen 2014 (OPTIMA)
Methods 78-week, multicentre, randomised, double-blind, placebo-controlled trial in 161 sites
across Europe (n = 71), North America (n = 73), South America (n = 5), Africa (n = 6),
Australia (n = 3), and New Zealand (n = 3)
Period 1: weeks 0 through 26, re-randomisation at week 26; period 2: weeks 26 through
78
Participants Period 1:
• Inclusion criteria: eligible patients were aged 18 years or older with active RA (<
1-year duration) according to1987-revised ACR classification criteria
• Exclusion criteria: we excluded patients if they had previously received anti-TNF
therapy, methotrexate, or more than 2 DMARDs, or if they were
immunocompromised, pregnant, or planning to become pregnant. Cotherapy with
NSAIDs or prednisone or a prednisone equivalent (≤ 10 mg/day) could continue if
maintained at a stable dose for 4 weeks or more before baseline.
Period 2:
• adalimumab + methotrexate during period 1 of the study, stable low disease
activity (DAS28-CRP < 3.2) at weeks 22 and 26
Baseline characteristics: mean (SD): age: intervention 50.1 (14.9), control 49.5 (15.3);
female: intervention 73%, control 73%; RF+: intervention 95%, control 89%; ACPA+:
intervention 90%, control 90%; disease duration in months: intervention 3.9 (3.3),
control 3.9 (2.9); percentage with ≥ 1 previous DMARDs: intervention 8.8%, control
9.5%
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Smolen 2014 (OPTIMA) (Continued)
Interventions Period 1: participants were randomised in a ratio 1:1 to:
• adalimumab (40 mg every other week) + MTX (n = 515);
• placebo + MTX (n = 517).
Period 2: participants in the adalimumab plus methotrexate group reaching DAS28-
CRP < 3.2 at weeks 22 and 26 were re-randomised in a 1:1 ratio to:
• continuation group: adalimumab + MTX (n = 105);
• withdrawal group: placebo + MTX (n = 102).
Outcomes Primary outcome (period 2): not described
Outcomes:
• Proportion of participants with ACR20/50/70
• Proportion of participants with DAS28-CRP < 3.2
• Proportion of participants with DAS28-CRP < 2.6
• Proportion of participants with SDAI < 11.0
• Proportion of participants with SDAI ≤ 3.3
• Proportion of participants with CDAI < 10.0
• Proportion of participants with CDAI ≤ 2.8
• Proportion of participants with 1mTSS ≤ 0.5 (from baseline to 78 weeks)
• Mean HAQ
• Adverse events
Analyses: ITT including all participants who had received at least 1 dose of study drug
in period 2. The primary endpoint was assessed using non-responder imputation (NRI)
. NRI or LOCF, or both, was used for additional clinical outcomes; LOCF was used for
functional outcomes. Markov chain Monte Carlo method was used to impute missing
radiographic data 10 times (multiple imputation)
Notes Acronym: OPTIMA
Funding: AbbVie
Disclosures: JSS has received grant fees, research fees, consulting fees, or other remu-
neration from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Cento-
cor-Janssen, GlaxoSmithKline, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo
Nordisk, Roche, Sandoz, and UCB. PE has provided paid expert advice and has done
trials for AbbVie, Merck, Pfizer, UCB, Roche, and Bristol-Myers Squibb. RF has received
research grants and consulting fees or other remuneration from AbbVie, Pfizer, Merck,
Roche, UCB, Celgene, Centocor-Janssen, Amgen, AstraZeneca, Bristol-Myers Squibb,
Lilly, and Novartis. RFvV has served as a consultant for, or received grant or research sup-
port from, AbbVie, GlaxoSmithKline, Merck, Pfizer, Roche, and UCB. KP has received
consulting fees or other remuneration and speaker honoraria from AbbVie, Pfizer,MSD,
Roche, Amgen, and Bristol-Myers Squibb. PD has served on speaker’s bureaus for BMS.
BG, HK, and VA are shareholders and employees of AbbVie. LR is a former employee
of AbbVie. AK has received grant fees, research fees, or provided paid expert advice to
AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Centocor-Janssen, Pfizer,
Roche, and UCB
EudraCT: 2006-004139-31
ClinicalTrials.gov: NCT00420927
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised trial, method not described
Allocation concealment (selection bias) Low risk “Patients were centrally randomised in
blocks of four by interactive voice response
system on the basis of information supplied
by the investigator”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk “During period 2, treatment reallocation of
patients who achieved the target was also
masked to patients and investigators”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk “During period 2, treatment reallocation of
patients who achieved the target was also
masked to patients and investigators”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias Low risk The study appears to be free of other
sources of bias.
van Herwaarden 2015 (DRESS)
Methods Pragmatic, multicentre, open-label, randomised, controlled, cost-effectiveness non-infe-
riority strategy trial, stratified for anti-TNF agent in 2 hospitals in the Netherlands
Participants Inclusion criteria: we enrolled consenting patients with rheumatoid arthritis (based on
2010 or 1987 ACR criteria, or clinical diagnosis by the treating rheumatologist) using
adalimumab or etanercept at any stable dose and interval for at least 6 months, with
stable low disease activity at 2 subsequent visits
Exclusion criteria: none described
Baseline characteristics: mean (SD): age: intervention 59 (10.5), control 58 (9.3); female:
intervention 62%, control 69%;median disease duration: intervention 10 (IQR 6 to 17),
control 10 (IQR 6 to 16), median number of previous DMARD treatment: intervention
2 (IQR 1 to 3), control 2 (IQR 1 to 3); median number of previous TNFi treatment:
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van Herwaarden 2015 (DRESS) (Continued)
intervention 0 (IQR 0 to 1), control 0 (IQR 0 to 1)
Interventions Participants were randomised (stratified by anti-TNF) in a ratio of 2:1
• Control group (n = 59): usual care with tight control (visit every 3 months,
DAS28 measurement on day of visit, aiming for DAS28 < 3.2)
• Intervenion group (n = 121): tight control and dose reduction (increase in the
interval every 3 months until stop and withdrawal strategy advice to the treating
rheumatologist. Only 1 attempt at dose reduction was done, and in the case of flare
and treatment escalation, no further attempts at reduction were made.
Increase in interval for adalimumab: start 14, 21, 28 days and stop, etanercept start 7,
10, 14 days and stop
Outcomes Primary outcome is to assess whether the difference in cumulative incidence in persistent
RA flares (DAS28 increase > 1.2 or DAS28 increase > 0.6 with a current DAS28 ≥ 3.2)
and a duration of > 3 months between the intervention group and the usual care group
does not exceed the non-inferiority margin of 20% after 18 months’ follow-up
Secondary outcomes include cost-effectiveness ratio between intervention and usual care
groups. Other secondary outcomes are predictive factors for successful dose reduction
and progression of radiological joint damage
Analyses: primary analyses were done PP by including only participants who (1) com-
pleted follow-up, (2) actually started dose reduction of TNF inhibitors in the dose re-
duction arm, and (3) had not stopped or reduced TNF inhibitor use at 18 months’
follow-up in the usual care arm. Additional ITT analyses were also done. No multiple
imputation was deemed necessary since almost no data were missing
Notes Dutch trial register: NTR3216
Acronym: DRESS
Funding: The study received no external funding.
Disclosures: JB received grants and personal fees from Pfizer and AbbVie during the
conduct of the study, and grants and personal fees from Roche, Bristol-Myers Squibb,
and Union Chimique Belge outside the submitted work. RvV received grants from Ab-
bVie, BMS, GlaxoSmithKline, Pfizer, Roche, and UCB, and personal fees from AbbVie,
Biotest, BMS, GlaxoSmithKline, Janssen, Lilly, Merck, Pfizer, Roche, UCB, and Vertex
outside the submitted work. The other authors declare no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation list generated by com-
puter”
Allocation concealment (selection bias) Low risk “To conceal the sequence until treatment
strategy was assigned, sequentially num-
bered sealed opaque envelopes that con-
tained the randomly assigned allocations
were used.”
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van Herwaarden 2015 (DRESS) (Continued)
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk “Open-label study”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study, and most outcomes
likely to be influenced. X-ray reading was
blinded: “Radiographs of hands and feet (at
baseline and 18 months) were assessed in
chronological order by twoblinded, trained
readers”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data < 10% and balanced
in numbers across intervention groups,
with similar reasons for missing data across
groups
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias Low risk Lack of DMARD cotreatment and a higher
level of radiological damage at baselinewere
more prevalent in the dose reduction group
than in the usual care group, but there was
a low chance of inducing bias
van Vollenhoven 2016 (DOSERA)
Methods 48-week, double-blind, randomised, placebo-controlled trial in 16 rheumatology units
in Sweden (n = 5), Denmark (n = 2), Finland (n = 2), Norway (n = 3), Hungary (n = 3)
, and Iceland (n = 1)
Period 1: 8-week run-in period; period 2: RCT period
Participants Inclusion criteria for period 1:
• adult patients diagnosed with RA (1987 ACR criteria)
• etanercept 50 mg + methotrexate weekly (in 1 single or 2 divided doses) for at
least 14 months
• in combination with methotrexate at a stable dose of 7.5 to 25 mg/week for at
least 4 months before baseline
• LDA (DAS28-ESR ≤ 3.2) at the time of screening
• evidence of LDA at least 11 months prior to the screening visit had to be
documented in either the clinical chart or a clinical registry, with no contrary data in
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van Vollenhoven 2016 (DOSERA) (Continued)
the interim
• no other concurrent antirheumatic therapy
• stable (for at least 4 weeks) low-dose (≤ 7.5 mg/day) prednisolone (or equivalent)
therapy was allowed
Exclusion criteria for period 1: key exclusions were: prior therapy with biologics except
anti-TNFs and a prior attempt at etanercept discontinuation or dose reduction for the
purpose of maintaining a good clinical result (i.e. for the same purpose to be assessed in
this study)
Inclusion criteria for period 2:
• maintaining a DAS ≤ 3.2 during period 1
Baseline characteristics: mean (SD): age 56.7 (11.0), female 70%, disease duration 13.
6 (8.8), RF+ 69%, prior treatment with DMARDs other than MTX 66%
Interventions Period 1: run-in period with etanercept + methotrexate. Methotrexate dose was kept
unchanged throughout the study, etanercept was provided in a once-weekly 50 mg dose
in the form of the lyophilised product. (n = 91)
Period 2: participants were randomised in a ratio 1:1:1
• ETN50: etanercept 50 mg weekly (unchanged) + methotrexate (n = 23)
• ETN25: etanercept 25 mg weekly (reduced dose) + methotrexate (n = 27)
• PBO: placebo + methotrexate (n = 23)
If a flare occurred during period 2, the participant was withdrawn from this phase.
Participantswhodiscontinuedperiod 2were designated as failures in the primary analysis,
transferred to the third phase (period 3), and received etanercept 50 mg weekly plus
methotrexate
Outcomes Primary outcome: proportion of non-failures for ETN50 versus PBO
Secondary outcomes:
• Comparison of non-failures between ETN25 and PBO
• Time to failure in period 2
• Time from failure to LDA/remission
• Predictors for failure
• Adverse events
Analyses: modified ITT consisting of the participants who had received a randomised
treatment assignment and who had at least 1 available evaluation after the first dose of
studymedication at randomisation. For dichotomous clinical outcomes, a non-responder
imputation was applied, designating a participant as a ‘failure’ if he/she had discontinued
double-blinded treatment for any reason. The primary analysis was performed on LOCF
data
Notes Acronym: DOSERA
Funding: This study was sponsored by Wyeth, which was acquired by Pfizer in October
2009
Disclosures: RFvV has received research support and honoraria from AbbVie (Abbott)
, BMS, GSK, Lilly, MSD, Pfizer, Roche, and UCB Pharma. MØ has received research
support or honoraria, or both from AbbVie (Abbott), BMS, Centocor, GSK, Janssen,
Merck, Mundipharma, Novo, Pfizer, Schering-Plough, Roche, UCB, and Wyeth. TU
has received research support and honoraria from AbbVie (Abbott), BMS, MSD, Pfizer,
Roche, and UCB Pharma. ML-R has been a consultant for Abbott, Pfizer, MSD, Roche,
and BMS. EL and MJ were employees of Pfizer Sweden at the time of the study; EL
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van Vollenhoven 2016 (DOSERA) (Continued)
is currently an employee of Eli Lilly. FB is an employee of Quanticate, who were paid
consultants to Pfizer in connection with statistical support for the development of this
manuscript. KF-L was an employee of Wyeth/Pfizer at the time of the conduct of the
study and is currently employed by the Swedish Medical Products Agency
EudraCT: 2007-006657-63
ClinicalTrials.gov: NCT00858780
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Pfizer generated a randomization sched-
ule. Allocation of subjects to treatment
groups proceeded through the use of the
Clinical Operations Randomization Envi-
ronment II (CORE II) system /Impala sys-
tem that was accessible 24 hours a day, 365
days a year.”
Allocation concealment (selection bias) Low risk “Pfizer generated a randomization sched-
ule. Allocation of subjects to treatment
groups proceeded through the use of the
Clinical Operations Randomization Envi-
ronment II (CORE II) system /Impala sys-
tem that was accessible 24 hours a day, 365
days a year.”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk “Double-blind trial”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk “Double-blind trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind trial”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
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van Vollenhoven 2016 (DOSERA) (Continued)
Other bias Low risk The study appears to be free of other
sources of bias.
Weinblatt 2017 (C-EARLY)
Methods Multicentre, double-blind randomised controlled trial conducted at 103 study centres
in Europe, Australia, North America, and Latin America (of the 181 that participated
in C-EARLY period 1)
Period 1: 52 weeks, double-blind. Period 2: week 52 to 104, double-blind (period of
interest)
Participants Inclusion for period 1:
• active RA according to the 2010 ACR/EULAR classification criteria
• DMARD-naive with early disease (diagnosis 1 year prior to randomisation, with
76% of patients randomised within 4 months of their diagnosis)
• poor prognostic factors for severe disease progression (positive at screening for
rheumatoid factor or anti-citrullinated protein antibody)
Exclusion period 1:
• use of intra-articular, intramuscular, or intravenous corticosteroids at any dose was
prohibited in the C-EARLY study
Inclusion for period 2:
• participants in C-EARLY period 1 who had achieved sustained low disease
activity at weeks 40 and 52 after 52 weeks of certolizumab pegol plus optimised
methotrexate treatment were eligible for enrolment into C-EARLY period 2
Exclusion period 2:
• patients who had used intra-articular corticosteroids within 28 days of baseline (in
C-EARLY period 1) were excluded from study enrolment. The maximum allowed dose
of oral corticosteroids during the study was ≤ 10 mg/day prednisone or equivalent,
with changes in dose allowed only between weeks 4 and 14 and between weeks 24 and
34 in period 1 of the study. Participants taking oral corticosteroids were therefore to
maintain their dosage during period 2.
Baseline characteristics:
CZP standard dose: mean (SD): age 49.1 (13.1), female 79%, RF+ 98%, ACPA+ 92%,
time since diagnosis in months 2.5 (2.5)
CZP reduced dose: age 49.2 (12.5), female 68%, RF+ 95%, ACPA+ 89%, time since
diagnosis in months 2.6 (2.8)
CZP stopped: age 47.6 (14.0), female 73%, RF+ 100%, ACPA+ 86%, time since diag-
nosis in months 2.9 (3.1)
Interventions Period 2: participants were randomised into 1 of 3 groups in ratio 2:3:2
• CZP standard group: 200 mg certolizumab pegol every 2 weeks plus methotrexate
• Reduced-frequency group: 200 mg certolizumab pegol every 4 weeks plus
methotrexate
• CZP stopped group: placebo every 2 weeks plus methotrexate
In the event of a confirmed disease flare, participants received a loading dose of cer-
tolizumab pegol (400 mg at 3 subsequent visits) followed by the standard dose (200 mg
every 2 weeks) until the end of the study
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Weinblatt 2017 (C-EARLY) (Continued)
Outcomes Primary: proportion of participants with sustained low disease activity (DAS28-ESR of
≤ 3.2 at both week 40 and week 52) who maintained low disease activity (DAS28-ESR
of ≤ 3.2) for all 5 consecutive study visits to week 104 without flares
Secondary outcome measures:
• Proportion participants in sustained remission
• Proportion low disease activity and normal physical function
• Radiographic non-progression during period 2
• Time to flare
Analyses: ITT. Missing data from participants who entered period 2 but withdrew before
the end of the study were imputed using non-responder imputation for the primary and
key secondary endpoints. Radiographic analyses used linear extrapolation. In post hoc
analyses, LOCF imputation was used for the proportions of participants achieving low
disease activity, remission, and normative physical function
Notes Acronym: C-EARLY period 2
Funding: supported by UCB Pharma
Disclosures: Dr Weinblatt has received consulting fees, speaking fees, and/or honoraria
from AbbVie, Amgen, Bristol-Myers Squibb, Roche (less than USD 10,000 each), Lilly,
Pfizer, UCB Pharma, AstraZeneca,Merck, Novartis, Crescendo Bioscience, andMedIm-
mune (more than USD 10,000 each). Dr Bingham has received consulting fees, speak-
ing fees, and/or honoraria from UCB Pharma (less than USD 10,000). Dr Burmester
has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol-My-
ers Squibb, Celgene, MSD, UCB Pharma, Roche, Pfizer, and Lilly (less than USD 10,
000 each). Dr Bykerk has received consulting fees, speaking fees, and/or honoraria from
Pfizer, AbbVie, Bristol-Myers Squibb, Sanofi, and UCB Pharma (less than USD 10,000
each). Dr Furst has received consulting fees, speaking fees, and/or honoraria from Ab-
bott, AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Cytori, Gilead, GlaxoSmithKline,
Janssen, NIH, Novartis, Pfizer, Roche/Genentech, and UCB Pharma (less than USD
10,000 each) and research grants from Abbott, Actelion, Amgen, Biogen, Bristol-Myers
Squibb, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, and UCB Pharma. Dr
Mariette has received consulting fees, speaking fees, and/or honoraria from Bristol-My-
ers Squibb, GlaxoSmithKline, Pfizer, and UCB Pharma (less than USD 10,000 each)
. Dr van der Heijde has received consulting fees, speaking fees, and/or honoraria from
AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim,
Celgene, Daiichi, Eli Lilly and Company, Galapagos, Gilead, Janssen, Merck, Novartis,
Pfizer, Regeneron, Roche,
Sanofi, andUCB Pharma (less thanUSD 10,000 each). Dr van Vollenhoven has received
consulting fees and/or honoraria from AbbVie, Biotest, Bristol-Myers Squibb, Celgene,
Crescendo Bioscience, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche,
UCBPharma, andVertex (less thanUSD10,000 each) and research grants fromAbbVie,
Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Roche, and UCB Pharma. Ms
VanLunen and Drs Ecoffet and Cioffi own stock or stock options in UCB Pharma. Dr
Emery has received consulting fees and/or honoraria from Pfizer, MSD, AbbVie, Bristol-
Myers Squibb, UCB Pharma, Roche, Novartis, Samsung, Sandoz, and Lilly (more than
USD 10,000 each)
EudraCT: 2011-001729-25
ClinicalTrials.gov: NCT01521923
Risk of bias
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Weinblatt 2017 (C-EARLY) (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Re-randomisation at week 52 was per-
formed centrally using an interactive voice/
web response system (IXRS)
Allocation concealment (selection bias) Low risk Re-randomisation at week 52 was per-
formed centrally using an interactive voice/
web response system (IXRS)
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Double-blind study. Placebo was supplied
as 0.9% saline, and certolizumab pegol was
supplied as a 200 mg solution. Both were
in prefilled syringes for subcutaneous injec-
tion and were administered up to week 102
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel were blinded with re-
spect to treatment, except for a separate
groupwho supervised and administered the
study medication and determined ESR but
who otherwise had no involvement in the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias High risk The number of included participants was
lower than anticipated in the sample size
calculation. “The primary end point of the
present study was not achieved. Fewer pa-
tients than projected from period 1 were
eligible to enter period 2 (i.e., achieved
sustained low disease activity), which may
have resulted in an underpowered study.”
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Yamanaka 2016 (ENCOURAGE)
Methods Multicentre, open-label randomised controlled study in Japan and Korea
Period 1: first year. Period 2: second year (period of interest for review)
Participants Period 1:
• Inclusion criteria: individuals with early-stage RA who had been diagnosed
according to the 1987 classification criteria for RA, whose disease duration from the
onset of symptoms was < 5 years, and whose disease activity was 3.2 ≤ DAS28 ≤ 5.1,
despite treatment with csDMARDs, including MTX for no less than 3 months.
Patients who had received any bDMARDs prior to the start of the study had to stop
using these agents for the following amounts of time prior to participation in this
study: no less than 8 weeks for infliximab, no less than 2 weeks for adalimumab, and
no less than 4 weeks for tocilizumab.
• Exclusion criteria: individuals who did not meet the guidelines for anti-TNF
therapy were excluded from the study. Other exclusion criteria included serious
infection, tuberculosis, pregnancy, and others, as in the clinical trials of anti-TNF
agents.
Period 2:
• Inclusion criteria: those participants in the etanercept + methotrexate group who
were in clinical remission, defined as DAS28 < 2.6 at both 6 months and 12 months.
Baseline characteristics: mean (SD): age: intervention 52.9 (14.9), control 49.8 (13.0);
female: intervention 88%, control 88%; RF+: intervention 71%, control 70%; DAS28:
intervention 1.8 (0.5), control 1.7 (0.5); disease duration in years: intervention 2.4 (1.
4), control 1.9 (1.4)
Interventions Period 1: participants were randomised into 1 of 2 groups at a ratio of 1:4
• MTX group: methotrexate 6 mg/week (n = 43)
• ETN + MTX group: methotrexate 6 mg/week and etanercept subcutaneous twice
a week (n = 179)
Period 2: participants were randomised at a ratio of 1:1
• ETN discontinuation (n = 50)
• ETN continuation (n = 49)
Outcomes Primary outcome period 2: maintenance of remission rates, including clinical remission,
structural remission, and functional remission rates at 12 months after the second ran-
domisation
Secondary outcomes:
• Resumption of remission in discontinuation group
• Changes in total Sharp score
Analyses: ITT and PP. Missing data were imputed using the LOCF strategy
Notes Acronym: ENCOURAGE
Funding: This investigator-initiated study was supported by a grant from Pfizer Inc
through the nonprofit corporationAdvancedClinical ResearchOrganization (www.npo-
acro.jp/), due to an international multicentre co-operative study led by the Institute of
Rheumatology, Tokyo Women’s Medical University
Disclosures: HY has received research grants from AbbVie, Asahi Kasei Pharma, Astellas,
Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Janssen, Mit-
subishi-Tanabe,MSD,NipponKayaku, Pfizer, Santen, Taisho-Toyama, Takeda, and Tei-
jin Pharma, and has received honorarium for lectures or consultancy fromTeijin Pharma,
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Yamanaka 2016 (ENCOURAGE) (Continued)
Chugai, Astellas, Bristol-Myers Squibb, AbbVie, Daiichi-Sankyo, Nippon Kayaku, Mit-
subishi-Tanabe, Pfizer, Takeda, and UCB. SN has received research grants from Abb-
Vie, Bristol-Myers Squibb, and Pfizer, and honorarium for lectures or consultancy from
Bristol-Myers Squibb and Pfizer. TK has received research grants from AbbVie, Astel-
las, Bristol-Myers Squibb, Chugai, Eisai, Mitsubishi-Tanabe, Pfizer, and Takeda, and
honorarium for lectures from Chugai, Astellas, AbbVie, and Mitsubishi-Tanabe. YU has
received speaking fees from Pfizer, Mitsubishi-Tanabe, Chugai, Bristol-Myers Squibb,
and Astellas. YS has received speaking fees from AbbVie and Pfizer. NT has received re-
search grant or speaking fee, or both fromMitsubishi-Tanabe Pharma, Chugai, Takeda,
Astellas, and Eisai. KS has received speaking fees from Mitsubishi-Tanabe, Chugai, Ei-
sai, AbbVie, Bristol-Myers Squibb, Takeda, and Astellas. YI has received speaking fees
from Eisai and Pfizer. YM has received research grants from Mitsubishi-Tanabe, Astel-
las, Pfizer, and Eisai. YT has received consulting fees, speaking fees, and/or honoraria
from AbbVie, Chugai, Astellas, Takeda, Santen, Mitsubishi-Tanabe, Pfizer, Janssen, Ei-
sai, Daiichi-Sankyo, UCB, GlaxoSmithKline, and Bristol-Myers Squibb, and research
grants from Mitsubishi-Tanabe, Chugai, MSD, Astellas, and Novartis. TTa has received
research grants from Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Mit-
subishi-Tanabe, Pfizer, Santen, Takeda, Teijin Pharma, AbbVie, Asahikasei Pharma,
Taisho-Toyama, and SymBio Pharmaceuticals; speaking fees fromAbbVie, Bristol-Myers
Squibb, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer, Takeda, Astellas, and Daiichi-
Sankyo; and consultant fees from AstraZeneca, Eli Lilly, Novartis, Mitsubishi-Tanabe,
Asahi Kasei Pharma, AbbVie, Daiichi-Sankyo, and Bristol-Myers Squibb
UMIN Clinical Trials Registry Japan: UMIN000002687
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the se-
quence generation process to permit judge-
ment of ‘low risk’ or ‘high risk’
Allocation concealment (selection bias) Low risk “Randomization of ENCOURAGE study
was conducted by the sealed envelope
method in central study secretariat”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk “Open-label study”
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Open-label study, but outcome not likely
to be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study, and most outcomes
likely to be influenced. X-ray reading
was blinded: “Assessment of outcome was
mostly conducted by the investigators
without blinding, but only radiological
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Yamanaka 2016 (ENCOURAGE) (Continued)
scores (Total Sharp score) was assessed cen-
trally by experts of evaluating scores, thus
radiological score was assessed by blinding
manner.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Proportion of missing data is likely to in-
duce clinically relevant bias
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias High risk The number of included participants was
lower than anticipated in the sample size
calculation
ACPA: Anti-Citrullinated Protein Antibody
ACR: American College of Rheumatology
bDMARD: biological DMARD
CCP: cyclic citrullinated peptide
CDAI: Clinical Disease Activity Index
CRP: C-reactive protein
csDMARD: conventional synthetic DMARD
CZP: certolizumab pegol
DAS28: disease activity score in 28 joints
DAS28-ESR: disease activity score in 28 joints using erythrocyte sedimentation rate
DAS44: disease activity score in 44 joints
DMARD: disease-modifying antirheumatic drug
ESR: erythrocyte sedimentation rate
ETN: etanercept
EULAR: European League Against Rheumatism
EQ-5D: European Quality of Life-5 Dimensions (a standardised measure of health-related quality of life)
FACIT: Functional Assessment of Chronic Illness Therapy
GH: growth hormone
HAQ-DI: Health Assessment Questionnaire-Disability Index
IA: intra-articular
IM: intramuscular
IV: intravenous
IQR: interquartile range
ITT: intention-to-treat
LDA: low disease activity
LOCF: last observation carried forward
mSvdH score: modified Sharp-van der Heijde score
mTSS: modified total Sharp score
MTX: methotrexate
NSAID: non-steroidal anti-inflammatory drug
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PP: per protocol
RA: rheumatoid arthritis
RCT: randomised controlled trial
RF: rheumatoid factor
SC: subcutaneous
SD: standard deviation
SDAI: Simplified Disease Activity Index
SF-36: 36-item short-form health survey
SJ: swollen joint
TJ: tender joint
TNF: tumour necrosis factor
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aletaha 2010 Overview article
Awan 2011 No anti-TNF continuation comparison group. No separate RA data
Bejarano 2010 After 1 year, all participants receiving infliximab plus methotrexate discontinued infliximab.
No comparison with infliximab continuation arm
CADTH Report 2014 Literature study
Detert 2013 (HIT-HARD) HIT-HARD study
After 24 weeks, all participants receiving adalimumab plus methotrexate discontinued adali-
mumab. No comparison with adalimumab continuation arm
Emery 2013 (PRIZE) PRIZE study
Etanercept reduced or discontinued, no continuation comparison arm
Greenberg 2014 Cohort study
Haraoui 2014 No certolizumab pegol dose below standard dose
Harigai 2012 (BRIGHT) BRIGHT study
Not an RCT or CCT according to theCochrane definition; randomisation based on physician
preference
Haschka 2016 (RETRO) RETRO study
Dose reduction of bDMARDs and sDMARDs at the same time
Heimans 2016 (IMPROVED) IMPROVED study
No comparison with an adalimumab continuation arm
Ichikawa 2007 Overview article
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Keystone 2003 Overview article
Klarenbeek 2011 BeSt study
In the combination therapy with infliximab arm, infliximab dose could be reduced and
stopped. No comparison with infliximab continuation arm
Kobelt 2011 No real participant data. Markov model
Kobelt 2014 No real participant data. Markov model
Oba 2017 (RRRR study) RRRR study
No comparison with a continuation arm
Quinn 2005 After 1 year, all participants receiving infliximab plus methotrexate discontinued infliximab.
No comparison with infliximab continuation arm
Rakieh 2013 Not an RCT or CCT according to the Cochrane definition; allocation based on patient
decision
Ramírez-Herráiz 2013 Retrospective study
Seddighzadeh 2014 (NORD-STAR) NORD-STAR study
No comparison with a continuation arm
Smolen 2012 (CERTAIN) CERTAIN study
No certolizumab pegol continuation comparison arm
Tada 2012 (PRECEPT) PRECEPT study
Participants who required biological therapy were randomly assigned to receive low-dose
versus standard-dose etanercept. Participants had not used etanercept before study start. No
dose reduction protocol
Tanaka 2013 (HONOR) HONOR study
Not an RCT or CCT according to the Cochrane definition
Tanaka 2014 (HOPEFUL-2) HOPEFUL-2
Not an RCT or CCT according to the Cochrane definition; allocation based on patient/
investigator decision
van den Broek 2011 BeSt study
In the combination therapy with infliximab arm, infliximab dose could be reduced and
stopped. No comparison with infliximab continuation arm
van der Kooij 2009 BeSt study
In the combination therapy with infliximab arm, infliximab dose could be reduced and
stopped. No comparison with infliximab continuation arm
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Villeneuve 2012 No etanercept continuation control arm, and no data after etanercept withdrawal
Wiland 2016 (PRIZE) PRIZE study
No comparison with etanercept continuation arm
bDMARD: biological DMARD
CCT: controlled clinical trial
DMARD: disease-modifying antirheumatic drug
RA: rheumatoid arthritis
RCT: randomised controlled trial
sDMARD: synthetic DMARD
TNF: tumour necrosis factor
Characteristics of ongoing studies [ordered by study ID]
2012-004631-22
Trial name or title TapERA: Maintaining remission in RA while tapering Etanercept
Methods Open-label randomised controlled trial
Participants People with established RA in remission for ≥ 6 months, treated with etanercept ≥ 1 year
Interventions • 50 mg etanercept every 2 weeks
• 50 mg etanercept every week (control)
Outcomes Primary outcome: the proportion of participants maintaining remission 6 months after decreasing the dose of
etanercept to 50 mg every 2 weeks compared to the proportion of participants maintaining remission while
continuing the established dose of 50 mg weekly
Secondary outcomes: baseline predictors, maintenance of remission, regaining remission after retreatment,
FLARE questionnaire, adverse events
Starting date 2012
Contact information Rene Westhovens, University Hospitals Leuven
Notes EudraCT Number: 2012-004631-22
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2017-001970-41
Trial name or title The BIODOPT trial (BIOlogical Dose OPTimisation). Dose reduction and discontinuation of biological
therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a 18
months randomised, open label, parallel-group, multi-centre trial
Methods Randomised, open-label, parallel group, multicentre
Participants People with RA, PsA, or SpA treated with a bDMARD in stable dose in sustained clinical remission
Interventions Dose optimisation tapering strategy for biological therapy
Outcomes The co-primary endpoint is: 1A Superiority: the proportion of participants who at 18 months are reduced to
50% or less of their inclusion dose of biological therapy. 1B Equivalence: disease activity assessed 18 months
from baseline
Starting date December 2017
Contact information MD Line Uhrenholt, The Department of Rheumatology, Aalborg University Hospital
Notes EudraCT: 2017-001970-41
NCT01793519
Trial name or title Stopping tumor necrosis factor-alpha inhibitors in rheumatoid arthritis
Methods Multicentre, randomised, double-blind, placebo-controlled, non-inferiority trial
Participants People with RA, remission for > 6 months while taking etanercept, adalimumab, or infliximab and at least 1
DMARD
Interventions Randomisation 2:1
Matching placebo OR current anti-TNF agent (etanercept/adalimumab/infliximab)
Outcomes Primary outcome: 48-week relapse-free status
Secondary outcomes: difference in progression of joint damage on radiographs, differences in physical function
and predictors of relapse
Starting date January 2013
Contact information Arthur Weinstein, MD/Michael M Ward, MD
Notes ClinicalTrials.gov: NCT01793519
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NCT01881308
Trial name or title Remission in rheumatoid arthritis - assessing withdrawal of disease-modifying antirheumatic drugs in a non-
inferiority design
Methods Randomised, open, controlled, parallel-group, multicentre, phase 4, non-inferiority strategy study in Norway
Participants People with RA with disease duration < 5 years, stable DAS28 remission > 12 months and unchanged
treatment with anti-TNF and/or sDMARDs > 12 months
Interventions Stable dose anti-TNF OR stepdown and withdrawal of anti-TNF (half-dose anti-TNF first 4 months, there-
after withdrawal) OR stable dose sDMARD OR sDMARD dose reduction (half-dose sDMARD for first 12
months, after 12 months re-randomisation, continue half-dose or withdraw DMARD) OR ARCTIC follow-
up
Outcomes Primary endpoint is the proportion of participants who are non-failures (have not experienced a flare) at 12
months’ follow-up
Secondary endpoints include composite disease activity scores and remission criteria, joint damage and in-
flammation assessed by various imaging modalities, work participation, healthcare resource use, and health-
related quality of life
Starting date June 2013
Contact information Siri Lillegraven, MD, MPH/Espen A Haavardsholm, MD, PhD
Notes ClinicalTrials.gov: NCT01881308
NCT02198651
Trial name or title PREDICTRA: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEch-
niques, Drug Levels and Patient Characteristics on theOutcome of Dose TaperIng of Adalimumab in Clinical
Remission Rheumatoid ArThritis (RA) Subjects
Methods Randomised, double-blind, phase 4 trial
Participants People with RA treated with adalimumab and methotrexate who are in sustained clinical remission
Interventions • Adalimumab continuation
• Placebo
Outcomes Primary outcome measures: hand and wrist synovitis RAMRIS score, bone marrow oedema RAMRIS score,
flare occurrence
Secondary outcomemeasures: time to flare, flare severity,DAS28, CDAI, SDAI,HAQ-DI, RAPID-3, TSQM,
WPAI, SF-36
Starting date December 2014
Contact information AbbVie
Notes ClinicalTrials.gov: NCT02198651
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NCT02373813
Trial name or title Study of etanercept monotherapy vs methotrexate monotherapy for maintenance of rheumatoid arthritis
remission
Methods Multicentre, double-blind randomised controlled study
Participants People with RA on etanercept plus methotrexate therapy in very good disease control for 6 months prior to
study entry
Interventions • Etanercept monotherapy
• Methotrexate monotherapy
• Etanercept plus methotrexate
Outcomes Primary outcome measure: SDAI remission at week 48
Secondary outcome measures: DAS28, CDAI, adverse events
Starting date February 2015
Contact information Amgen
Notes ClinicalTrials.gov: NCT02373813
NTR3903
Trial name or title Dose-to-target of etanercept treatment: a dose-tapering randomised controlled trial in patients with rheuma-
toid arthritis, ankylosing spondylitis or psoriatic arthritis
Methods Open randomised controlled study of a dose-to-target step-down treatment strategy in the Netherlands
Participants People with RA, PsA, and AS, etanercept treatment 50 mg/week > 6 months and minimal disease activity
Interventions Continuation of etanercept 50 mg/week OR etanercept 50 mg/2 weeks
After 6 months among participants still in a state of minimal disease activity, etanercept 50 mg/2 weeks in
the original continuation group and etanercept discontinuation in the original etanercept 50 mg/2 weeks
Outcomes Primary outcome: proportion of participants with RA, AS, PsA maintaining minimal disease activity after
dose interval prolongation of etanercept
Secondary outcomes: cost-effectiveness of tapering down etanercept treatment, whether the lowest effective
etanercept dose will reduce the risk of adverse events, predictive value of serum etanercept through levels and
other participant-related factors for successful down-titration
Starting date May 2013
Contact information Dr GJ Wolbink
Notes Dutch trial register: NTR3903
AS: ankylosing spondylitis
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bDMARD: biological DMARD
CDAI: Clinical Disease Activity Index
DAS28: disease activity score in 28 joints
DMARD: disease-modifying antirheumatic drug
HAQ-DI: Health Assessment Questionnaire-Disability Index
PsA: psoriatic arthritis
RA: rheumatoid arthritis
RAMRIS: Rheumatoid Arthritis Magnetic Resonance Imaging Score
RAPID-3: Routine Assessment of Patient Index Data 3
SDAI: Simplified Disease Activity Index
sDMARD: synthetic DMARD
SF-36: 36-item Short Form Health Survey
SpA: spondyloarthritis
TNF: tumour necrosis factor
TSQM: Treatment Satisfaction Questionnaire for Medication
WPAI: Work Productivity and Activity Impairment
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D A T A A N D A N A L Y S E S
Comparison 1. Anti-TNF dose reduction versus anti-TNF continuation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean disease activity score
(DAS28)
2 501 Mean Difference (IV, Random, 95% CI) 0.06 [-0.11, 0.24]
2 Proportion persistent remission
(DAS28)
2 612 Risk Ratio (IV, Random, 95% CI) 1.01 [0.80, 1.28]
3 Proportion switched to another
biologic
1 323 Risk Ratio (IV, Random, 95% CI) 0.40 [0.17, 0.93]
4 Proportion radiographic
progression (mSvdH > 0.5)
2 553 Risk Ratio (IV, Random, 95% CI) 1.22 [0.76, 1.95]
5 Function (Health Assessment
Questionnaire)
2 501 Mean Difference (IV, Random, 95% CI) 0.09 [-0.00, 0.19]
6 Number of serious adverse events 5 1084 Risk Ratio (IV, Random, 95% CI) 1.09 [0.65, 1.82]
7 Withdrawals due to adverse
events
3 937 Risk Ratio (IV, Random, 95% CI) 1.07 [0.51, 2.24]
8 Proportion of participants with a
flare
3 Risk Ratio (IV, Random, 95% CI) Subtotals only
9 Quality of life 2 501 Mean Difference (IV, Random, 95% CI) -0.00 [-0.04, 0.03]
Comparison 2. Anti-TNF discontinuation versus anti-TNF continuation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean disease activity score
(DAS28)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Discontinuation without
restarting, or with restarting
and LOCF analysis
2 733 Mean Difference (IV, Random, 95% CI) 0.96 [0.67, 1.25]
1.2 Discontinuation with
restarting without LOCF
analysis
1 692 Mean Difference (IV, Random, 95% CI) 0.29 [0.14, 0.44]
2 Proportion persistent remission
(DAS28)
6 Risk Ratio (IV, Random, 95% CI) Subtotals only
3 Proportion radiographic
progression (mSvdH > 0.5)
3 549 Risk Ratio (IV, Random, 95% CI) 1.69 [1.10, 2.59]
4 Function (Health Assessment
Questionnaire)
4 1498 Mean Difference (IV, Random, 95% CI) 0.18 [0.05, 0.31]
5 Number of serious adverse events 8 2095 Risk Ratio (IV, Random, 95% CI) 1.29 [0.82, 2.03]
6 Withdrawals due to adverse
events
4 1116 Risk Ratio (IV, Random, 95% CI) 1.46 [0.75, 2.84]
7 Proportion flare 5 Risk Ratio (IV, Random, 95% CI) Totals not selected
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7.1 DAS28 ≥ 3.2 and 1DAS
≥ 0.6 (24 to 52 weeks’ follow-
up)
3 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 DAS28 ≥ 3.2 OR 1DAS
≥ 0.6 (follow-up 52 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 DAS28 ≥ 2.6 OR 1DAS
> 1.2 (follow-up 28 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Proportion failure (follow-
up 48 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Quality of life 2 733 Mean Difference (IV, Random, 95% CI) -0.10 [-0.13, -0.07]
Comparison 3. Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean disease activity score
(DAS28)
3 357 Mean Difference (IV, Random, 95% CI) 0.25 [-0.17, 0.67]
2 Proportion persistent remission
(DAS28)
1 180 Risk Ratio (IV, Random, 95% CI) 0.89 [0.75, 1.06]
3 Proportion switched to another
biologic
2 317 Risk Ratio (IV, Random, 95% CI) 0.62 [0.25, 1.54]
4 Proportion radiographic
progression (mSvdH > 0.5 or >
1.0)
2 312 Risk Ratio (IV, Random, 95% CI) 1.45 [0.77, 2.73]
5 Function (Health Assessment
Questionnaire)
1 123 Mean Difference (IV, Random, 95% CI) 0.20 [-0.02, 0.42]
6 Number of serious adverse events 2 317 Risk Ratio (IV, Random, 95% CI) 1.24 [0.42, 3.70]
7 Proportion flare 3 Risk Ratio (IV, Random, 95% CI) Totals not selected
7.1 DAS28-ESR >2.6 with
DAS28-ESR > 0.6 after 18
months
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 1DAS28-CRP > 1.2
OR 1DAS28-CRP > 0.6 and
current DAS28-CRP ≥ 3.2
for > 3 months at 9 months’
follow-up
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 1DAS28-CRP > 1.2
OR 1DAS28-CRP > 0.6 and
current DAS28-CRP ≥ 3.2
for > 3 months at 18 months’
follow-up
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 1DAS28-CRP > 1.2
OR 1DAS28-CRP > 0.6 and
current DAS28-CRP ≥ 3.2
for < 3 months at 9 months’
follow-up
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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7.5 1DAS28-CRP > 1.2
OR 1DAS28-CRP > 0.6 and
current DAS28-CRP ≥ 3.2
for < 3 months at 18 months’
follow-up
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.6 DAS28 > 2.6, SDAI > 5
or ACR/EULAR criteria not
fulfilled (follow-up 24 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.7 DAS28 > 2.6, SDAI > 5
or ACR/EULAR criteria not
fulfilled (follow-up 48 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.8 DAS28 > 2.6, SDAI > 5
or ACR/EULAR criteria not
fulfilled (follow-up 72 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.9 DAS28 > 2.6, SDAI > 5
or ACR/EULAR criteria not
fulfilled (follow-up 96 weeks)
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Change in other medication 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
8.1 Use of intramuscular or
intra-articular glucocorticoid
injections at 18 months
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Use of oral glucocorticoids
at 18 months
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 DMARDs reduction
or discontinuation after 18
months
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 DMARD initiation or
dose escalation after 18 months
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.5 Use of a DMARD at 18
months
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 1 Mean
disease activity score (DAS28).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 1 Mean disease activity score (DAS28)
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ibrahim 2017 (OPTTIRA) 47 2.11 (0.94) 50 2.16 (0.92) 23.4 % -0.05 [ -0.42, 0.32 ]
Smolen 2013 (PRESERVE) 202 2.5 (1.1) 202 2.4 (1) 76.6 % 0.10 [ -0.11, 0.31 ]
Total (95% CI) 249 252 100.0 % 0.06 [ -0.11, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 2 Proportion
persistent remission (DAS28).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 2 Proportion persistent remission (DAS28)
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Smolen 2013 (PRESERVE) 121/201 134/201 53.9 % 0.90 [ 0.78, 1.05 ]
Weinblatt 2017 (C-EARLY) 90/126 52/84 46.1 % 1.15 [ 0.94, 1.41 ]
Total (95% CI) 327 285 100.0 % 1.01 [ 0.80, 1.28 ]
Total events: 211 (anti-TNF dose reduction), 186 (anti-TNF continuation)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.69, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 3 Proportion
switched to another biologic.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 3 Proportion switched to another biologic
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Raffeiner 2015 7/159 18/164 100.0 % 0.40 [ 0.17, 0.93 ]
Total (95% CI) 159 164 100.0 % 0.40 [ 0.17, 0.93 ]
Total events: 7 (anti-TNF dose reduction), 18 (anti-TNF continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 4 Proportion
radiographic progression (mSvdH > 0.5).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 4 Proportion radiographic progression (mSvdH > 0.5)
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Smolen 2013 (PRESERVE) 21/184 20/184 66.9 % 1.05 [ 0.59, 1.87 ]
Weinblatt 2017 (C-EARLY) 18/113 7/72 33.1 % 1.64 [ 0.72, 3.73 ]
Total (95% CI) 297 256 100.0 % 1.22 [ 0.76, 1.95 ]
Total events: 39 (anti-TNF dose reduction), 27 (anti-TNF continuation)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 5 Function
(Health Assessment Questionnaire).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 5 Function (Health Assessment Questionnaire)
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ibrahim 2017 (OPTTIRA) 47 0.75 (0.8) 50 0.73 (0.78) 8.8 % 0.02 [ -0.29, 0.33 ]
Smolen 2013 (PRESERVE) 202 0.6 (0.5) 202 0.5 (0.5) 91.2 % 0.10 [ 0.00, 0.20 ]
Total (95% CI) 249 252 100.0 % 0.09 [ 0.00, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 6 Number of
serious adverse events.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 6 Number of serious adverse events
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ibrahim 2017 (OPTTIRA) 3/47 0/50 3.1 % 7.44 [ 0.39, 140.25 ]
Raffeiner 2015 13/159 10/164 41.6 % 1.34 [ 0.61, 2.97 ]
Smolen 2013 (PRESERVE) 7/202 12/202 31.7 % 0.58 [ 0.23, 1.45 ]
van Vollenhoven 2016 (DOSERA) 1/27 1/23 3.6 % 0.85 [ 0.06, 12.87 ]
Weinblatt 2017 (C-EARLY) 9/127 4/83 20.1 % 1.47 [ 0.47, 4.62 ]
Total (95% CI) 562 522 100.0 % 1.09 [ 0.65, 1.82 ]
Total events: 33 (anti-TNF dose reduction), 27 (anti-TNF continuation)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.00, df = 4 (P = 0.41); I2 =0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours dose reduction Favours continuation
87Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low
disease activity (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 7
Withdrawals due to adverse events.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Raffeiner 2015 6/159 5/164 40.1 % 1.24 [ 0.39, 3.97 ]
Smolen 2013 (PRESERVE) 4/202 7/202 37.1 % 0.57 [ 0.17, 1.92 ]
Weinblatt 2017 (C-EARLY) 7/127 2/83 22.9 % 2.29 [ 0.49, 10.74 ]
Total (95% CI) 488 449 100.0 % 1.07 [ 0.51, 2.24 ]
Total events: 17 (anti-TNF dose reduction), 14 (anti-TNF continuation)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.01, df = 2 (P = 0.37); I2 =1%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 8 Proportion
of participants with a flare.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 8 Proportion of participants with a flare
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ibrahim 2017 (OPTTIRA) 6/21 8/50 1.79 [ 0.71, 4.52 ]
Ibrahim 2017 (OPTTIRA) 3/26 8/50 0.72 [ 0.21, 2.49 ]
van Vollenhoven 2016 (DOSERA) 15/27 11/23 1.16 [ 0.67, 2.00 ]
Weinblatt 2017 (C-EARLY) 3/126 7/84 0.29 [ 0.08, 1.07 ]
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Anti-TNF dose reduction versus anti-TNF continuation, Outcome 9 Quality of
life.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 1 Anti-TNF dose reduction versus anti-TNF continuation
Outcome: 9 Quality of life
Study or subgroup
anti-TNF
dose
reduction
anti-TNF
continua-
tion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ibrahim 2017 (OPTTIRA) 47 0.76 (0.24) 50 0.77 (0.21) 15.8 % -0.01 [ -0.10, 0.08 ]
Smolen 2013 (PRESERVE) 202 0.8 (0.2) 202 0.8 (0.2) 84.2 % 0.0 [ -0.04, 0.04 ]
Total (95% CI) 249 252 100.0 % 0.00 [ -0.04, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 1 Mean
disease activity score (DAS28).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 1 Mean disease activity score (DAS28)
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Discontinuation without restarting, or with restarting and LOCF analysis
Pavelka 2017 168 4.1 (1.3) 163 3.3 (1.3) 46.8 % 0.80 [ 0.52, 1.08 ]
Smolen 2013 (PRESERVE) 200 3.5 (1.4) 202 2.4 (1) 53.2 % 1.10 [ 0.86, 1.34 ]
Subtotal (95% CI) 368 365 100.0 % 0.96 [ 0.67, 1.25 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.56, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 6.41 (P < 0.00001)
2 Discontinuation with restarting without LOCF analysis
Ghiti Moghadam 2016 (POEET) 451 2.38 (1.0618) 241 2.09 (0.9315) 100.0 % 0.29 [ 0.14, 0.44 ]
Subtotal (95% CI) 451 241 100.0 % 0.29 [ 0.14, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.71 (P = 0.00020)
Test for subgroup differences: Chi2 = 15.72, df = 1 (P = 0.00), I2 =94%
-2 -1 0 1 2
Favours discontinuation Favours continuation
91Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low
disease activity (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 2
Proportion persistent remission (DAS28).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 2 Proportion persistent remission (DAS28)
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chatzidionysiou 2016 (ADMIRE) 2/15 13/16 0.16 [ 0.04, 0.61 ]
Pavelka 2017 22/168 55/163 0.39 [ 0.25, 0.61 ]
Smolen 2013 (PRESERVE) 58/197 134/201 0.44 [ 0.35, 0.56 ]
Smolen 2014 (OPTIMA) 67/101 90/105 0.77 [ 0.66, 0.91 ]
Weinblatt 2017 (C-EARLY) 37/78 52/84 0.77 [ 0.57, 1.02 ]
Yamanaka 2016 (ENCOURAGE) 15/28 28/32 0.61 [ 0.42, 0.89 ]
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 3
Proportion radiographic progression (mSvdH > 0.5).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 3 Proportion radiographic progression (mSvdH > 0.5)
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Smolen 2013 (PRESERVE) 29/167 20/184 65.1 % 1.60 [ 0.94, 2.71 ]
Weinblatt 2017 (C-EARLY) 14/74 7/72 25.5 % 1.95 [ 0.83, 4.54 ]
Yamanaka 2016 (ENCOURAGE) 4/23 3/29 9.4 % 1.68 [ 0.42, 6.77 ]
Total (95% CI) 264 285 100.0 % 1.69 [ 1.10, 2.59 ]
Total events: 47 (anti-TNF discontinuation), 30 (anti-TNF continuation)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 4 Function
(Health Assessment Questionnaire).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 4 Function (Health Assessment Questionnaire)
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ghiti Moghadam 2016 (POEET) 365 0.69 (0.5731) 193 0.59 (0.5557) 27.2 % 0.10 [ 0.00, 0.20 ]
Pavelka 2017 168 0.9 (0.7) 163 0.6 (0.6) 23.5 % 0.30 [ 0.16, 0.44 ]
Smolen 2013 (PRESERVE) 200 0.8 (0.6) 202 0.5 (0.5) 26.4 % 0.30 [ 0.19, 0.41 ]
Smolen 2014 (OPTIMA) 102 0.38 (0.56) 105 0.35 (0.5167) 22.9 % 0.03 [ -0.12, 0.18 ]
Total (95% CI) 835 663 100.0 % 0.18 [ 0.05, 0.31 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 14.10, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 5 Number
of serious adverse events.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 5 Number of serious adverse events
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chatzidionysiou 2016 (ADMIRE) 3/15 1/16 4.1 % 3.20 [ 0.37, 27.49 ]
Ghiti Moghadam 2016 (POEET) 34/531 8/286 19.8 % 2.29 [ 1.07, 4.88 ]
Pavelka 2017 7/176 0/167 2.4 % 14.24 [ 0.82, 247.34 ]
Smolen 2013 (PRESERVE) 15/200 12/202 20.5 % 1.26 [ 0.61, 2.63 ]
Smolen 2014 (OPTIMA) 11/102 12/105 19.4 % 0.94 [ 0.44, 2.04 ]
van Vollenhoven 2016 (DOSERA) 0/23 1/23 2.0 % 0.33 [ 0.01, 7.78 ]
Weinblatt 2017 (C-EARLY) 6/81 4/83 10.5 % 1.54 [ 0.45, 5.25 ]
Yamanaka 2016 (ENCOURAGE) 9/40 15/45 21.3 % 0.68 [ 0.33, 1.37 ]
Total (95% CI) 1168 927 100.0 % 1.29 [ 0.82, 2.03 ]
Total events: 85 (anti-TNF discontinuation), 53 (anti-TNF continuation)
Heterogeneity: Tau2 = 0.12; Chi2 = 10.18, df = 7 (P = 0.18); I2 =31%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 6
Withdrawals due to adverse events.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 6 Withdrawals due to adverse events
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pavelka 2017 6/176 3/167 23.8 % 1.90 [ 0.48, 7.47 ]
Smolen 2013 (PRESERVE) 5/200 7/202 34.9 % 0.72 [ 0.23, 2.24 ]
Smolen 2014 (OPTIMA) 7/102 3/105 25.4 % 2.40 [ 0.64, 9.03 ]
Weinblatt 2017 (C-EARLY) 4/81 2/83 16.0 % 2.05 [ 0.39, 10.88 ]
Total (95% CI) 559 557 100.0 % 1.46 [ 0.75, 2.84 ]
Total events: 22 (anti-TNF discontinuation), 15 (anti-TNF continuation)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.33, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 7
Proportion flare.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 7 Proportion flare
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 DAS28≥ 3.2 and DAS≥ 0.6 (24 to 52 weeks’ follow-up)
Weinblatt 2017 (C-EARLY) 10/79 7/84 1.52 [ 0.61, 3.80 ]
Pavelka 2017 134/168 85/163 1.53 [ 1.30, 1.81 ]
Ghiti Moghadam 2016 (POEET) 213/531 34/286 3.37 [ 2.42, 4.70 ]
2 DAS28≥ 3.2 OR DAS≥ 0.6 (follow-up 52 weeks)
Ghiti Moghadam 2016 (POEET) 272/531 52/286 2.82 [ 2.17, 3.65 ]
3 DAS28≥ 2.6 OR DAS > 1.2 (follow-up 28 weeks)
Chatzidionysiou 2016 (ADMIRE) 12/15 8/16 1.60 [ 0.92, 2.78 ]
4 Proportion failure (follow-up 48 weeks)
van Vollenhoven 2016 (DOSERA) 20/23 11/23 1.82 [ 1.15, 2.87 ]
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Analysis 2.8. Comparison 2 Anti-TNF discontinuation versus anti-TNF continuation, Outcome 8 Quality of
life.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 2 Anti-TNF discontinuation versus anti-TNF continuation
Outcome: 8 Quality of life
Study or subgroup
anti-TNF
discontinua-
tion
anti-TNF
continua-
tion
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pavelka 2017 168 0.6 (0.2) 163 0.7 (0.2) 57.3 % -0.10 [ -0.14, -0.06 ]
Smolen 2013 (PRESERVE) 200 0.7 (0.3) 202 0.8 (0.2) 42.7 % -0.10 [ -0.15, -0.05 ]
Total (95% CI) 368 365 100.0 % -0.10 [ -0.13, -0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 6.01 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 1 Mean disease activity score (DAS28).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 1 Mean disease activity score (DAS28)
Study or subgroup dose tapering continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bejerano 2016 (OPTIBIO) 23 2.73 (0.68) 25 2.3 (1.16) 27.3 % 0.43 [ -0.10, 0.96 ]
Fautrel 2016 (STRASS) 64 2.7 (1.1) 73 2.2 (1.2) 34.5 % 0.50 [ 0.11, 0.89 ]
van Herwaarden 2015 (DRESS) 115 2.4 (0.95) 57 2.5 (1) 38.3 % -0.10 [ -0.41, 0.21 ]
Total (95% CI) 202 155 100.0 % 0.25 [ -0.17, 0.67 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 6.58, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 2 Proportion persistent remission (DAS28).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 2 Proportion persistent remission (DAS28)
Study or subgroup dose tapering continuation Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
van Herwaarden 2015 (DRESS) 86/121 47/59 100.0 % 0.89 [ 0.75, 1.06 ]
Total (95% CI) 121 59 100.0 % 0.89 [ 0.75, 1.06 ]
Total events: 86 (dose tapering), 47 (continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 3 Proportion switched to another biologic.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 3 Proportion switched to another biologic
Study or subgroup dose tapering continuation Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Fautrel 2016 (STRASS) 4/64 6/73 55.1 % 0.76 [ 0.22, 2.58 ]
van Herwaarden 2015 (DRESS) 4/121 4/59 44.9 % 0.49 [ 0.13, 1.88 ]
Total (95% CI) 185 132 100.0 % 0.62 [ 0.25, 1.54 ]
Total events: 8 (dose tapering), 10 (continuation)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 4 Proportion radiographic progression (mSvdH > 0.5 or > 1.0).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 4 Proportion radiographic progression (mSvdH > 0.5 or > 1.0)
Study or subgroup dose tapering continuation Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Fautrel 2016 (STRASS) 22/64 23/73 56.3 % 1.09 [ 0.68, 1.76 ]
van Herwaarden 2015 (DRESS) 37/116 9/59 43.7 % 2.09 [ 1.08, 4.04 ]
Total (95% CI) 180 132 100.0 % 1.45 [ 0.77, 2.73 ]
Total events: 59 (dose tapering), 32 (continuation)
Heterogeneity: Tau2 = 0.13; Chi2 = 2.46, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 5 Function (Health Assessment Questionnaire).
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 5 Function (Health Assessment Questionnaire)
Study or subgroup dose tapering continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fautrel 2016 (STRASS) 58 0.6 (0.7) 65 0.4 (0.5) 100.0 % 0.20 [ -0.02, 0.42 ]
Total (95% CI) 58 65 100.0 % 0.20 [ -0.02, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.071)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 6 Number of serious adverse events.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 6 Number of serious adverse events
Study or subgroup dose tapering continuation Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Fautrel 2016 (STRASS) 6/64 10/73 46.5 % 0.68 [ 0.26, 1.78 ]
van Herwaarden 2015 (DRESS) 30/121 7/59 53.5 % 2.09 [ 0.98, 4.48 ]
Total (95% CI) 185 132 100.0 % 1.24 [ 0.42, 3.70 ]
Total events: 36 (dose tapering), 17 (continuation)
Heterogeneity: Tau2 = 0.43; Chi2 = 3.21, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 7 Proportion flare.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 7 Proportion flare
Study or subgroup dose tapering continuation Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 DAS28-ESR >2.6 with DAS28-ESR > 0.6 after 18 months
Fautrel 2016 (STRASS) 49/64 34/73 1.64 [ 1.24, 2.18 ]
2 DAS28-CRP > 1.2 OR DAS28-CRP > 0.6 and current DAS28-CRP ≥ 3.2 for > 3 months at 9 months’ follow-up
van Herwaarden 2015 (DRESS) 7/121 2/59 1.71 [ 0.37, 7.96 ]
3 DAS28-CRP > 1.2 OR DAS28-CRP > 0.6 and current DAS28-CRP ≥ 3.2 for > 3 months at 18 months’ follow-up
van Herwaarden 2015 (DRESS) 15/121 6/59 1.22 [ 0.50, 2.98 ]
4 DAS28-CRP > 1.2 OR DAS28-CRP > 0.6 and current DAS28-CRP ≥ 3.2 for < 3 months at 9 months’ follow-up
van Herwaarden 2015 (DRESS) 66/121 12/59 2.68 [ 1.58, 4.56 ]
5 DAS28-CRP > 1.2 OR DAS28-CRP > 0.6 and current DAS28-CRP ≥ 3.2 for < 3 months at 18 months’ follow-up
van Herwaarden 2015 (DRESS) 88/121 16/59 2.68 [ 1.74, 4.13 ]
6 DAS28 > 2.6, SDAI > 5 or ACR/EULAR criteria not fulfilled (follow-up 24 weeks)
Bejerano 2016 (OPTIBIO) 1/23 0/25 3.25 [ 0.14, 76.01 ]
7 DAS28 > 2.6, SDAI > 5 or ACR/EULAR criteria not fulfilled (follow-up 48 weeks)
Bejerano 2016 (OPTIBIO) 3/23 3/25 1.09 [ 0.24, 4.86 ]
8 DAS28 > 2.6, SDAI > 5 or ACR/EULAR criteria not fulfilled (follow-up 72 weeks)
Bejerano 2016 (OPTIBIO) 5/23 5/25 1.09 [ 0.36, 3.27 ]
9 DAS28 > 2.6, SDAI > 5 or ACR/EULAR criteria not fulfilled (follow-up 96 weeks)
Bejerano 2016 (OPTIBIO) 7/23 6/25 1.27 [ 0.50, 3.22 ]
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Analysis 3.8. Comparison 3 Anti-TNF disease activity-guided dose tapering versus anti-TNF continuation,
Outcome 8 Change in other medication.
Review: Down-titration and discontinuation strategies of tumour necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity
Comparison: 3 Anti-TNF disease activity guided dose tapering versus anti-TNF continuation
Outcome: 8 Change in other medication
Study or subgroup dose tapering continuation Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Use of intramuscular or intra-articular glucocorticoid injections at 18 months
van Herwaarden 2015 (DRESS) 43/121 14/59 1.50 [ 0.89, 2.51 ]
2 Use of oral glucocorticoids at 18 months
van Herwaarden 2015 (DRESS) 8/121 6/59 0.65 [ 0.24, 1.79 ]
3 DMARDs reduction or discontinuation after 18 months
van Herwaarden 2015 (DRESS) 12/121 16/59 0.37 [ 0.19, 0.72 ]
4 DMARD initiation or dose escalation after 18 months
van Herwaarden 2015 (DRESS) 16/121 2/59 3.90 [ 0.93, 16.41 ]
5 Use of a DMARD at 18 months
van Herwaarden 2015 (DRESS) 74/121 41/59 0.88 [ 0.71, 1.10 ]
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A P P E N D I C E S
Appendix 1. The Cochrane Library search strategy
#1 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
#2 caplan* near/2 syndrome
#3 felty* near/2 syndrome
#4 “rheumatoid nodule*”
#5 “rheumatoid vasculitis”
#6 sjogren* near/2 syndrome
#7 “still* disease”
#8 arthritis near/2 rheumat*
#9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10 MeSH descriptor: [Tumor Necrosis Factor-alpha] this term only and with qualifier(s) [Antagonists & Inhibitors - Al]
#11 MeSH descriptor: [Adalimumab] this term only
#12 MeSH descriptor: [Certolizumab Pegol] this term only
#13 MeSH descriptor: [Etanercept] this term only
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#14 MeSH descriptor: [Infliximab] this term only
#15 “anti-tumor necrosis factor”
#16 “anti-tumour necrosis factor”
#17 anti-tnf
#18 “tumor necrosis factor” near/3 inhibit*
#19 “tumour necrosis factor” near/3 inhibit*
#20 tnf near/3 inhibit*
#21 tnfi
#22 tnf near/3 block*
#23 bDMARD*
#24 “biologic* DMARD*”
#25 adalimumab
#26 humira
#27 etanercept
#28 enbrel
#29 benepali
#30 infliximab
#31 remicade
#32 remsima
#33 inflectra
#34 golimumab
#35 simponi
#36 certolizumab near/2 pegol
#37 cimzia
#38 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37)
#39 MeSH descriptor: [Dose-Response Relationship, Drug] this term only
#40 MeSH descriptor: [Drug Administration Schedule] this term only
#41 MeSH descriptor: [Remission Induction] this term only
#42 MeSH descriptor: [Withholding Treatment] this term only
#43 down near/3 titrat*
#44 dose near/3 reduc*
#45 dose near/3 de-escalat*
#46 discontinu*
#47 dose near/3 taper*
#48 spac*
#49 cessat*
#50 stop*
#51interval near/3 widen*
#52 biologic near/2 free
#53 withdraw*
#54 dose near/3 titrat*
#55 (#39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54)
#56 (#9 and #38 and #55)
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Appendix 2. MEDLINE search strategy
1 exp arthritis, rheumatoid/
2 (arthritis adj2 rheumat$).tw.
3 (felty$ adj2 syndrome).tw.
4 (caplan$ adj2 syndrome).tw.
5 rheumatoid nodule$.tw.
6 rheumatoid vasculitis.tw.
7 (sjogren$ adj2 syndrome).tw.
8 still$ disease.tw.
9 or/1-8
10 Adalimumab/
11 Certolizumab Pegol/
12 Etanercept/
13 Infliximab/
14 Infliximab.tw.
15 remicade.tw.
16 remsima.tw.
17 inflectra.tw.
18 adalimumab.tw.
19 humira.tw.
20 (Certolizumab adj2 pegol).tw.
21 cimzia.tw.
22 Etanercept.tw.
23 enbrel.tw.
24 benepali.tw.
25 Golimumab.tw.
26 simponi.tw.
27 Tumor Necrosis Factor-alpha/ai [Antagonists & Inhibitors]
28 anti-tnf.tw.
29 anti-tumor necrosis factor.tw.
30 anti-tumour necrosis factor.tw.
31 (Tumor Necrosis Factor adj3 inhibit$).tw.
32 (tumour necrosis factor adj3 inhibit$).tw.
33 (tnf adj3 inhibit$).tw.
34 Tnfi.tw.
35 (tnf adj3 block$).tw.
36 bDMARD$.tw.
37 biologic$ DMARD$.tw.
38 or/10-37
39 Dose-Response Relationship, Drug/
40 (down adj3 titrat$).tw.
41 (dose adj3 titrat$).tw.
42 (dose adj3 reduc$).tw.
43 (dose adj3 de-escalat$).tw.
44 withdraw$.tw.
45 discontinu$.tw.
46 (dose adj3 taper$).tw.
47 (biologic adj2 free).tw.
48 spac$.tw.
49 cessat$.tw.
50 stop$.tw.
51 (interval adj3 widen$).tw.
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52 Drug Administration Schedule/
53 remission induction/
54 Withholding Treatment/
55 or/39-54
56 randomized controlled trial.pt.
57 controlled clinical trial.pt.
58 randomized.ab.
59 randomised.ab
60 placebo.ab.
61 clinical trials as topic.sh.
62 randomly.ab.
63 trial.ti.
64 or/56-63
65 exp animals/ not humans.sh.
66 64 not 65
67 9 and 38 and 55
68 66 and 67
Appendix 3. Embase search strategy
1 exp arthritis, rheumatoid/
2 (arthritis adj2 rheumat$).tw.
3 (felty$ adj2 syndrome).tw.
4 (caplan$ adj2 syndrome).tw.
5 rheumatoid nodule$.tw.
6 rheumatoid vasculitis.tw.
7 (sjogren$ adj2 syndrome).tw.
8 still$ disease.tw.
9 or/1-8
10 infliximab.tw.
11 infliximab/
12 remicade.tw.
13 remsima.tw.
14 inflectra.tw.
15 humira.tw.
16 adalimumab/
17 adalimumab.tw.
18 cimzia.tw.
19 certolizumab pegol/
20 (certolizumab adj2 pegol).tw.
21 enbrel.tw.
22 etanercept/
23 etanercept.tw.
24 benepali.tw.
25 simponi.tw.
26 golimumab/
27 golimumab.tw.
28 tumor necrosis factor antibody/
29 anti-tnf.tw.
30 anti-tumor necrosis factor.tw.
31 anti-tumour necrosis factor.tw.
32 (Tumor Necrosis Factor adj3 inhibit$).tw.
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33 (Tumour Necrosis Factor adj3 inhibit$).tw.
34 (tnf adj3 inhibit$).tw.
35 Tnfi.tw.
36 (tnf adj3 block$).tw.
37 bDMARD$.tw.
38 biologic$ DMARD$.tw.
39 or/10-38
40 (down adj3 titrat$).tw.
41 (biologic adj2 free).tw.
42 drug dose reduction/
43 (dose adj3 reduc$).tw.
44 (dose adj3 de-escalat$).tw.
45 discontinu$.tw.
46 (dose adj3 taper$).tw.
47 spac$.tw.
48 cessat$.tw.
49 stop$.tw.
50 (interval adj3 widen$).tw.
51 withdraw$.tw.
52 (dose adj3 titrat$).tw.
53 remission/
54 treatment withdrawal/
55 dose response/
56 or/40-55
57 9 and 39 and 56
58 random$.tw.
59 factorial$.tw.
60 crossover$.tw.
61 cross over.tw.
62 cross-over.tw.
63 placebo$.tw.
64 (doubl$ adj blind$).tw.
65 (singl$ adj blind$).tw.
66 assign$.tw.
67 allocat$.tw.
68 volunteer$.tw.
69 crossover procedure/
70 double blind procedure/
71 randomised controlled trial/
72 single blind procedure/
73 or/58-72
74 57 and 73
108Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low
disease activity (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 4. Web of Science search strategy
#1 rheumat* NEAR/2 arthritis or caplan* NEAR/2 syndrome or felty* NEAR/2 syndrome or “rheumatoid nodule*” or “rheumatoid
vasculitis” or sjogren* NEAR/2 syndrome or “still* disease”
#2 “anti-tumor necrosis factor” or “anti-tumour necrosis factor” or “tumor necrosis factor” NEAR/3 inhibit* or “tumour necrosis
factor” NEAR/3 inhibit* or anti-tnf or tnf NEAR/3 inhibit* or tnf NEAR/3 block* or tnfi or adalimumab or humira or etanercept
or enbrel or benepali or infliximab or remicade or remsima or inflectra or golimumab or simponi or certolizumab NEAR/2 pegol or
cimzia or bDMARD* or “biologic* DMARD*”
#3 down NEAR/3 titrat* or dose NEAR/3 reduc* or dose NEAR/3 de-escalat* or discontinu* or dose NEAR/3 taper* or spac* or
cessat* or stop* or interval NEAR/3 widen* or dose NEAR/3 titrat* or withdraw* or biologic NEAR/2 free
#4 trial* or random* or control*
#5 #1 AND #2 AND #3 AND #4
Appendix 5. Search strategies trial registries
Registry: US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov/)
Date of search: 11 April 2018
Search terms and results:
Date Terms Hits
11-4-2018 Rheumatoid arthritis AND biologics 470
11-4-2018 Rheumatoid arthritis AND anti TNF 291
11-4-2018 Rheumatoid arthritis AND etanercept 168
11-4-2018 Rheumatoid arthritis AND adalimumab 201
11-4-2018 Rheumatoid arthritis AND infliximab 119
11-4-2018 Rheumatoid arthritis AND golimumab 38
11-4-2018 Rheumatoid arthritis AND certolizumab 71
11-4-2018 Rheumatoid arthritis AND discontinuing 14
11-4-2018 Rheumatoid arthritis AND reducing 250
11-4-2018 Rheumatoid arthritis AND withdrawal 96
11-4-2018 Rheumatoid arthritis AND “dose reduction” 25
Registry: EU Clinical Trials Register ( www.clinicaltrialsregister.eu/)
Date of search: 11 April 2018
Search terms and results:
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Date Terms Hits
11-4-2018 Rheumatoid arthritis AND biologics 66
11-4-2018 Rheumatoid arthritis AND anti TNF 144
11-4-2018 Rheumatoid arthritis AND etanercept 141
11-4-2018 Rheumatoid arthritis AND adalimumab 159
11-4-2018 Rheumatoid arthritis AND infliximab 119
11-4-2018 Rheumatoid arthritis AND golimumab 53
11-4-2018 Rheumatoid arthritis AND certolizumab 56
11-4-2018 Rheumatoid arthritis AND discontinuing 4
11-4-2018 Rheumatoid arthritis AND reducing 25
11-4-2018 Rheumatoid arthritis AND withdrawal 62
11-4-2018 Rheumatoid arthritis AND “dose reduction” 12
Registry: Dutch trial register ( www.trialregister.nl)
Date of search: 11-4-2018
Search terms and results:
Date Terms Hits
11-4-2018 Rheumatoid arthritis 59
11-4-2018 TNF-blockers 1
11-4-2018 Anti-TNF 11
11-4-2018 TNF 19
Registry: World Health Organization International Clinical Trials Registry Platform ( www.who.int/ictrp/en/)
Date of search: 11 April 2018
Search terms and results:
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Date Terms Hits
11-4-2018 Anti-TNF OR biologic OR adalimumab OR etanercept
OR certolizumab OR infliximab OR golimumab
AND
Rheumatoid arthritis
AND
dose OR taper OR withdrawal OR discontinuation OR
reduce OR titration
(recruitment status: ALL)
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Appendix 6. Risk of bias
Article nr:
Reviewer: BvdB/LV
Date:
Domain Support for judgement Judgement
low risk of bias, high risk of bias, or unclear risk of bias
Selection bias
Random sequence generation
Allocation concealment
Performance bias
Blinding of participants and personnel
Detection bias
Blinding of outcome assessment
(subjective outcomes)
Blinding of outcome assessment
(objective outcomes)
Attrition bias
Incomplete outcome data
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(Continued)
Reporting bias
Selective reporting
Other bias
Other sources of bias
F E E D B A C K
Comments - Lo and Tejani, 30 March 2015
Summary
Comment: Written by:
Elaine Lo, MSc. (Clin Pharm), BCPS, PharmD Student Aaron M Tejani, BSc.Pharm, PharmD
We read with interest the review on down-titration and discontinuation strategies of tumor necrosis factor (TNF)-blocking agents for
rheumatoid arthritis (RA) in patients with low disease activity and there are a few points we wish to address.
The authors concluded that dose reduction of etanercept after at least 3 to 12 months of low disease activity, seems as effective as
continuing the standard dose with respect to disease activity and functional outcomes; while discontinuation of adalimumab and
etanercept is inferior to continuation of treatment. The conclusion is drivenmainly by the results of the PRESERVE trial2, which weighs
59.7% and 30% in the meta-analyses of the dose reduction and discontinuation endpoint respectively. We feel that the conclusion
should be rephrased as “in patients who were put on anti-TNF agents (with methotrexate) and improved from moderate to low disease
activity for at least 3 to 12 months” to reflect the patient population studied in the PRESERVE trial. This would prevent unintentional
extrapolation of the conclusion to patients who start out with severe disease activity or whose disease activity remains unchanged on
anti-TNF agents.
The PRESERVE trial is rated as having a low risk of bias for all parameters except “incomplete outcome data” and that differs from our
evaluation. PRESERVE is the largest study (n=604) included in the review and the only trial identified for many endpoints. Thus an
accurate evaluation of its risk of bias is important in the synthesis of data. Though not reported in PRESERVE, injection site reaction is
a significant adverse event with etanercept. In the Cochrane review by Lethaby et al3, more patients receiving etanercept plus DMARD
developed injection site reactions than those taking DMARD alone (at six months: 25.6% versus [vs] 3.8%, RR 6.9; 95% CI 2.2 to
21.3). For patients who were given etanercept for 9 months in the open-label phase, the sudden lack of injection site reaction might be
a trigger for unblinding in the placebo group despite the double blind design and identical drug package. By the same token, assessors/
study investigators could have been unblinded by the lack of injection site reaction in the placebo group. Potentially compromised
blinding for a subjective outcome like Disease activity score-28 (DAS28) meets the criteria for judgment of high risk of performance
bias.4 Inadequate blinding combined with blocked randomization might increase the risk of selection bias. With a block size of 3,
when assignments are revealed because of the characteristic injection site reaction, it might be possible to predict future assignments,
thus undermining allocation concealment. The chance of seeing a pattern and hence being able to predict assignment is arguably small
in a trial that involves 80 centres recruiting 834 patients. Yet we have no information regarding the distribution of recruitment among
centres and how many centres were recruiting at the same time. Selection bias should be unclear rather than low.4
We agree with the authors’ assessment that the attrition risk is high in PRESERVE. There were significantly more treatment discon-
tinuation due to unsatisfactory responses in the placebo group compared to the 25mg etanercept and 50mg etanercept group (43
(21.5%) vs 27 (13.4%) vs 4 (2%)). Patients were assumed to be non-responders if they discontinued early because of poor efficacy.
This might exaggerate the number of non-responders, especially in the placebo group. There is no objective criteria for discontinuation
due to inefficacy described in the trial - patient may not have reached the point of being considered a non-responder when they left
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the study. Though the benefit of etanercept continuation withstands the test of sensitivity analysis for the outcome of DAS28<3.2,
other endpoints with a smaller effect size or lower incidence e.g. normal HAQ-DI and ACR70 may have become insignificant should a
different analysis be used. Having mentioned that the risk of unblinding is high, the threshold of discontinuation for a “perceived” lack
of drug effect might be lower in PRESERVE than an adequately blinded study. As for patients who discontinued for reasons other than
unsatisfactory response, missing data were imputed with last observation carried forward (LOCF) method. There is no information
about the number of patients that were affected by LOCF. A patient may be categorized as having low disease activity when he was lost
to follow up and imputed as a responder but indeed would be rated as having high disease activity if assessment was done at week 88.
It appears that the review authors took the data straight from Table 3 of the PRESERVE trial which do not account for the uncertainty
around imputation. We suggest communicating with the authors of PRESERVE about the extent of LOCF/ non-responder imputation
and performing sensitivity analyses for outcomes presented in the review (e.g. DAS28<2.6, HAQ-DI etc) like those performed for
DAS28<3.2 in the supplementary appendix of PRESERVE.2
We also feel that the reporting for assessment of adverse events (AE) and co-intervention (e.g. methotrexate and glucocorticoid dose) was
inadequate in PRESERVE. Besides cost, another reason to attempt dose reduction or discontinuation is to avoid unnecessary exposure
to drug toxicity. PRESERVE is the only trial included for the evaluation of serious adverse events (SAE). However, the trial authors did
not describe how SAE were assessed or adjudicated. Indeed, PRESERVE captured significantly less SAE and AE compared to other
trials comparing etanercept plus methotrexate vs methotrexate alone (e.g. Emery, 20085: SAE 12%, any AE 91%; Weinblatt, 19996:
infection 51-63%; Klareskog, 20047: infection AE 81%, 67%-64% PRESERVE2: SAE 3-8%, any AE 53-61%, infection 1-2%). The
dose of methotrexate and glucocorticoid is not reported but is deemed pertinent as there seemed to be no restriction on adjustment of
these drugs for lack of efficacy. The review authors should consider explaining the risk explicitly to the readers and incorporating this
as part of the quality assessment.
The terms “low disease activity” and “remission” were used loosely in the review. Uninformed readers might find this misleading and
confusing. For instance, in the plain language summary, the author stated the impact of stopping or lowering the dose of anti-TNF
drugs on “RA remission”. However, this is referred to as “persistent low disease activity” in the main text. Under this umbrella of
“persistent low disease activity”, the authors pooled outcomes on DAS28 remission, non-failure and DAS28-CRP<2.7 - not remission
alone. We suggest the authors revising the wording in the plain language summary from “RA remission” to “persistent low disease
activity” for the sake of consistency.
We noted with regret that the authors of the review changed themajor outcome from “proportion of patients with a flare” to “proportion
of patients with persistent low disease activity”, claiming that the two are highly comparable. Despite the understanding that only 2
of the included studies reported the former outcome, we still want to acknowledge its merit as an endpoint. As revealed in a study
by the OMERACT group8, the validated flare criteria (i.e. an increase in DAS28>1.2 or >0.6 if DAS28>3.2) was found to be more
discriminating and more valid than a threshold criteria (i.e. DAS28>2.6 or 3.2) (see Table 1) It gives a good balance of specificity/
sensitivity in the transition scale where patient/ physician were asked whether disease activity had changed compared with the last visit
on a 7-point Likert scale (criterion validity), and is well associated with DMARD/ corticosteroid and CRP change. As pointed out by
the review authors, in addition to mean disease activity, a validated RA flare criterion like the OMERACT DAS28-based flare criteria
should be considered. We look forward to seeing studies with standardized outcomes for future meta-analyses.
We hope this provides some constructive feedbacks for the next review. We look forward to hearing from you.
1. vanHerwaardenN, denBroeder AA, JacobsW, van derMaas A, Bijlsma JW, vanVollenhovenRF.Down-titration and discontinuation
strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. The Cochrane Library
2013.
2. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and
methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381(9870):
918-29. 10.1016/s0140-6736(12)61811-x
3. Lethaby A, Lopez-Olivo MA, Maxwell LJ, Burls A, Tugwell, P., Wells GA. Etanercept for the treatment of rheumatoid arthritis. The
Cochrane Library 2013.
4. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The
Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
5. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept
in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;
372(9636):375-82. 10.1016/s0140-6736(08)61000-4
6.Weinblatt ME,Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein,
in patients with rheumatoid arthritis receiving methotrexate. The New England journal of medicine 1999;340(4):253-9. 10.1056/
NEJM199901283400401
113Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low
disease activity (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared
with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363(9410):
675-81. 10.1016/S0140-6736(04)15640-7
8. van der Maas A, Lie E, Christensen R, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis
flare criteria: an OMERACT cohort validation study. Annals of the rheumatic diseases 2013;72(11):1800-5. 10.1136/annrheumdis-
2012-202281
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
Hereby our response:
We read the comment by Lo et al on our review ’Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents
for rheumatoid arthritis in patients with low disease activity’ with interest. Herewith we thank them for taking the time and effort to
do this, and provide a point to point response:
First it should be noted that we plan to update the review within the next year already. This because in the original review the majority
of studies had not yet been published as a full text article. Since then, some important trials have been published in full, and also we
expect some strategy studies to be published within the next months. In this update, we will incorporate the comments by Lo et all
were applicable.
With respect to our conclusion that “dose reduction of etanercept after at least 3 to 12 months of low disease activity, seems as effective
as continuing the standard dose with respect to disease activity and functional outcomes; while discontinuation of adalimumab and
etanercept is inferior to continuation of treatment.” We think that this statement is correct. Although PRESERVE study weights in
heavily, both Botsios 2007 and van Vollenhoven 2012 did not include only patients that had only moderate disease activity at study
start. We therefore think that our conclusion is still valid. In the update we will hopefully be able to include STRASS and DRESS
strategy studies, that also did not limit patient inclusion to patients with moderate disease activity at study start
With regard to risk of bias being high due to possible unblinding and blocked randomisation, we disagree. Injection site reaction can
occur, but are firstly for the most part limited to the first 6 months of treatment. Also, patients with severe ISR stop treatment. Secondly,
low dose etanercept patients could not have been unblinded by sudden, as ISR do not seem to depend on dose. Also, even when
unblinding occurred in some patients, it could only give bias in the conservative direction, ie patients and physicians would expect a
flare more so in these patients. Estimates for disease activity would not he lower, but higher in these patients. Finally, for radiographic
outcome, any unblinding would not play a role. Of course classifying a certain characteristic of a study as having a risk of bias remains
a judgement call, but we do not think that it is fair to expect a large risk of bias in the estimates of this study. In the update of the
review, we will address these issues more in depth.
Adverse event reporting is indeed overall suboptimal, and we have mentioned this in our conclusion. The same holds true for absence
of any cost effectiveness analyses. In the upcoming update, we expect to have more data on this.
“We suggest the authors revising the wording in the plain language summary from “RA remission” to “persistent low disease activity”
for the sake of consistency. ”. Thanks for the suggestion, we will do this in the next update.
Finally, we agree wholeheartedly with the suggestion to add % patients with flare as outcome. We are the authors by the way of the
OMERACT flare criteria paper that is referred to, so we are quite familiar with the upside of using this outcome. Unfortunately, this
outcome was not used in the trials we have identified. Furthermore, in strategy studies, the outcome of prolonged flare is probably better
reflecting (non) inferiority of a certain tapering strategy, see for ample discussion about this in our recent BMJ paper. www.bmj.com/
content/350/bmj.h1389-0.long
Thank again for taking the time to review our systematic review.
Best regards,
Contributors
Dr A.A. (Alfons) den Broeder, on behalf of all co-authors.
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WH A T ’ S N E W
Date Event Description
3 June 2019 Amended Correction to article metadata; no impact on article content
H I S T O R Y
Protocol first published: Issue 4, 2013
Review first published: Issue 9, 2014
Date Event Description
22 May 2019 New citation required and conclusions have changed One previously included trial was excluded in this update.
We included eight additional trials, for a total of 14 studies
29 March 2018 New search has been performed Conclusions have changed. We have now more evidence
on other tumour necrosis factor blocking agents, and dis-
ease activity tapering is comparable to continuation of
treatment with respect to the proportion of participants
with persistent remission and may be comparable regard-
ing disease activity
20 May 2015 Feedback has been incorporated Incorporated feedback from Lo and Tejani
C O N T R I B U T I O N S O F A U T H O R S
Title and protocol: AAdB, NvH.
Review of abstracts and full-text articles: BJFvdB, NvH, AAdB, LMV.
Data extraction: BJFvdB, NvH, LMV.
Results and analyses: NvH, BJFvdB, WJ, AAdB, AvdM, LMV.
Interpretation of data: NvH, BJFvdB, WJ, AAdB, AvdM, JEV, FHJvdH, MH, LMV.
Draft of the review: NvH, BJFvdB, AAdB, LMV.
Editing of the draft: WJ, AvdM, JEV, FHJvdH, MH.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We removed the sentence: “The intervention should include the option for a patient to restart the anti-TNF agent in case of loss
of response.” from Types of interventions. We did this because the largest study included in this review did not include the option to
restart the anti-TNF agent in case of loss of response. It was not always clear for the other included studies whether participants could
restart the anti-TNF agent. We believe the possibility of restarting an anti-TNF agent in case of loss of response is important.
• Different review authors for selecting studies: BJFvdB replaced AAdB in selecting studies, abstracting data, and assessing risk of
bias. AAdB was the referee. This change was made because AAdB had time limitations.
• Switch in primary outcome: We made “Proportion of patients with persistent low disease activity” a major outcome and
“Proportion of patients with a flare” a minor outcome. We switched these outcomes because the two are highly comparable. Most
included studies used the first outcome.
• Additional types of studies: Both superiority and non-inferiority trials were included. One of the studies included in this review
was reported to be a non-inferiority study. Also, some of the identified ongoing trials were reported to be non-inferiority studies. A
non-inferiority design is the best study design for a down-titration strategy.
• Additional types of participants: standard (or lower) anti-TNF dose. We added the “or lower dose” because some studies might
also include participants who used a lower-than-standard dose before entering the study.
• Addition to other sources of bias: We added imbalance in prognostic variables as another source of bias, as we believe this is an
important addition for the ’Risk of bias’ assessment in our review.
• The outcome “proportion persistent loss of response, refractory to re-instalment of the tapered anti-TNF” was changed to
“proportion of participants that switched to another biologic due to persistent loss of response, refractory to re-instalment of the
116Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low
disease activity (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
tapered anti-TNF in the intervention group”. We made this change since the definition was not specific enough and insufficiently
distinct from the other outcome measures.
• For the outcome “proportion participants with persistent low disease activity” we have chosen to report the proportion of
participants in persistent remission to have more data available for this outcome. Since remission is more stringent than low disease
activity, we might be more sensitive to differences between continuation and down-titration of anti-TNF.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal, Humanized; Antirheumatic Agents [∗therapeutic use]; Arthritis, Rheumatoid [∗drug therapy]; Randomized
Controlled Trials as Topic; Receptors, Tumor Necrosis Factor [∗therapeutic use]; Recurrence; Remission Induction; Tumor Necrosis
Factor-alpha [∗antagonists & inhibitors]
MeSH check words
Female; Humans; Male; Middle Aged
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